日本臨牀　別冊　免疫症候群（第2版）II

出版社： 日本臨牀社
発行日： 2016-01-20
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 免疫症候群（第2版）II―その他の免疫疾患を含めて―
電子書籍版： 2016-01-20 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

21,450 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

21,450 円(税込)

購入する

目次

  • 日本臨牀　別冊　免疫症候群（第2版）II

    ―目次―

    特集　免疫症候群（第2版）II―その他の免疫疾患を含めて―

    V．アレルギー性疾患
    　1．アレルギー概論：分類と発症機序
    　2．アレルギー性鼻炎
    　3．アレルギー性結膜疾患
    　4．蕁 麻 疹
    　5．アトピー性皮膚炎
    　6．汗アレルギー
    　7．アレルギー性接触皮膚炎
    　8．喘　　息
    　9．好酸球増加症候群
    　10．肥満細胞症
    　11．過敏性肺炎
    　12．食物アレルギー
    　13．Breast feeding anaphylaxis
    　14．昆虫アレルギー
    　15．ペットアレルギー
    　16．ダニアレルギー・アナフィラキシー
    　17．金属接触アレルギーと全身型金属アレルギー
    　18．香粧品によるアレルギー
    　19．Heiner症候群(ミルクアレルギーによる肺出血)
    　20．Hopkins 症候群(急性喘息後萎縮症)
    　21．アレルギー性緊張弛緩症候群
    　22．運動誘発アナフィラキシー
    　23．化学物質過敏症
    　24．薬物アレルギー
    　25．職業性アレルギー疾患

    VI．続発性免疫不全症候群―各種疾患・病態にみられる免疫異常―
    　1．感染症にみられる免疫異常
    　2．造血器疾患にみられる免疫異常
    　3．医薬品による免疫異常
    　4．その他の病態にみられる免疫異常

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

V アレルギー性疾患

P.15 掲載の参考文献
1) Chinen J, et al : Adaptive immunity. In : Middleton's Allergy : Principles and Practice, 8th ed (ed by Adkinson NF Jr), Vol. 1, p20-29, Elsevier, Philadelphia, 2014.
 
2) Saito H, et al : Mast cells and IgE : from history to today. Allergol Int 62 : 3-12, 2013.
PubMed
3) Lund S, et al : Type2 Innate Lymphoid Cells in Allergic Disease. Curr Immunol Rev 9 : 214-221, 2013.
 
4) Tamari M, et al : Genome-wide association studies of allergic diseases. Allergol Int 62 : 21-28, 2013.
 
5) Bradding P, Saito H : Biology of mast cells and their mediators. In : Middleton's Allergy : Principles and Practice, 8th ed (ed by Adkinson NF Jr), Vol. 1, p228-251, Elsevier, Philadelphia, 2014.
 
6) Nakae S, et al : Role of interleukin-33 in innate-type immune cells in allergy. Allergol Int 62 : 13-20, 2013.
PubMed
7) Leung DY, Guttman-Yassky E : Deciphering the complexities of atopic dermatitis : shifting paradigms in treatment approaches. J Allergy Clin Immunol 134 : 769-779, 2014.
PubMed
8) Yamada T, et al : Present state of Japanese cedar pollinosis : the national affliction. J Allergy Clin Immunol 133 : 632-639, 2014.
PubMed
9) Ohta K, et al : Japanese Guideline for Adult Asthma 2014. Allergol Int 63 : 293-333, 2014.
 
10) Hamasaki Y, et al : Japanese Guideline for Childhood Asthma 2014. Allergol Int 63 : 335-356, 2014.
 
11) Katayama I, et al : Japanese Guideline for Atopic Dermatitis 2014. Allergol Int 63 : 377-398, 2014.
 
12) Devereux G, et al : Epidemiology of asthma and allergic airway diseases. In : Middleton's Allergy : Principles and Practice, 8th ed (ed by Adkinson NF Jr), Vol. 1, p754-789, Elsevier, Philadelphia, 2014.
 
13) Hamilton RG : Clinical laboratory assessment of immediate-type hypersensitivity. J Allergy Clin Immunol 125 : S284-296, 2010.
PubMed
14) Matsumoto K, Saito H : Epicutaneous immunity and onset of allergic diseases- per- "eczema" tous sensitization drives the allergy march. Allergol Int 62 : 291-296, 2013.
 
15) Du Toit G, et al : Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 372 : 803-813, 2015.
PubMed
P.22 掲載の参考文献
1) 鼻アレルギー診療ガイドライン作成委員会 : 第3章 アレルギー性鼻炎発症のメカニズム. 鼻アレルギー治療ガイドライン-通年性鼻炎と花粉症- (改訂第5版), p13-16, ライフサイエンスメディカ, 2005.
 
2) Okuda M : Epidemiology of Japanese cedar pollinosis throughout Japan. Ann Allergy Asthma Immunol 91 : 288-296, 2003.
PubMed
3) Okubo K, et al : Prevalence of Japanese cedar pollinosis in children aged under 15 years throughout Japan. Clin Exp Allergy Rev 4 : 31-34, 2004.
 
4) 馬場廣太郎, 中江公裕 : 鼻アレルギーの全国疫学調査 2008 (1998年との比較)-耳鼻咽喉科医およびその家族を対象として-. Progressin Medicine 28 : 2001-2012, 2008.
 
5) 大久保公裕 : アレルギー性鼻炎の臨床研究-pathophysiology and immunology-. アレルギー 63 (10) : 1317-1324, 2014.
Medical*Online
6) Barnes PJ : Neuropeptide in human airways : Function and clinical implications. Am Rev Respir Dis 136 : S77- S83, 1987.
 
7) Raphael GD, et al : The pathophysiology of rhinitis II : Assessment of the source of protein in histamine-induced nasal secretions. Am Rev Respir Dis 139 : 791-800, 1989.
PubMed
8) Takeyama K, et al : Epidermal growth factor systems regulates mucin production in airways. Proc Natl Acad Sci U S A 96 : 3081-3086, 1999.
PubMed
9) 奥田稔 : 6. 病理組織学. 鼻アレルギー, p84-87, 医薬ジャーナル, 1999.
 
10) 大久保公裕 : アレルギー性鼻炎の基礎と臨床. 診断と治療 87 (2) : 275-281, 1999.
Medical*Online
11) 今野昭義, 大久保公裕 : 患者満足度からみた花粉症治療-花粉症患者アンケート調査結果から-. Progressin Medicine 23 : 2705-2709, 2003.
 
P.28 掲載の参考文献
1) 高村悦子ほか ; 日本眼科アレルギー研究会アレルギー性結膜疾患診療ガイドライン編集委員会 : アレルギー性結膜疾患診療ガイドライン (第2版). 日眼会誌 114 : 829-870, 2010.
 
2) 日本眼科医会アレルギー眼疾患調査研究班, 大野重昭 (編) : アレルギー性結膜疾患の疫学. 日本眼科医会アレルギー眼疾患調査研究班業績集, 日本眼科医会, 1995.
 
3) Uchio E, et al : Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol 246 : 291-296, 2008.
PubMed
4) Wong A H, et al : Seasonal and perennial allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov 8 : 139-153, 2014.
PubMed
5) 福島敦樹ほか : スギ花粉以外の抗原によるアレルギー性結膜炎の薬物療法-ヒスタミンH1受容体拮抗点眼薬とメディエーター遊離抑制点眼薬の効果について. あたらしい眼科 22 : 225-229, 2005.
Medical*Online
6) 海老原伸行 : 【アレルギー性結膜疾患の現在】メディエーター遊離抑制薬点眼の初期療法. アレルギーの臨床 28 : 261-266, 2008.
 
7) Armaly MF : Effect of corticosteroids on intraocular pressure and fluid dynamics. II : the effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol 70 : 492-499, 1963
PubMed
P.31 掲載の参考文献
1) Takamura E, et al : Japanese guideline for allergic conjunctival diseases. Allergol Int 60 : 191-203, 2011.
PubMed
2) Takano Y, et al : Dramatic healing of an allergic corneal ulcer persistent for 6 months by amniotic membrane patching in a patient with atopic keratoconjunctivitis : a case report Cornea 23 (7) : 723-725, 2004.
 
3) Tanaka M, et al : The relation of conjunctival and corneal findings in severe ocular allergies. Cornea 23 : 464-467, 2004.
PubMed
4) Ebihara N, et al : A large prospective observational study of novel cyclosporine 0.1 % aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 25 : 365-372, 2009.
 
5) Fukushima A, et al : Therapeutic effects of 0.1 % tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement Br J Ophthalmol 98 : 1023-1027, 2014.
PubMed
6) Dogru M, et al : Ocular surface and MUC5AC alterations in atopic patients with corneal shield ulcers. Curr Eye Res 30 : 897-908, 2005.
PubMed
7) Fujishima H, et al : The role of Staphylococcal enterotoxin in atopic keratoconjunctivitis and corneal ulceration. Allergy 67 : 799-803, 2012.
PubMed
8) Kawakita T, et al : Quantitative evaluation of eyelid elasticity using the cutometer SEM575 and its clinical application in assessing the efficacy of tacrolimus ointment treatment in eyelid atopic dermatitis. Cornea 23 : 468-471, 2004.
PubMed
9) Ibrahim OM, et al : In vivo confocal microscopy evaluation of meibomian gland dysfunction in atopic-keratoconjunctivitis patients. Ophthalmology 119 : 1961-1968, 2012.
PubMed
10) Miyake-Kashima M, et al : Kaposi varicelliform eruption associated with 0.1 % tacrolimus ointment treatment in atopic blepharitis. Cornea 23:190-193, 2004.
 
11) Ohashi Y, et al : A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1 % in severe allergic conjunctivitis. J Ocul Pharmacol Ther 26 : 165-174, 2010.
 
12) Fujishima H, et al : Combined medical and surgical treatment of severe vernal keratoconjunctivitis. Jpn J Ophthalmol 44 : 511-515, 2000.
PubMed
P.38 掲載の参考文献
1) Ebihara N, et al : A large prospective observational study of novel cyclosporine 0.1 % aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 25 (4) : 365-372, 2009.
 
2) Ohashi Y, et al : A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1 % in severe allergic conjunctivitis. J Ocul Pharmacol Ther 26 (2) : 165-174, 2010.
 
3) Gokhale NS, et al : Oral cyclosporine therapy for refractory severe vernal keratoconjunctivitis. Indian J Ophthalmol 60 (3) : 220-223, 2012.
PubMed
4) Guo P, et al : Surgical resection and amniotic membrane transplantation for treatment of refractory giant papillae in vernal keratoconjunctivitis. Cornea 32 (6) : 816-820, 2013.
PubMed
5) de Klerk TA, et al : Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS 17 (3) : 305-306, 2013.
PubMed
P.41 掲載の参考文献
1) アレルギー結膜疾患診断ガイドライン編集委員会 : アレルギー結膜疾患診断ガイドライン (第2版). 日眼会誌 114 : 831-870, 2010.
 
2) Spring TF : Reaction to hydrophilic lenses. Med J Aust 1 : 449-450, 1974.
PubMed
3) Korb DR, et al : Prevalence of conjunctival changes in wearers of hard contact lenses. Am J Ophthalmol 90 : 336-341, 1980.
PubMed
4) 日本眼科医会医療対策部 : コンタクトレンズによる眼障害アンケート調査の集計結果報告 (平成21年度). 日本の眼科 81 : 408-412, 2010.
 
5) Allansmith MR, et al : Giant papillary conjunctivitis induced by hard or soft contact lens wear : quantitative histology. Trans Am Acad Ophthalmol Otol 85 : 766-778, 1978.
PubMed
6) Allansmith MR, et al : Vernal conjunctivitis and contact lens-associated giant papillary conjunctivitis compared and contrasted. Am J Ophthalmol 87 : 544-555, 1979.
PubMed
7) Henriquez AS, et al : Mast cell ultrastructure : comparison in contact lens-associated giant papillary conjunctivitis and vernal conjunctivitis. Arch Ophthalmol 99 : 1266-1272, 1981.
PubMed
8) Trocme SD, et al : Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis. Am J Ophthalmol 108 : 57-63, 1989.
PubMed
9) Allansmith MR, et al : Giant papillary conjunctivitis in contact lens wearers. Am J Ophthalmol 83 : 697-708, 1977.
PubMed
10) 寺井和都, 山田潤 : ソフトコンタクトレンズ装用眼にみられた巨大乳頭結膜炎に対する0.1%シクロスポリン点眼液の臨床効果. あたらしい眼科 29 : 109-112, 2012.
Medical*Online
11) 佐野研二 : コンタクトレンズ素材と汚染性. 日コンタクトレンズ会誌 42 : 68-73, 2000.
 
12) 清水健太郎ほか : イオン性ソフトコンタクトレンズに付着したタンパク質に対するこすり洗いの効果. 日コンタクトレンズ会誌 49 : 23-25, 2007.
 
P.47 掲載の参考文献
1) 秀道広ほか : 日本皮膚科学会ガイドライン蕁麻疹診療ガイドライン. 日本皮膚科学会雑誌 121 : 1339-1388, 2011.
 
2) 田中稔彦ほか : 広島大学皮膚科外来での蕁麻疹の病型別患者数. アレルギー 55 : 134-139, 2006.
Medical*Online
3) Maurer M, et al : Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report Allergy 66 : 317-330, 2011.
PubMed
4) Hellgren L : The prevalence of urticaria in the total population. Acta Allergol 27 : 236-240, 1972.
PubMed
5) Zuberbier T, et al : Epidemiology of urticaria : a representative cross-sectional population survey. Clin Exp Dermatol 35 : 869-873, 2010.
PubMed
6) 高萩俊輔, 秀道広 : 自己免疫性蕁麻疹. 小児科診療 73 : 2215-2219, 2010.
 
7) Saini SS : Chronic spontaneous urticaria : etiology and pathogenesis. Immunol Allergy Clin North Am 34 : 33-52, 2014.
PubMed
8) 秀道広 : 蕁麻疹の痒みup date. MB Derma 104 : 36-41, 2005.
 
9) 秀道広 : 皮疹の種類とその発症機序 膨疹. Medicina 51 : 802-807, 2014.
 
10) 秀道広 : 慢性蕁麻疹はいつ治るのか. EBM皮膚疾患の治療 2008-2009 (宮地良樹編), p48-52, 中外医学社, 2008.
 
11) Hiragun M, et al : Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy 68 : 229-235, 2013.
 
P.50 掲載の参考文献
1) 田中稔彦ほか : 広島大学皮膚科外来での蕁麻疹の病型別患者数. アレルギー 55 : 134-139, 2006.
Medical*Online
2) 西脇冬子ほか : 染毛剤によるアナフィラキシーショックの2例. 皮膚科の臨床 53 : 705-708, 2011.
 
3) 海老原香子ほか : 塩酸セフォチアムによる接触蕁麻疹症候群の1例. 皮膚科の臨床 44 : 1401-1404, 2002.
 
4) Iwata M, et al : Contact urticaria due to a face mask coated with disinfectant liquid spray. Acta Derm Venereol 95 : 628-629, 2015.
PubMed
5) 森田栄伸 : 肥満細胞と皮膚疾患 蕁麻疹. MB Derma 120 : 41-46, 2006.
 
6) Sheikh A, et al : Adrenaline (epinephrine) for the treatment of anaphylaxis with and without shock Cochrane Database Syst Rev (4) : CD006312, 2008.
PubMed
P.54 掲載の参考文献
1) 田中稔彦ほか : 広島大学皮膚科外来での蕁麻疹の病型別患者数. アレルギー 55 : 134-139, 2006.
Medical*Online
2) Fukunaga A, et al : Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. J Allergy Clin Immunol 116 : 397-402, 2005.
PubMed
3) 秀道広ほか : 蕁麻疹診療ガイドライン. 日皮会誌 121 : 1339-1388, 2011.
 
4) Asero R et al : Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 119 : 705-710, 2007.
PubMed
5) Horikaw T, et al : Urticaria and Angioedema, p73-80, Springer, 2010.
 
P.61 掲載の参考文献
1) 原田晋ほか : アスピリン蕁麻疹のもつ多面性. アレルギーの臨床 21 : 979-984, 2001.
 
2) 宮城拓也, 上里博 : アスピリン不耐症. MB Derma 229 : 163-169, 2015.
 
3) Kowalski ML, et al : Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 68 : 1219-1232, 2013.
 
4) 谷口正実ほか : NSAIDs不耐症. 薬疹のすべて (池沢善郎ほか編), p 252-258, 南江堂, 2008.
 
5) 守屋真希ほか:NSAIDs不耐症による蕁麻疹および血管性浮腫, 本邦76例の解析. アレルギー 60 : 699-707, 2011.
Medical*Online
6) Cavkaytar O, et al : Challenge-proven aspirin hypersensitivity in children with chronic spontaneous urticaria. Allergy 70 : 153-160, 2015.
PubMed
7) Ortega N, et al : Practical guidelines for diagnosing hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. J Investig Allergol Clin Immunol 24 : 308-323, 2014.
PubMed
8) Tournoij E, et al : The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherosclerosis. Eur J Vase Endovasc Surg 37 : 597-603, 2009.
 
9) Dona I, et al : NSAIDs-induced urticaria/angioedema does not evolve into chronic urticaria : a 12-year follow-up study. Allergy 69:438-444, 2014.
 
10) Matsuo H, et al : Aspirin augments IgE-mediated histamine release from human basophils via Syk kinase activation. Allergol Int 62 : 503-511, 2013.
PubMed
11) Togo K et al : Aspirin and salicylates modulate IgE-mediated leukotriene secretion in mast cells through a dihydro pyridine receptor-mediated Ca2+ influx. Clin Immunol 131:145-156, 2009.
 
12) Suzuki Y, et al : L-type Ca2+ channels : A new player in the regulation of Ca2+ signaling, cell activation and survival in immune cells. Mol Immunol 47 : 640-648, 2010.
PubMed
13) Asero R et al : Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs. Ann Allergy Asthma Immunol 88 : 468-472, 2002.
PubMed
14) Shin YS, et al : Serum specific IgE to thyroid peroxidase activates basophils in aspirin intolerant urticaria. J Korean Med Sci 30 : 705-709, 2015.
 
15) Aihara M, et al : Food-dependent excerise-induced anaphylaxis : influence of concurrent aspirin administration on skin testing and provocation. Br J Dermatol 146 : 466-472, 2002.
 
16) Fukunaga A, et al : Limited influence of aspirin intake on mast cell activation in patients with fooddependent exercise-induced anphylaxis : comparison using skin prick and histamine release test. Acta Derm Venereol 92 : 480-483, 2012.
 
17) Kim SH, et al : Genetic mechanism of aspirin-induced urticarial/angioedema. Curr Opin Allergy Clin Immunol 6 : 266-270, 2006.
PubMed
18) 長野徹ほか : 特異な皮疹と臨床症状を呈したアスピリン不耐症の1例. 皮膚 34 : 669-672, 1992.
 
19) 堀川達弥 : 自己血清中の因子が関与する蕁麻疹としてのアスピリン蕁麻疹と物理性蕁麻疹. 皮膚病診療 27 : 502-506, 2005.
 
20) 堀川達弥 : アレルギーの救急. MB Derma 229 : 199-205. 2015.
 
21) Morita E, et al : Food-depedndent exercise-induced anaphylaxis. J Dermatol Sci 47 : 109-117, 2007.
PubMed
22) Nizankowska-Mogilnicka E, et al : EAACI/GAL2LEN guideline : aspirin provocation tests for diagnosis of aspirin hypersensitivity. Allergy 62 : 1111-1118, 2007.
PubMed
23) Lambrakis P, et al : Aspirin hypersensitivity and desensitization protocols : implications for cardiac patients. Ther Adv Drug Saf 2 : 263-270, 2011.
PubMed
24) Rijo Y, et al : Aspirin desensitizeation in a patient with NSAIDs-indueced delayed angioedema. J Investig Allergol Clin Immunol 25 : 156-158, 2015.
 
P.65 掲載の参考文献
1) 秀 道広ほか : 蕁麻疹診療ガイドライン. 日皮会誌 121 : 1339-1388, 2011.
 
2) Kontou-Fili K, et al : Physical urticaria : classification and diagnostic guidelines. An EAACI position paper. Allergy 52 : 504-513, 1997.
PubMed
3) 田中稔彦ほか : 広島大学皮膚科外来での蕁麻疹病型別患者数. アレルギー 55 : 134-139, 2006.
 
4) Oda Y, et al : Combined cholinergic urticaria and cold-induced cholinergic urticarial with acquired idiopathic generalized anhidrosis. Allergol Int 64 : 214-215, 2015.
PubMed
5) Zuberbier T, etal : CEAACI/GA (2) LEN/EDF/WAO guideline : management of urticaria. Allergy 64 : 1427-1443, 2009.
 
6) Bentley-Phillips CB, et al : Induced tolerance in cold urticaria caused by cold-evoked histamine release. Lancet 2 : 63-66, 1976.
PubMed
7) Fukunaga A et al : Localized heat urticaria in a patient is associated with a wealing response to heated autologous serum. Br J Dermatol 147:994-997, 2002.
 
8) 後藤典子ほか : アスピリン内服が有効であった温熱蕁麻疹の1例. J Environ Dermatol Cutan Allergol 4 : 214-219, 2010.
 
9) Fukunaga A, et al : The inhibition spectrum of solar urticaria suppresses the wheal-flare response following intradermal injection with photo-activated autologous serum but not with compound 48/80. Photodermatol Photoimmunol Photomed 22 : 129-132, 2006.
 
10) Uetsu N, et al : The clinical and photobiological characteristics of solar urticaria in 40 patients. Br J Dermatol 142 : 32-38, 2000.
PubMed
11) Masuoka E, et al : Successful and long-lasting treatment of solar urticaria with UVA rush hardening therapy. Br J Dermatol 167 : 198-201, 2012.
PubMed
12) Haylett AK, et al : Systemic photoprotection in solar urticaria with ff-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-α-MSH. Br J Dermatol 164 : 407-414, 2011.
 
13) Morioke S, et al : Pressure challenge test and histopathological inspections for 17 Japanese cases with clinically diagnosed delayed pressure urticaria. Arch Dermatol Res 302 : 613-617, 2010.
PubMed
P.70 掲載の参考文献
1) Champion RH, et al : Urticaria and angioedema : A review of 554 patients. Br J Dermatol 81 : 588-597, 1969.
PubMed
2) Zuberbier T, et al : Prevalence of cholinergic urticaria in young adults. J Am Acad Dermatol 31 : 978-981, 1994.
PubMed
3) Sabroe RA : Cholinergic urticaria and exercise-induced anaphylaxis. In : Urticaria and Angioedema 1st ed (ed by Zuberbier T, et al), p81-89, Springer, Heidelberg, 2010.
 
4) Horikawa T, et al : New concepts of hive formation in cholinergic urticaria. Curr Allergy Asthma Rep 9 : 273-279, 2009.
PubMed
5) Kaplan AP, Garofalo J : Identification of a new physically induced urticaria : cold-induced cholinergic urticaria. J Allergy Clin Immunol 68 : 438-441, 1981.
PubMed
6) Oda Y, et al : Combined cholinergic urticaria and cold-induced cholinergic urticarial with acquired idiopathic generalized anhidrosis. Allergol Int 64 : 214-215, 2015.
PubMed
7) Davis RS, et al : Evaluation of a patient with both aquagenic and cholinergic urticaria. J Allergy Clin Immunol 68 : 479-483, 1981.
PubMed
8) Mihara S, Hide M : Adrenergic urticaria in a patient with cholinergic urticaria. Br J Dermatol 158 : 629-631, 2008.
 
9) Takahagi S, et al : Sweat antigen induces histamine release from basophils of patients with cholinergic urticaria associated with atopic diathesis. Br J Dermatol 160 : 426-428, 2009.
PubMed
10) Fukunaga A et al : Steroid treatment can improve the impaired quality of life patients with acquired idiopathic generalized anhidorosis. Br J Dermatol 172 : 537-538, 2015.
PubMed
11) Fukunaga A et al : Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. J Allergy Clin Immunol 116 : 397-402, 2005.
PubMed
12) Sawada Y, et al : Cholinergic urticaria : studies on the muscarinic cholinergic receptor M3 in anhidrotic and hypohidrotic skin. J Invest Dermatol 130 : 2683-2686, 2010.
PubMed
13) Hiragun M, et al : Elevated serum IgE against MGL_1304 in patients with atopic dermatitis and cholinergic urticaria. Allergol Int 63 : 83-93, 2014.
PubMed
14) Sawada Y, et al : Decreased expression of acetylcholine esterase in cholinergic urticaria with hypohidrosis or anhidrosis. J Invest Dermatol 134 : 276-279, 2014.
PubMed
15) Kozaru T, et al : Rapid desensitization with autologous sweat in cholinergic urticaria. Allergol Int 60 : 277-281, 2011.
PubMed
P.74 掲載の参考文献
1) Basketter D, Lahti A : Immediate contact reactions. In : Contact Dermatitis, 5th ed (ed by Johasen JD, et al), p 137-153, Springer, Berlin, 2011.
 
2) Weidinger S, et al : Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 127 : 724-726, 2007.
PubMed
3) Saito M, Nakada T : Contact urticaria syndrome from eye drops : levofloxacin hydrate ophthalmic solution. J Dermatol 40 (2) : 130-131, 2013.
PubMed
4) Creytens K, et al : Contact urticaria syndrome caused by polyaminopropyl biguanide in wipes for intimate hygiene. Contact Dermatitis 71 (5) : 307-309, 2014.
PubMed
5) Vanden Broecke K, et al : Contact urticaria syndrome caused by direct hair dyes in a hairdresser. Contact Dermatitis 71 (2) : 124-126, 2014.
 
6) Inomata N, et al : Case of rice allergy induced by epicutaneous sensitization with rice bran due to the handling rice bran pickles. J Dermatol 39 : 1079-1080, 2012.
 
7) Aalto-Korte K, Makinen-Kiljunen S : Specific immunoglobulin E in patients with immediate persulfate hypersensitivity. Contact Dermatitis 49 : 22-25, 2003.
PubMed
8) Babilas P, et al : Anaphylactic reaction following hair bleaching. Hautarzt 56 : 1151-1155, 2005.
 
9) Krautheim AB, et al : Chlorhexidine anaphylaxis : a case report and review of the literature. Contact Dermatitis 50 : 113-116, 2004.
PubMed
10) Maibach HI, Johnson HL : Contact urticaria syndrome. Contact urticaria to diethyltoluamide (immediate type hypersensitivity). Arch Dermatol 111 : 726-730, 1975.
PubMed
11) Von Krogh G, Maibach HI : The contact urticaria syndrome. Semin Dermatol 1 : 59-66, 1982.
 
12) 日本ラテックスアレルギー研究会, ラテックスアレルギー安全対策ガイドライン作成委員会 : ラテックスアレルギー安全対策ガイドライン 2013～化学物質による遅延型アレルギーを含む～, 協和企画. 2013.
 
13) 松永佳世子 : ブリックテストのすすめ. 日臨皮医会誌 63 : 54-58, 2000.
 
14) Lachapelle JM, Maibach HI : Patch Testing and Prick Testing (A practical guide second edition), p144, Springer-Verlag, Berlin, Heidelberg, 2009.
 
15) Hjorth N, Roed-Petersen J : Occupatioinal protein contact dermatisis in food handlers. Contact Dermatitis 2 : 28-42, 1976.
 
P.82 掲載の参考文献
1) 秀道広ほか : 蕁麻疹・血管性浮腫の治療ガイドライン. 日皮会誌 115 (5) : 703-715, 2005.
 
2) 堀内孝彦 : 遺伝性血管性浮腫 (HAE) ガイドライン 2010-作成の背景とその意義-. 補体 52 (1) : 16-20, 2014.[http://square.umin.ac.jp/compl/HAE/HAEGuideline.html] (遺伝性血管性浮腫のガイドライン2010から)
 
3) 堀内孝彦 : 遺伝性血管性浮腫 (HAE) ガイドライン 改訂2014年版の発表にあたって. 補体 52 (2) : 22-23, 2014.
 
4) 岩本和真ほか : 遺伝性血管性浮腫の全国実態調査. アレルギー 60 (1) : 26-32, 2011.
Medical*Online
5) 池澤善郎 : 血管性浮腫の診断と治療の進歩. 臨床免疫・アレルギー科 55 (3) : 312-321, 2011.
 
6) Grattan C, et al : Management and diagnostic guidelines for urticaria and angio-oedema. Br J Dermatol 144 : 708-714, 2001.
PubMed
7) Nzeako UC, et al : Hereditary angioedema : a broad review for clinicians. Arch Intern Med 161 (20) : 2417-2429, 2001.
PubMed
8) Markovic SN, et al : Acquired C1 esterase inhibitor deficiency. Ann Intern Med 132 (2) : 144-150, 2000.
PubMed
9) Higa S, et al : Autoimmune acquired form of angioedema that responded to danazol therapy. Intern Med 41 (5) : 398-402, 2002.
PubMed
10) Chikama R, et al : Nonepisodic angioedema associated with eosinophilia; report of 4 cases and review of 33 young female patients reported in Japan. Dermatology 197 (4) : 321-325, 1998.
PubMed
11) Donaldson VH, Evans RR : A biochemical abnormality in hereditary angioneurotic edema : Absence of serum inhibitor of C' 1-esterase. Am J Med 35 : 37-44, 1963.
 
12) Agostoni A, et al : Hereditary and acquired angioedema : problems and progress : proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114 (3 Suppl ) : S51-131, 2004.
 
13) Bork K, et al : Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163 (10) : 1229-1235, 2003.
PubMed
14) Bork K, et al : Hereditary angioedema : new findings concerning symptoms, affected organs, and course. Am J Med 119 (3) : 267-274, 2006.
PubMed
15) Bork K, et al : Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 101 (3) : 619-627, 2006.
PubMed
16) Frank MM, et al : Hereditary angioedema : the clinical syndrome and its management Ann Intern Med 84 (5) : 580-593, 1976.
PubMed
17) Agostoni A Cicardi M : Hereditary and acquired C1-inhibitor deficiency : biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71:206-215, 1992.
PubMed
18) Compels MM, et al : C1 inhibitor deficiency : consensus document Clin Exp Immunol 139 (3) : 379-394, 2005.
 
19) Bock SC, et al : Human C1 inhibitor : primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25 (15) : 4292-4301, 1986.
PubMed
20) Davis AE, et al : Human inhibitor of the first component of complement C1 : characterization of cDNA clones and localization of the gene to chromosome 11. Proc Natl Acad Sci USA 83 (10) : 3161-3165, 1986.
PubMed
21) Tosi M, et al : Molecular cloning of human CI inhibitor : sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily. Gene 42 (3) : 265-272, 1986.
 
22) Heiner DC, Blitzer JR : Familial paroxysmal dysfunction of the autonomic nervous system (a periodic disease), often precipitated by emotional stress. Pediatrics 20 (5 Part 1) : 782-793, 1957.
 
23) HAEdb-C1 inhibitor gene mutation database, [http://hae.enzim.hu/stat.php]
 
24) Bork K, et al : Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 356 (9225) : 213-217, 2000.
PubMed
25) Nielsen EW, et al : Hereditary angio-oedema : new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses. J Intern Med 239 (2) : 119-130, 1996.
PubMed
26) Davis AE III : Hereditary angioedema : a current state-of-the-art review, III : mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 100 (1 Suppl 2) : S7-12, 2008.
 
27) Davis AE III, et al : C1 inhibitor : biologic activities that are independent of protease inhibition. Immunobiology 212 (4-5) : 313-323, 2007.
 
28) Nussberger J, et al : Plasma bradykinin in angio-oedema. Lancet 351 (9117) : 1693-1697, 1998.
PubMed
29) Nussberger J, et al : Bradykinin-mediated angioedema. N Engl J Med 347 (8) : 621-622, 2002.
PubMed
30) 池澤善郎ほか : 血管性浮腫 (血管神経性浮腫). 重篤副作用疾患別対応マニュアル第2集, p31-50, (財)日本医薬情報センター, 2008.
 
31) 高島明子ほか : 妊娠継続が困難であった遺伝性血管神経性浮腫 (hereditary angioneurotic edema : HANE) 合併妊娠の1例. 日産婦関東連会報 40 : 437-440, 2003.
 
32) Yamamoto T, et al : Hereditary angioedema in Japan : genetic analysis of 13 unrelated cases. Am J Med Sci 343 (3) : 210-214, 2012.
PubMed
33) Iwamoto K, et al : A large heterozygous deletion including the entire C1 inhibitor gene in a sporadic case of hereditary angio-oedema. Clin Exp Dermatol 37 (1) : 20-23, 2012.
 
34) 池澤善郎ほか : 非ステロイド性抗炎症薬による蕁麻疹/血管性浮腫. 重篤副作用疾患別対応マニュアル第2集, p63-75, (財) 日本医薬情報センター, 2008.
 
35) 池澤善郎ほか : 喉頭浮腫. 重篤副作用疾患別対応マニュアル第2集, p51-62, (財) 日本医薬情報センター, 2008.
 
P.87 掲載の参考文献
1) 斉藤隆三 : 蕁麻疹様血管炎. 最新皮膚科学大系4巻 (玉置邦彦編), p138-141, 中山書店, 2003.
 
2) 秀道広ほか : 蕁麻疹診療ガイドライン. 日皮会誌 121 : 1339-1388, 2011.
 
3) 川名誠司 : 低補体血症性蕁麻疹様血管炎. 日本臨牀 71 (増刊号 1) : 427-432, 2013.
 
4) 寺井千尋 : Immune complex vasculitis 2. Hypocomplementemic urticarial vasculitis (Anti- C1q vasculitis). 最新医学 68 : 203-209, 2013.
Medical*Online
5) 白藤宜紀, 岩月啓氏 : hypocomplementemic urticarial vasculitis (anti- C1q vasculitis). リウマチ科 50 : 471-475, 2013.
 
6) Mehregan DR, et al : Urticarial vasculitis : a histopathologic and clinical review of 72 cases. J Am Acad Dermatol 26 : 441-448, 1992.
 
7) 出光俊郎 : 症例から学ぶ慢性蕁麻疹 蕁麻疹様血管炎の病態と治療. 日本臨床皮膚科医会雑誌 25 : 344-347, 2008.
 
8) Demitsu T, et al : Urticarial vasculitis with hemorrhagic vesicles successfully treated with reserpine. J Eur Acad Dermatol Venereol 22 : 1006-1008, 2008.
PubMed
9) Demitsu T, et al : Urticarial vasculitis presenting as erythema gyratum repens-like eruption. J Eur Acad Dermatol Venereol 23 : 215-217, 2009.
 
10) 飯田絵理ほか : 蕁麻疹様血管炎-ループス腎炎の診断の契機となった1例-. 皮膚科の臨床 50 : 1154-1155, 2008.
 
11) 加倉井真樹ほか : アナフィラクトイド紫斑の経過中に生じた蕁麻疹様血管炎-コルヒチンが有効であった1例. 臨床皮膚科 62 : 27-30, 2008.
 
12) Demitsu T, et al : Neutrophilic, urticaria-like erythema associated with immunoglobulin A monoclonal gammopathy of undetermined significance. J Dermatol 35 : 293-296, 2008.
PubMed
13) Demitsu T, et al : Clinical efficacy of reserpine as add-on therapy to antihistamines in patients with recalcitrant chronic idiopathic urticaria and urticarial vasculitis. J Dermatol 37 : 827-829, 2010.
 
14) Jachiet M, et al ; French Vasculitis Study Group : The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis : data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol 67 : 527-534, 2015.
 
15) Kai AC, et al : Improvement in quality of life impairment followed by relapse with 6-monthly periodic administration of omalizumab for severe treatment-refractory chronic urticaria and urticarial vasculitis. Clin Exp Dermatol 39 : 651-652, 2014.
PubMed
P.91 掲載の参考文献
1) Hartmann K, Henz BM : Mastocytosis : recent advances in defining the disease. Br J Dermatol 144 (4) : 682-695, 2001.
PubMed
2) Horny HP, et al : Mastocytosis. In : WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, 4th ed (ed by Swerdlow SH, et al), p54-63, International Agency of Research and Cancer (IARC), Lyon, 2008.
 
3) 江川裕美ほか : 成人肥満細胞症の1例 1995年以降の本邦報告例36例についての臨床統計を含めて. 臨床皮膚科 61 (1) : 11-14, 2007.
 
4) 古橋卓也, 森田明理 : 先天性皮膚疾患肥満細胞症. Derma. 164号 : 197-202, 2010.
 
5) Bodemer C, et al : Pediatricmastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 130 (3) : 804-815, 2010.
PubMed
6) Longley BJ Jr, et al : Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 328 (18) : 1302-1307, 1993.
PubMed
7) 出光俊郎, 井上多恵 : 肥満細胞症 (肥満細胞腫). 最新皮膚科学体系 13, p341-354, 中山書店, 2004.
 
8) Longley J, et al : The mast cell and mast cell disease. J Am Acad Dermatol 32 (4) : 545-561, 1995.
PubMed
9) 朝比奈昭彦 : 色素性蕁麻疹. 最新皮膚科学体系 13, p263-267, 中山書店, 2004.
 
10) Brockow K : Urticaria pigmentosa. Immunol Allergy Clin North Am 24 (2) : 287-316, 2004.
PubMed
11) 今山修平 : 基本の Pathology (細胞) 浸潤 (cellular) infiltrate : 肥満細胞mast cell. Visual Dermatology 9 (10) : 1106-1111, 2010.
 
12) 浅井康一ほか : 肥満細胞症 (色素性蕁麻疹) の小児2例. 小児科臨床 62 (11) : 2427-2432, 2009.
Medical*Online
13) Pardanani A : Systemic mastocytosis in adults : 2015 update on diagnosis, risk stratification, and management. Am J Hematol 90 (3) : 250-262, 2015.
PubMed
14) Brockow K, et al : Anaphylaxis in patients with mastocytosis : a study on history, clinical features and risk factors in 120 patients. Allergy 63 (2) : 226-232, 2008.
 
15) Koide T, et al : Systemic mastocytosis and recurrent anaphylactic shock. Lancet 359 (9323) : 2084, 2002.
PubMed
P.96 掲載の参考文献
1) Schnitzler L, et al : Urticaire chronique, lesions osseuses, macroglobulinemie IgM : maladie de Waldenstrom? 2 presentation. Bull Soc Fr Dermatol Syphil 81 : 363, 1974.
 
2) 秀道広ほか : 蕁麻疹診療ガイドライン. 日皮会誌 121 : 1339-1388, 2011.
 
3) Mc Dermott M F, et al : Germline mutations in the extracellular domains of the 55kDa TNF receptor. TNFR1. Define a family of dominantly inherited autoinflammatory syndromes. Cell 97 : 133-144, 1999.
 
4) Simon A, et al : Schnitzler's syndrome : diagnosis, treatment, and follow-up. Allergy 68 : 562-568, 2013.
 
5) de Koning HD, et al : Myeloid lineage-restricted somatic mosaicism of NLRP3 mutations in patients with variant Schnitzler syndrome. J Allergy Clin Immunol 135 : 561-564, 2015.
PubMed
6) Nakamura Y, et al : Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med 206 : 1037-1046, 2009.
PubMed
7) de Koning HD, et al : Mast-cell interleukin-1β, neutrophil interleukin-17 and epidermal antimicrobial proteins in the neutrophilic urticarial dermatosis in Schnitzler's syndrome. Br J Dermatol 172 : 448-456, 2015.
 
8) Lipsker D, et al : The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore) 80 : 37-44, 2001.
PubMed
9) de Koning HD, et al : Schnitzler syndrome : beyond the case reports : review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum 37 : 137-148, 2007.
PubMed
10) Demitsu T, et al : Neutrophilic, urticaria-like erythema associated with immunoglobulin A monoclonal gammopathy of undetermined significance. J Dermatol 35 : 293-296, 2008.
PubMed
11) Pesek R, Fox R : Successful treatment of Schnitzler syndrome with Canakinumab. Cutis 94 : E11- E12, 2014.
 
12) Krause K, et al : Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome : an open-label study. Allergy 67 : 943-950, 2012.
PubMed
13) Krause K, et al : Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 129 : 848-850, 2012.
PubMed
14) 黒田裕行ほか : インフリキシマブが奏効したIgG-λ型M蛋白血症を伴う亜型Schnitzler症候群の1例. リウマチ科 47 : 446-452, 2012.
 
P.101 掲載の参考文献
1) Hoffman HM, et al : Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle- Wells syndrome. Nat Genet 29 : 301-305, 2001.
PubMed
2) Feldmann J, et al : Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 71 : 198-203, 2002.
PubMed
3) Agostini L, et al : NALP3 formsan IL-1-beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20 : 319-325, 2004.
 
4) Tanaka N, et al : High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome : results of an International Multicenter Collaborative Study. Arthritis Rheum 63 : 3625-3632, 2011.
PubMed
5) Nakamura Y, et al : Mast cells mediate neutrophil recruitment and vascular leakage through the NLRP3 inflammasome in histamine-independent urticaria. J Exp Med 206 : 1037-1046, 2009.
PubMed
6) Nakamura Y, et al : Critical role for mast cells in interleukin-1β-driven skin inflammation associated with an activating mutation in the nlrp3 protein. Immunity 37 : 85-95, 2012.
 
7) Meng G, et al : A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30 : 860-874, 2009.
PubMed
8) Brydges SD, et al : Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30 : 875-887, 2009.
 
9) Yokoyama K, et al : Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway. Arthritis Rheumatol 67 : 302-314, 2015.
PubMed
10) Aksentijevich I, et al : De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID) : a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46 : 3340-3348, 2002.
PubMed
11) Jeru I, et al : Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 105 : 1614-1619, 2008.
PubMed
12) Romberg N, et al : Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet 46 : 1135-1139, 2014.
PubMed
13) Canna SW, et al : An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet 46 : 1140-1146, 2014.
PubMed
14) Kitamura A, et al : An inherited mutation in NLRC4 causes autoinflammation in human and mice. J Exp Med 211 : 2385-2396, 2014.
PubMed
15) Gandhi C, et al : Familial atypical cold urticaria : description of a new hereditary disease. J Allergy Clin Immun 124 : 1245-1250, 2009.
PubMed
16) Quartier P, et al : Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360 : 2416-2425, 2009.
PubMed
17) Hawkins PN, et al : Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 348 : 2583-2584, 2003.
PubMed
18) Aksentijevich I, et al : An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 360 : 2426-2437, 2009.
PubMed
19) Hoffman HM, et al : Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364 : 1779-1785, 2004.
PubMed
P.106 掲載の参考文献
1) Rudikoff D, Lebwohl M : Atopic dermatitis. Lancet 351 (9117) : 1715-1721, 1998.
PubMed
2) Baba M, Yamaguchi K : "The allergy march" : Can it be prevented. Allergy Clin Immunol News 1 : 71-73, 1989.
 
3) Alanne S, et al : Quality of life in infants with atopic dermatitis and healthy infants : a follow-up from birth to 24 months. Acta Paediatr 100 (8) : e65-70, 2011.
PubMed
4) アトピー性皮膚炎診療ガイドライン2015作成委員会 : アトピー性皮膚炎診療ガイドライン 2015, p22, 協和企画, 2015.
 
5) Odhiambo JA, et al ; ISAAC Phase Three Study Group : Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 124 (6) : 1251-1258, e23, 2009.
 
6) Deckers IA, et al : Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010 : a systematic review of epidemiological studies. PloS One7 (7) : e39803, 2012.
 
7) 文部科学省 : 平成26年度学校保健統計調査 (確定値) の公表について, 2015. [http://www.mext.go.jp/component/b_menu/other/_icsFiles/afieldfile/2015/03/27/1356103_1.pdf]
 
8) De Benedetto A, et al : Atopic dermatitis : a disease caused by innate immune defects? J Invest Dermatol 129 (1) : 14-30, 2009.
PubMed
9) Kuo IH, et al : The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol 131 (2) : 266-278, 2013.
PubMed
10) Nemoto-Hasebe I, et al : FLG mutation p.Lys4021X in the C-terminal imperfect filaggrin repeat in Japanese patients with atopic eczema. Br J Dermatol 161 (6) : 1387-1390, 11, 2009.
 
11) Kunz B, et al : Clinical validation and guidelines for the SCORAD index : consensus report of the European Task Forceon Atopic Dermatitis. Dermatology 195 (1) : 10-19, 1997.
 
12) Hanifin JM, et al : The eczema area and severity index (EASI) : assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 10 (1) : 11-18, 2001.
PubMed
13) Foley P, et al : The frequency of common skin conditions in preschool-aged children in Australia : seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol 139 (3) : 318-322, 2003.
PubMed
14) Yaghmaie P, et al : Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol 131 (2) : 428-433, 2013.
PubMed
15) Long CC, et al : A practical guide to topical therapy in children. Br J Dermatol 138 (2) : 293-296, 1998.
PubMed
P.112 掲載の参考文献
1) 古江増隆ほか : アトピー性皮膚炎診療ガイドライン. 日皮会誌 119 : 1515-1534, 2009.
 
2) 日本アレルギー学会アトピー性皮膚炎ガイドライン専門部会 : アトピー性皮膚炎ガイドライン 2012 (片山一朗, 河野陽一監), 協和企画, 2012.
 
3) Hirota T, et al : Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet 44 : 1222-1226, 2012.
PubMed
4) Kabashima K : New concept of the pathogenesis of atopic dermatitis : interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 70 : 3-11, 2013.
 
5) Dillon SR, et al : Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5 : 752-760, 2004.
PubMed
6) Tominaga M, Takamori K : Itch and nerve fibers with special reference to atopic dermatitis : therapeutic implications. J Dermatol 41 : 205-212, 2014.
PubMed
6) Wilson SR, et al : The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155 : 285-295, 2013.
PubMed
8) Grewe M, et al : Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 105 : 407-410, 1995.
PubMed
9) 中原剛士 : アトピー性皮膚炎の最前線抗炎症 : 外用剤. MB Derma 224 : 45-51, 2014.
 
10) Schmitt J, et al : Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema : systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 164 : 415-428, 2011.
PubMed
11) Williams HC, Strachan DP : The natural history of childhood eczema : observations from the British 1958 birth cohort study. Br J Dermatol 39 : 834-839, 1998.
PubMed
12) Ricci G, et al : Long-term follow-up of atopic dermatitis : retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol 55 : 765-771, 2006.
PubMed
P.117 掲載の参考文献
1) Adachi J, et al : Demonstration of sweat allergy in cholinergic urticaria. J Dermatol Sci 7 : 142-149, 1994.
PubMed
2) Adachi K, Aoki T : IgE antibody to sweat in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 144 : 83-87, 1989.
PubMed
3) Hide M, et al : IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis. Acta Derm Venereol 82 : 335-340, 2002.
PubMed
4) Tanaka A, et al : Semi-purification of the immunoglobulin E-sweat antigen acting on mast cells and basophils in atopic dermatitis. Exp Dermatol 15 : 283-290, 2006.
PubMed
5) Takahagi S, et al : Sweat antigen induces histamine release from basophils of patients with cholinergic urticaria associated with atopic diathesis. Br J Dermatol 160 : 426-428, 2009.
PubMed
6) Hiragun T, et al : Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. J Allergy Clin Immunol 132 : 608-615, 2013.
PubMed
7) Simon- Nobbe B, et al : The spectrum of fungal allergy. Int Arch Allergy Immunol 145 : 58-86, 2008.
PubMed
8) Hiragun M, et al : Elevated serum IgE against MGL_1304 in patients with atopic dermatitis and cholinergic urticaria. Allergol Int 63 : 83-93, 2014.
PubMed
9) 亀好良一ほか : アトピー性皮膚炎に対する学校でのシャワー浴の効果. アレルギー 57 : 130-137, 2008.
Medical*Online
10) Akaza N, et al : Malassezia globosa tends to grow actively in summer conditions more than other cutaneous Malassezia species. J Dermatol 39 : 613-616, 2012.
PubMed
11) 信藤肇ほか : アトピー性皮膚炎に対するタンニン酸配合湯上り製剤およびスプレー剤の臨床的有用性の検討. アレルギー 60 : 33-42, 2011.
Medical*Online
12) 田中稔彦ほか : 汗の減感作療法が奏効したコリン性蕁麻疹の1例. アレルギー 56 : 54-57, 2007.
Medical*Online
13) Kozaru T, et al : Rapid desensitization with autologous sweat in cholinergic urticaria. Allergol Int 60 : 277-281, 2011.
PubMed
P.121 掲載の参考文献
1) 日本皮膚科学会接触皮膚炎診療ガイドライン委員会 : 接触皮膚炎診療ガイドライン. 日皮会誌 119 (9) : 1757-1793, 2009.
 
2) 西岡清 : アレルギー性接触皮膚炎. 最新皮膚科学大系 3 (玉置邦彦ほか編), p13-18, 中山書店, 2002.
 
3) Schornick LP, et al : Mice deficientin IL-1β manifest impaired contact hypersensitivity to trinitrochlorobenzene. J Exp Med 183 : 1427-1436, 1996.
 
4) Enk AH, Katz SI : Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 89 : 1398-1402, 1992.
PubMed
5) Grabbe S, Schwarz T : Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 19 : 37-44, 1998.
 
6) Yokozeki H, et al : STAT6 is essential in the induction of contact sensitvity. J Exp Med 191 : 995-1004, 2000.
 
7) Takeshita K, et al : CRTH2 is a prominent effector in contact hypersensitivity-induced neutrophil inflammation. Int Immunol 16 : 947-959, 2004.
PubMed
8) Satoh T, et al : Prostaglandin D2 plays an essential role in chronic allergic inflammation of the skin via CRTH2 receptor. J Immunol 177 (4) : 2621-2629, 2006.
PubMed
9) Yokozeki H, et al : Th2 cytokine, IgE and mast cells play a crucial role in the induction of paraphenylenediamine-induced contact hypersensitivity in mice. Clin Exp Immunol 132 : 385-392, 2003.
PubMed
10) Honda T, et al : Update of immune events in the murine contact hypersensitivity model : toward the understanding of allergic contact dermatitis. J Invest Dermatol 133 : 303-315, 2013.
PubMed
11) Spergel JM, et al : Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. J Clin Invest 101 : 1614-1622, 1998.
PubMed
12) Nakae S, et al : Antigen-specific T cell sensitization is impaired in IL-17 deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 178 : 375-387, 2002.
 
13) Iwakura Y, et al : The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226 : 57-79, 2008.
PubMed
14) Ring S, et al : CD4+ CD25+ regulatory T cells suppress contact hypersensitivity reaction by blocking influx of effector T cells into inflamed tissues. Eur J Immunol 36 : 2981-2992, 2006.
PubMed
P.130 掲載の参考文献
1) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監修) : 喘息予防・管理ガイドライン 2012, p3, 協和企画, 2012.
 
2) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監修) : 喘息予防・管理ガイドライン 2015, p2, 協和企画, 2015.
 
3) 西間三馨ほか : 西日本小学児童におけるアレルギー疾患有症率調査-1992, 2002. 2012年の比較-. 日本小児アレルギー学会誌 27 : 149-169, 2013.
Medical*Online
4) Fukutomi Y, et al : Time trend in the prevalence of adult asthma in Japan : findings from population-based surveys in Fujieda City in 1985, 1999, and 2006. Allergol Int 60 : 443-448, 2011.
PubMed
5) 厚生労働省平成20年患者調査 [http://www.mhlw.go.jp/toukei/saikin/hw/kanja/08/index.html].
 
6) Kobayashi T, et al : An essential role of mast cells in Hie development of airway hyperresponsiveness in a murine asthma model. J Immunol 164 : 3855-3861. 2000.
 
7) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監修) : 喘息予防・管理ガイドライン 2015, p58, 協和企画, 2015.
 
8) Grainge CL, et al : Effect of bronchoconstriction on airway remodeling in asthma N Engl J Med 364 : 2006-2015, 2011.
PubMed
9) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監修) : 喘息予防・管理ガイドライン 2015, p59, 協和企画, 2015.
 
10) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監修) : 喘息予防・管理ガイドライン 2012, p4, 協和企画, 2012.
 
11) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監修) : 喘息予防・管理ガイドライン 2015, p140, 協和企画, 2015.
 
12) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監修) : 喘息予防・管理ガイドライン 2015, p155, 協和企画, 2015.
 
13) Ohta K, et al : Prevalence and impact of rhinitis in asthma. SACRA, a cross-sectional nation-wide study in Japan. Allergy 66 : 1287-1295, 2011.
 
14) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監修) : 喘息予防・管理ガイドライン 2015, p238, 協和企画, 2015.
 
P.137 掲載の参考文献
1) 日本小児アレルギー学会 : 小児気管支喘息治療・管理ガイドライン 2012, 協和企画, 2011.
 
2) Asher MI, et al : International Study of Asthma and Allergies in Childhood (ISAAC) : rationale and methods. Eur Respir J 8 : 483-491, 1995.
 
3) 西間三馨ほか : 西日本小学児童におけるアレルギー疾患有症率調査-1992, 2002. 2012年の比較-. 日本小児アレルギー学会誌 27 : 149-169, 2013.
Medical*Online
4) van den Toorn LM, et al : Asthma remission : does it exist? Curr Opin Pulm Med 9 : 15-20, 2003.
PubMed
5) Tamari M, et al : Genome-wide association studies of allergic diseases. Allergol Int 62 : 21-28, 2013.
 
6) Bach JF : The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 : 911-920, 2002.
PubMed
7) von Hertzen L, et al : Natural immunity. Biodiversity loss and inflammatory diseases are two global megatrends that might be related. EMBO Rep 12 : 1089-1093, 2011.
PubMed
8) Ege MJ, et al : Exposure to environmental microorganisms and childhood asthma. N Engl J Med 364 : 701-709, 2011.
PubMed
9) Caliskan M, et al : Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. N Engl J Med 368 : 1398-1407, 2013.
PubMed
10) Rava M, et al : Gene-environment interactions in the study of asthma in the postgenomewide association studies era. Curr Opin Allergy Clin Immunol 15 : 70-78, 2015.
 
11) Lambrecht BN, Hammad H : The immunology of asthma. Nat Immunol 16 : 45-56, 2015.
PubMed
12) Sharma S, et al : Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program. J Allergy Clin Immunol 122:921-928, e4, 2008.
 
13) Bisgaard H, et al : Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 171 : 315-322, 2005.
PubMed
14) Price DB, et al : Effect of montelukast on lung function in asthma patients with allergic rhinitis : analysis from the COMPACT trial. Allergy 61 : 737-742, 2006.
PubMed
15) Barnes PJ : Theophylline : new perspectives for an old drug. Am J Respir Crit Care Med 167 : 813-818, 2003.
PubMed
P.142 掲載の参考文献
1) 思春期及び20歳代早期の喘息. 喘息予防・管理ガイドライン 2012, p 214-215, 協和企画, 2012.
 
2) 日本小児アレルギー学会 : 思春期-青年期喘息. 小児気管支喘息治療-管理ガイドライン 2012, p 166-175, 協和企画, 2012.
 
3) 福冨友馬ほか : 本邦における病院通院成人喘息患者の実態調査-国立病院機構ネットワーク共同研究-. アレルギー 59 (1) : 37-46, 2010.
Medical*Online
4) Riedler J, et al : Exposure to farming in early life and development of asthma and allergy : a cross-sectional survey. Lancet 358 (9288) : 1129-1133, 2001.
PubMed
5) Ladrup Carlsen KC, et al : Lung function trajectories from birth through puberty reflect asthma phenotypes with allergic comorbidity. J Allergy Clin Immunol 134 (4) : 917-923, 2014.
 
6) Taylor DR et al : Asthma in remission : can relapse in early adulthood be predicted at 18 years of age? Chest 127 (3) : 845-850, 2005.
PubMed
7) Moore wc, et al : Identification of asthma phenolypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 181 (4) : 315-323, 2010.
PubMed
8) Sekiya K et al : Age-specific characteristics of inpatients with severe asthma exacerbation. Allergol Int 62 (3) : 331-336, 2013.
PubMed
P.147 掲載の参考文献
1) Connolly MJ, et al : Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax 47 : 410-413, 1992.
PubMed
2) National Heart, Lung and Blood Institute, NAEPP Working Group Report : Considerations for Diagnosing and Managing Asthma in the Elderly. National Institutes of Health pub. No.96-3662, Bethesda, 1996.
 
3) Diagnosis of Diseases of Chronic Airflow Limitation : Asthma , COPD and Asthma -COPD Overlap Syndrome (ACOS), 2014. [http://www.ginasthma.org] [http://www.goldcopd-org]
 
4) Matsunaga K, et al : Importance of assistance by caregivers for inhaled corticosteroid therapy in elderly patients with asthma. J Am Geriatr Soc 54 : 1626-1627, 2006.
PubMed
5) Lipworth BJ : Systemic adverse effects of inhaled corticosteroid therapy : A systematic review and meta-analysis. Arch Intern Med 159:941-955, 1999.
PubMed
6) Newman SP : Inhaler treatment option in COPD. Eur Respire Rev 14 : 102-108, 2005.
 
7) Global Initiative for Asthma Management and Prevention. NHLBI/WHO Workshop Report National Institutes Heart, Lung, and Blood Instite, p56, 2006.
 
8) Marcus P, et al : Use of nebulized inhaled corticosteroids among older adult patients : an assessment of outcomes. Ann Allercv Asthma Immunol 96 : 736-743. 2006.
PubMed
9) 堀口高彦ほか : 高齢者喘息の特徴を考慮した治療ナビゲーション-吸入薬の手技確認と理解度に関する検討-. Allergology & Immunology 17 (6) : 108-115, 2010.
 
10) 東田有智ほか : 正しい吸入療法を身につけよう, 独立行政法人環境再生保全機構, 2015.
 
11) Tim R, et al : Cardiac arrhythmias during acute exacerbations of chronic airflow limitation : effect of fall in plasma potassium concentration induced by nebulised beta 2-agonist therapy. Postgrad Med J 65 : 449-452, 1989.
 
12) Price D, et al : Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 364 : 1695-1707, 2011.
PubMed
13) Nielsen-Kudsk JE, et al : Effects of pinacidil on guinea-pig airway smooth muscle contracted by asthma mediators. Eur J Pharmacol 157 : 221-226, 1988.
PubMed
14) 喘息予防・管理ガイドライン 2015 (JGL2015) (一般社団法人日本アレルギー学会喘息ガイドライン専門部会編), 協和企画, 2015.
 
15) Ullah MI, et al : Influence of age on response to ipratropium and salbutamol in asthma Thorax 36 : 523-529, 1981.
PubMed
16) Stoodley RG, et al : The role of ipratropium bromide in the emergency management of acute asthma exacerbation : a metaanalysis of randomized clinical trials. Ann Emerg Med 34 : 8-18, 1999.
PubMed
17) Gross NJ, et al : Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 139 : 1188-1191, 1989.
PubMed
18) Barros MJ. Rees PJ : Bronchodilator responses to sulbutamol followed by ipratropium bromide in partially reversible airflow obstruction. Respir Med 84 : 371-375, 1990.
 
19) Gong H Jr, et al : Effects of oral cetirizine, a selective H1 antagonist, on allergen- and exercise-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 85 : 632-641, 1990.
PubMed
20) Simons FE, Simons KJ : The pharmacology and use of H1-resceptor-antagonist drugs. N Engl J Med 330 : 1663-1670, 1994.
 
P.153 掲載の参考文献
1) 濱崎雄平ほか : 小児気管支喘息治療・管理ガイドライン 2012, 2011.
Medical*Online
2) Jones RS, et al : The effect of exercise on ventilatory function in the child with asthma Br J Dis Chest 56 : 78-86, 1962.
PubMed
3) Milgrom H, Taussig LM : Keeping children with exercise-induced asthma active. Pediatrics 104 : e38, 1999.
PubMed
4) Becker JM, et al : Asthma deaths during sports : report of a 7-year experience. J Allergy Clin Immunol 113 : 264-267, 2004.
PubMed
5) Hallstrand TS, et al : Inflammatory basis of exerase-induced bronchoconstriction. Am J Respir Crit Care Med 172 : 679-686, 2005.
PubMed
6) Tan RA, Spector SL : Exercise-induced asthma : diagnosis and management Ann Allergy Asthma Immunol 89 : 226-235, 2002.
PubMed
7) Lai Y, et al : Increased density of intraepithelial mast cells in patients with exercise-induced bronchoconstriction regulated through epithelially derived thymic stromal lymphopoietin and IL-33. J Allergy Clin Immunol 133 : 1448-1455, 2014.
PubMed
8) 板澤寿子ほか : 小児喘息コントロールテスト (Childhood Asthma Control Test : C-ACT) の有用性と問題点. 日小児難治喘息・アレルギー会誌 9 : 30-35, 2011.
 
9) 西牟田敏之ほか : JAPANESE PEDIATRIC ASTHMA CONTROL PROGRAM (JPAC) の有用性に関する検討. 日小児アレルギー会誌 22 : 135-145. 2008.
Medical*Online
10) Kano S, et al : Change in osmolarity of disodium cromoglycate solution and protection against exercise-induced bronchospasm in children with asthma Eur Respir J 9 : 1891-1895, 1996.
PubMed
11) Reiff DB, et al : The effect of prolonged submaximal warm-up exercise on exercise-induced asthma. Am Rev Respir Dis 139 : 479-484, 1989.
PubMed
12) Bateman ED, et al : Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 : 836-844. 2004.
PubMed
13) Pauwels RA, et al : Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 : 1405-1411, 1997.
 
14) Dahlen SE, et al : +eukotrienes are potent constrictors of human bronchi Nature 288 : 484-486, 1980.
 
15) Kikawa Y, et al : Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol 89 : 1111-1119, 1992.
PubMed
16) Reiss TF, et al : Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast a cysteinyl leukotriene receptor antagonist Thorax 52 : 1030-1035, 1997.
PubMed
17) Leff JA, et al : Montelukast a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 339 : 147-152, 1998.
PubMed
18) 勝呂元ほか : Pranlukast Hydrate 2週間投与による運動誘発喘息抑制効果の検討. アレルギー 49 : 646-652, 2000.
Medical*Online
19) Makker HK, et al : The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 147 : 1413-1418, 1993.
PubMed
20) Jones RM, et al : Bronchodilator effects of disodium cromoglycate in exercise-induced bronchoconstriction. Br J Dis Chest 77 : 362-369, 1983.
PubMed
21) Obata T, et al : Preventive effect and duration of action of disodium cromoglycate and procaterol on exercise-induced asthma in asthmatic children. Ann Allergy 70 : 123-126, 1993.
PubMed
22) Storm van's Gravesande K, et al : Preventive effect of 2 and 10 mg of sodium cromoglycate on exercise-induced bronchoconstriction. Eur J Pediatr 159 : 759-763, 2000.
PubMed
23) Evans DJ, et al : A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337 : 1412-1418. 1997.
 
24) Lipworth BJ, et al : Effects of adding a leukotriene antagonist or a long-acting beta (2)-agonist in asthmatic patients with the glycine-16 beta (2)-adrenoceptor genotype. Am J Med 109 : 114-121, 2000.
 
25) Simons FE, et al : Montelukast added to budesonide in children with persistent asthma : a randomized, double-blind, crossover study. J Pediatr 138 : 694-698, 2001.
PubMed
26) Lofdahl CG, et al : Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ 319 : 87-90, 1999.
PubMed
27) Tamaoki J, et al : Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 155 : 1235-1240. 1997.
 
28) Busse XV, et al : Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 103 : 1075-1080, 1999.
 
29) Fish JE, et al : Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 120 : 423-430, 2001.
PubMed
30) Nelson HS, et al : Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast J Allergy Clin Immunol 106 : 1088-1095, 2000.
PubMed
31) Wilson AM, et al : Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 119 : 1021-1026, 2001.
 
32) Stelmach I, et al : Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol 121 : 383-389, 2008.
PubMed
33) 杉本日出雄ほか : EIB (exercise-induced bronchospasm) に及ぼすprocaterol aerosolの効果. 小児科診療 52 : 1447-1450, 1989.
 
P.158 掲載の参考文献
1) Koyanagi K, et al : An analysis of factors that exacerbate asthma based on a Japanese questionnaire. Allergol Int 58 : 519-527, 2009.
PubMed
2) Weiler JM, et al : Asthma in United States Olympic athletes who participated in the 1996 Summer Games. J Allergy Clin Immunol 102 : 722-726, 1998.
 
3) Weiler JM, Ryan EJ 3rd : Asthma in United States Olympic athletes who participated in the 1998 Olympic winter games. J Allergy Clin Immunol 106 : 267-271, 2000.
 
4) Tanaka J, et al : Pulmonary function analysis of Japanese athletes : possibly even more asthmatics in the field. Allergol Int 59 : 53-57, 2010.
PubMed
5) 小屋俊之ほか : アスリートを対象とした気管支喘息の解析. 臨床免疫・アレルギー科 53 : 61-68, 2010.
 
6) Anderson SD, Kippelen P : Airway injury as a mechanism for exerase-induced bronchoconstriction in elite athletes. J Allergy Clin Immunol 122 : 225-235; quiz 236-237, 2008.
 
7) Sue-Chu M : Winter sports athletes : Long-term effects of cold air exposure. Br J Sports Med 46 : 397-401, 2012.
PubMed
8) 財団法人日本アンチドーピング機構 : 医師のためのTUE申請ガイドブック 2015, 2015.
 
9) Boulet LP, O'Byrne PM : Asthma and exercise-induced bronchoconstriction in athletes. N Engl J Med 372 : 641-648, 2015.
PubMed
10) Parsons JP, et al; American Thoracic Society Subcommittee on Exercise-induced B : An official American Thoracic Society clinical practice guideline : exercise-induced bronchoconstriction. Am J Respir Crit Care Med 187 : 1016-1027, 2013.
 
11) Hoshino Y, et al : Effect of inhaled corticosteroids on bronchial asthma in Japanese athletes. Allergol Int 64 : 145-149, 2015.
PubMed
12) Koya T, et al : Effect of ciclesonide on bronchial asthma in athletes. J Asthma 46 : 1032-1036, 2009.
PubMed
13) Helenius I, et al : Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma : A 5-year prospective follow-up study of 42 highly trained swimmers-J Allergy Clin Immunol 109 : 962-968, 2002.
 
14) Bougault V, et al : Airway hyperresponsiveness in elite swimmers : Is it a transient phenomenon? J Allergy Clin Immunol 127 : 892-898, 2011.
PubMed
15) Fitch KD, et al : Asthma and the elite athlete : summary of the International Olympic Committee's consensus conference, Lausanne, Switzerland, January 22-24, 2008. J Allergy Clin Immunol 122 : 254-260, 260.el-7, 2008.
 
P.164 掲載の参考文献
1) Stevenson DD, Szczeklik A : Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 118 : 773-786, 2006.
PubMed
2) 谷口正実 : アスピリン喘息 (NSAIDs過敏喘息). 日内会誌 102 (6) : 1426-1432, 2013.
 
3) Kowalski ML et al : Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)-classification, diagnosis and management : review of the EAACI/ENDA (#) and GA2LEN/HANNA*. Allergy 66 : 818-829, 2011.
PubMed
4) Szczeklik A, Sanak M : The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 32 : 339-342, 2002.
PubMed
5) Morales DR et al : Safely risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors : Meta-analysis of controlled clinical trials. J Allergy Clin Immunol 134 (1) : 40-45, 2014.
 
6) 福冨友馬ほか : 本邦における病院通院成人喘息患者の実態調査 国立病院機構ネットワーク共同研究. アレルギー 59 : 37-46, 2010.
Medical*Online
7) Rajan JP, et al : Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients : A meta-analysis of the literature. J Allergy Clin Immunol 135 : 676-681, 2015.
PubMed
8) Szczeklik A, et al : Natural history of aspirin-induced asthma MANE Investigators. European Network on Aspirin-Induced Asthma . Eur Respir J 16 : 432-436, 2000.
 
9) Mascia K, et al : Aspirin sensitivity and severity of asthma : evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 116 : 970-975, 2005.
PubMed
10) Group TES : Hie ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 22 : 470-477. 2003.
 
11) Moore WC, et al : Characterization of the severe asthma phenotype by the National Heart Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 119 : 405-413, 2007.
PubMed
12) Fukutomi Y, et al : Obesity and aspirin intolerance are risk factors for difficult-to-treat asthma in Japanese non-atopic women. Clin Exp Allergy 42 : 738-746, 2012.
PubMed
13) Virchow C, et al : Intolerance to tartrazine in aspirin-induced asthma : results of a multicenter study. Respiration 53 : 20-23. 1988.
PubMed
14) Abo M, Fujimura M : Tacholiquine inhalation and aspirin-induced asthma. Chest 119 : 670, 2001.
PubMed
15) Christie PE, et al : Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 143 (5 Pt 1) : 1025-1029, 1991.
 
16) Kawagishi Y, et al : Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 109 : 936-942, 2002.
PubMed
17) Higashi N, et al : Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria) : Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol 113 : 277-283, 2004.
PubMed
18) Higashi N, et al : Profile of eicosanoid generation in aspirin-intolerant asthma and anaphylaxis assessed by new biomarkers. J Allergy Clin Immunol 125 : 1084-1091, 2010.
PubMed
19) Yamaguchi H, et al : Urinary concentrations of 15-epimer of lipoxin A (4) are lower in patients with aspirin-intolerant compared with aspirin-tolerant asthma. Clin Exp Allergy 41 : 1711-1718, 2011.
PubMed
20) Picado C, et al : Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 160 : 291-296, 1999.
PubMed
21) Mitsui C, et al : Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2015. pii : S0091-6749 (15) 00795-2. [Epub ahead of print]
 
22) 谷口正実 : 気道過敏性検査とアスピリン負荷試験の実際. アレルギー 58 : 87-96, 2009.
Medical*Online
23) Settipane RA, et al : Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 96 : 480-485, 1995.
PubMed
24) 谷口正実 : アスピリン喘息における点滴静注ステロイド薬の使い方. アレルギーの臨床 23 : 87-89, 2003.
 
25) Szczeklik A : Hypersensitivity to systemic corticosteroids in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 128 : 904-905, 2011.
PubMed
26) Taniguchi M, Sato A : Aspirin-induce asthmatics have cross-sensitivity with the steroid succinate esters. Abstracts of the XIII Congress of Allergy Cin Immunol, Montreux, Switzerland, 1998 ; abst 358.
 
27) Dahlen SE, et al : Improvement of aspirin-intolerant asthma by montelukast a leukotriene anagonist : a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 165 : 9-14, 2002.
 
28) Dallien B : Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med 161 (2 Pt 2) : S137-141, 2000.
 
29) Micheletto C, et al : Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics : a controlled study vs placebo. Allergy 59 : 289-294, 2004.
PubMed
30) 妹川史朗ほか : クロモグリク酸ナトリウムは発作寛解期のアスピリン喘息患者に対して急性気管支拡張効果を有する. アレルギー 41 : 1515-1520, 1992.
Medical*Online
31) Meltzer EO, Hamilos DL : Rhinosinusitis diagnosis and management for the clinician : a synopsis of recent consensus guidelines. Mayo Clin Proc 86 (5) : 427-443, 2011.
PubMed
P.170 掲載の参考文献
1) Braman SS, et al : Chronic cough as the sole presenting manifestation of bronchial asthma. N Engl J Med 300 : 633-1637, 1979.
PubMed
2) 咳嗽に関するガイドライン第2版, 日本呼吸器学会「咳嗽に関するガイドライン」作成委員会 (委員長河野茂) , メディカルレビュー社, 2012.
 
3) Niimi A, et al : Eosinophilic airway disorders associated with chronic cough. Pulm Pharmacol Ther 22 : 114-120, 2009.
PubMed
4) Fujimura M, et al : Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. Clin Exp Allergy 30 : 41-47, 2000.
PubMed
5) Fujimura M, et al : Comparison of atopic cough with cough variant asthma : is atopic cough a precursor of asthma? Thorax 58 : 14-18, 2003.
PubMed
6) Niimi A : Geography and cough aetiology. Pulm Pharmacol Ther 20 : 383-387, 2007.
PubMed
7) Matsumoto H, et al : Prevalence and clinical manifestations of gastro-oesophageal reflux-assodated chronic cough in the Japanese population. Cough 3 : 1, 2007.
PubMed
8) Takemura M, et al : Atopic features of cough variant asthma and classic asthma with wheezing. Clin Exp Allergy 37 : 1833-1839, 2007.
PubMed
9) Tajiri T, et al : Prevalence and clinical relevance of allergic rhinitis in patients with classic asthma and cough variant asthma. Respiration 87 : 211-218, 2014.
PubMed
10) Niimi A et al : Eosinophilic inflammation in cough variant asthma. Eur Respir J 11 : 1064-1069, 1998.
PubMed
11) Matsuoka H, et al : Inflammatory subtypes in cough variant asthma : Association with maintenance doses of inhaled corticosteroids. Chest 138 : 1418-1425, 2010.
PubMed
12) Niimi A, et al : Nature of airway inflammation and remodeling in chronic cough. J Allergy Clin Immunol 116 : 565-570, 2005.
 
13) Niimi A, et al : Airway remodelling in cough-variant asthma. Lancet 356 : 564-565, 2000.
PubMed
14) Takemura M, et al : Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma Respiration 83 : 308-315, 2012.
PubMed
15) Irwin RS, et al : Interpretation of positive result of a methacholine inhalation challenge and 1 week of inhaled bronchodilator use in diagnosing and treating cough-variant asthma. Arch Intern Med 157 : 1981-1987, 1997.
PubMed
16) 新実彰男 : 咳喘息の最新の話題. 最新医学 70 : 1710, 2015.
Medical*Online
P.175 掲載の参考文献
1) Wenzel SE : Complex phenotypes in asthma : current definitions. Pulm Pharmacol Ther 26 : 710-715, 2013.
PubMed
2) Marsh SE, et al : Proportional classifications of COPD phenotypes. Thorax 63 : 761-767, 2008.
PubMed
3) Diagnosis of Disease of Chronic Airflow limitation : Asthma COPD and Asthma -COPD Overlap Syndrome (ACOS). The Global Strategy for Asthma Management and Prevention and the Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2015. Available from : URL : http://www.ginasthma.org/locaI/uploads/files/ACOS_2015.pdf.
 
4) Gibson PG. McDonald VM : Asthma -COPD overlap 2015 : now we are SIX. Thorax 70 : 683-691, 2015.
PubMed
5) Gibson PG, Simpson JL : The overlap syndrome of asthma and COPD : what are its features and how important is it? Thorax 64 : 728-735, 2009.
PubMed
6) Kauppi P, et al : Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 48 : 279-285, 2011.
PubMed
7) Menezes AM, et al : Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype : COPD-asthma Chest 145 : 297-304, 2014.
PubMed
8) Meyer PA, et al : Characteristics of adults dying with COPD. Chest 122 : 2003-2008, 2002.
PubMed
9) Shaya FT, et al : Burden of concomitant asthma and COPD in a Medicaid population. Chest 134 : 14-19, 2008.
 
10) Cowan DC, et al : Effects of steroid therapy on inflammatory cell subtypes in asthma Thorax 65 : 384-390, 2010.
 
11) Chanez P, et al : Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 155 : 1529-1534. 1997.
PubMed
12) D'silva L, et al : Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice. Can Respir J 18 : 144-148, 2011.
PubMed
13) Fu JJ, et al : Systemic inflammation in older adults with asthma-COPD overlap syndrome. Allergy Asthma Immunol Res 6 : 316-324, 2014.
PubMed
14) Iwamoto H, et al : Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J 43 : 421-429, 2014.
PubMed
15) Silva GE, et al : Asthma as a risk factor for COPD in a longitudinal study. Chest 126 : 59-65, 2004.
 
P.179 掲載の参考文献
1) ARIA2008 日本語版編集委員:ARIA2008《日本語版》協和企画, 2008.
 
2) Madonini E, et al : Seasonal increse of bronchial reactivity in allergic rhinitis- J Allergy Clin Immunol 79 : 358-363. 1987.
 
3) Corren J, et al : Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 89 : 611-618. 1992.
PubMed
4) Gaga M, et al : Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy 20 : 663-669, 2000.
 
5) Braunstahl GJ, et al : Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 161 : 2051-2057, 2000.
PubMed
6) Settipane RJ, et al : Long-term risk factors for developing asthma and allergic rhinitis : a 23-year follow-up study of college students. Allergy Proc 15 : 21-25, 1994.
PubMed
7) Moller C, et al : Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 109 : 251-256, 2002.
PubMed
8) Price DB, et al : Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy 35 : 282-287. 2005.
 
9) Crystal-Peters J, et al : Treating allergic rhinitis in patients with comorbid asthma : the risk of asthma-related hospitalizations and emergency visits. J Allergy Clin Immunol 109 (1) : 57-62, 2002.
PubMed
10) Ohta K et al : Prevalence and impact of allergic rhinitis in asthma SACRA, a cross-sectional nation-wide study in Japan. Allergy 66 : 1287-1295, 2011.
 
11) Varner AE, Lemanske RF Jr : Asthma and Rhinitis, 2nd ed. p 1172-1185, Blackwell Science, Oxford, 2000.
 
12) 「喘息予防・管理ガイドライン 2015」作成委員会 : 喘息予防・管理ガイドライン 2015, p 240-241, 協和企画. 2015.
 
P.183 掲載の参考文献
1) Chusid MJ, et al : The hypereosinophilic syndrome : analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54 : 1-27, 1975.
PubMed
2) Roufosse F, et al : Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 27 : 389-413, 2007.
PubMed
3) Cools J, et al : A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 : 1201-1214, 2003.
PubMed
4) Cheah CY, et al : Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 123 : 3574-3577, 2014.
PubMed
5) Yoshida C, et al : A novel t (1 ; 8) (q25 ; p11.2) translocation associated with 8p11 myeloproliferative syndrome. Br J Haematol 156 : 271-273, 2012.
 
6) 松尾佳美, 猪熊茂子 : Idiopathic Hypereosinophilic Syndrome (idiopathic HES).アレルギー 60 : 1-8, 2011.
 
7) Chen YY, et al : Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol 133 : 1195-1202, 2014.
PubMed
8) Crane MM, et al : Incidence of myeloproliferative hypereosinophillc syndrome in Hie United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 126 : 179-181, 2010.
 
9) Sada A, et al : A multicenter analysis of the FIP1L1-alphaPDGFR fusion gene in Japanese idiopathic hypereosinophilic syndrome : an aberrant splicing skipping the alphaPDGFR exon 12. Ann Hematol 86 : 855-863, 2007.
 
10) Roufosse F, et al : Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 109 : 540-548, 2000.
PubMed
11) Bain BJ, Fletcher SH : Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 27 : 377-388, 2007.
PubMed
12) Ogbogu PU, et al : Hypereosinophilic syndrome : a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 124 : 1319-1325, 2009.
PubMed
13) Dahabreh IJ, et al : Management of hypereosinophilic syndrome : a prospective study in the era of molecular genetics. Medicine (Baltimore) 86 : 344-354, 2007.
PubMed
14) Rothenberg ME, et al : Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 : 1215-1228, 2008.
PubMed
15) Lefebvre C, et al : Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 140 : 253-257, 1989.
PubMed
P.188 掲載の参考文献
1) 藤枝重治ほか : 好酸球性副鼻腔炎診断ガイドライン (JESREC Study). 日耳鼻会報 118 : 728-735, 2015.
 
2) 春名眞一ほか : 好酸球性副鼻腔炎. 耳鼻咽喉科展望 44 : 195-201, 2001.
 
3) 藤枝重治ほか : 好酸球性副鼻腔炎 (JESREC Study).アレルギー 64 : 38-45, 2015.
Medical*Online
4) Tokunaga T, et al : Novel scoring system and algorithm for classifying chronic rhino sinusitis : the JESREC Study. Allergy 70 : 995-1003, 2015.
 
5) 藤枝重治ほか : 好酸球性気道炎症の疫学と臨床. Monthry Book ENTONI 182 : 23-29, 2015.
 
6) Akdis CA, et al : Endotypes and phenotypes of chronic rhino sinusitis : a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 131 : 1479-1490, 2013.
 
7) Kato A : Immunopathology of chronic rhinosinusitis. Allergol Int 64 : 121-130, 2015.
PubMed
8) Stevens WW, et al : Cytokines in Chronic Rhinosinusitis : Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease. Am J Respir Crit Care Med 192 : 682-694, 2015.
PubMed
9) Okano M, et al : Association and management of eosinophilic inflammation in upper and lower airways. Allergol Int 64 : 131-138, 2015.
PubMed
10) Takabayashi T, et al : Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol 132 : 584-592, e4, 2013.
 
11) Takabayashi T, et al : Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med 187 : 49-57, 2013.
PubMed
12) Pauwels B, et al : Emerging biologies for the treatment of chronic rhinosinusitis. Expert Rev Clin Immunol 11 : 349-361, 2015.
 
13) Van Zele T, et al : Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy 28 : 192-198, 2014.
PubMed
P.193 掲載の参考文献
1) Meltzer EO, et al : Rhino sinusitis : developing guidance for clinical trials. J Allergy Clin Immunol 118 : S17-61, 2006.
 
2) Matsuwaki Y, et al : Chronic rhinosinusitis : risk factors for the recurrence of chronic rhinosinusitis based on 5-year follow-up after endoscopic sinus snidery. Int Arch Allergy Immunol 146 (Suppl 1) : 77-81, 2008.
 
3) 松脇由典 : 好酸球性副鼻腔炎と周辺疾患 好酸球性鼻副鼻腔炎の外科的治療. アレルギー・免疫 22 : 46-53, 2014.
 
4) 春名眞一ほか : 好酸球性副鼻腔炎 (Eosinophilic Sinusitis). 耳鼻咽喉科展望 44 : 195-201, 2001.
 
5) Ueki S, et al : Eosinophil extracellular trap cell death-derived DNA traps : Their presence in secretions and functional attributes. J Allergy Clin Immunol , 2015. [Epub ahead of print]
 
6) Inoue Y, et al : Nonpathogenic, environmental fungi induce activation and degranulation of human eosinophils. J Immunol 175 : 5439-5447, 2005.
PubMed
7) Matsuwaki Y, et al : Recognition of fungal protease activities induces cellular activation and eosinophil-derived neurotoxin release in human eosinophils. J Immunol 183 : 6708-6716, 2009.
PubMed
8) 松脇由典 : 好酸球性副鼻腔炎真菌の関与について. 日鼻科会誌 48 : 37-39, 2009.
 
9) 松脇由典 : アレルギー性真菌l生鼻副鼻腔炎 (AFRS) について. 日耳鼻会報 115 : 646-647, 2012.
 
10) Matsuwaki Y, et al : Alternaria fungus induces the production of GM-CSF, interleukin-6 and interleukin-8 and calcium signaling in human airway epithelium through protease-activated receptor 2. Int Arch Allergy Immunol 158 (Suppl 1) : 19-29, 2012.
 
11) 松脇由典ほか : Allergic Fungal Sinusitisの検討. 日耳鼻会報 105 : 1157-1165. 2002.
 
12) Cody DT 2nd, et al : Allergic fungal sinusitis : the Mayo Clinic experience. Laryngoscope 104 : 1074-1079, 1994.
 
13) Marple BF : Allergic fungal rhinosinusitis : current theories and management strategies. Laryngoscope 111 : 1006-1019, 2001.
PubMed
14) 中山次久ほか : アレルギー性真菌性鼻副鼻腔炎 (AFRS) の検討. 耳鼻咽喉科展望 51 : 82-91, 2008.
 
15) 松脇由典 : アレルギーに関する画像とその解説アレルギー性真菌性鼻副鼻腔炎の画像所見. アレルギー・免疫 19 : 614-623, 2012.
 
P.198 掲載の参考文献
1) 富岡幸子, 湯浅涼 : 気管支喘息患者における難治性中耳炎. Otol Jpn 2 : 603, 1992.
 
2) 松谷幸子ほか : 気管支喘息患者の難治性中耳炎-好酸球性中耳炎- (Eosinophilic Otitis Media). 耳喉頭頸外科 67 : 712-713. 1995.
 
3) 松原篤 : 好酸球性中耳炎の診断. 耳鼻臨床 107 : 600-601, 2014.
 
4) 鈴木秀明ほか : 好酸球性中耳炎全国疫学調査. Otol Jpn 14 : 112-117, 2004.
 
5) Nonaka M, et al : IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. Acta Otolaryngol 123 : 383-387, 2003.
PubMed
6) Iino Y, et al : Eosinophil chemo attractants in the middle ear of patients with eosinophilic otitis media. Clin Exp Allergy 35 : 1370-1376, 2005.
 
7) Iino Y, et al : Eustachian tube function in patients with eosinophilic otitis media associated with bronchial asthma evaluated by sonotubometry. Arch Otolaryngol Head Neck Surg 132 : 1109-1114, 2006.
PubMed
8) 松原篤 : 好酸球性中耳炎. 症例から見る 難治性疾患の診断と治療 1. 耳科領域編 (加賀君孝監), p 15-26, 国際医学出版社, 2011.
 
9) 松谷幸子 : 鼻・副鼻腔手術後に発症した中耳炎. アレルギーの臨床 23 : 78-81, 2003.
 
10) Kanazawa H, et al : Antigen-specific IgE in middle ear effusion of patients with eosinophilic otitis media. Ann Allergy Asthma Immunol 113 : 88-92, 2014.
PubMed
11) Nishizawa H, et al : The role of periostin in eosinophilic otitis media. Acta Otolaryngol 132 : 838-844, 2012.
PubMed
12) Iino Y, et al : Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx 38 : 456-461, 2011.
PubMed
13) Nakagawa T, et al : Intractable otitis media with eosinophils : importance of diagnosis and validity of treatment for hearing preservation. ORL J Otorhinolaryngol Relat Spec 68 : 118-122, 2006.
PubMed
14) Matsubara A, et al : An experimental study of inner ear injury in an animal model of eosinophilic otitis media Acta Otolaryngol 134 : 227-232, 2014.
 
15) 松原篤ほか : 綜説好酸球性中耳炎の内耳病態. 耳鼻咽喉科展望 58 (5) : 242-248. 2015.
 
P.202 掲載の参考文献
1) Liu P, Baughman KL : Myocarditis. In : Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine (ed by Bonow RO, et al), p1595-1610, Elsevier Saunders, Philadelphia, 2012.
 
2) 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告, 班長 : 和泉徹) 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf]
 
3) 猪又孝元 : 好酸球性心筋炎. 綜合臨牀 59 : 1772-1775, 2010.
Medical*Online
4) Morimoto S, et al : Changes in the peripheral eosinophil count in patients with acute eosinophilic myocarditis. Heart Vessel 18 : 193-196, 2003.
PubMed
5) Fozing T, et al : Management of a patient with eosinophilic myocarditis and normal peripheral count : case report and literature review. Circ Heart Fail 7 : 692-694, 2014.
PubMed
6) Rizkallah J, et al : Eosinophilic myocarditis : two case reports and review of the literature. BMC Research Notes 6 : 538, 2013.
PubMed
7) Tani H, et al : T2-weighted and delayed enhancement MRI of eosinophilic myocarditis : relationship with clinical phases and global cardiac function. Jpn J Radiol 30 : 824-831, 2012.
PubMed
8) Kawano S, et al : Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period. Intern Med 50 : 975-981, 2011.
 
9) Yanagisawa T, et al : Clinical significance of corticosteroid therapy for eosinophilic myocarditis. Int Heart J 52 : 110-113, 2011.
PubMed
10) Martinez S, et al : Giant cell myocarditis associated with amoxicillin hypersensitivity reaction. Forensic Sci Med Pathol 9 : 403-406, 2013.
PubMed
P.207 掲載の参考文献
1) Prasad GA, et al : Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 7 : 1055-1061, 2009.
PubMed
2) Fujishiro H, et al : Eosinophilic esophagitis investigated by upper gastrointestinal endoscopy in Japanese patients. J Gastroenterol 46 : 1142-1144, 2011.
PubMed
3) Shimura S, et al : Reliability of symptoms and endoscopic findings for diagnosis of esophageal eosinophilia in a Japanese population. Digestion 90 : 49-57, 2014.
 
4) Kinoshita Y, et al : Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis. J Gastroenterol 48 : 333-339, 2013.
PubMed
5) Kinoshita Y, et al : Clinical characteristics of Japanese patients with eosinophilic esophagitis and eosinophilic gastroenteritis. J Gastroenterol 48 : 333-339, 2013.
PubMed
6) Gonsalves N, et al : Elimination diet effectively treats eosinophilic esophagitis in adults ; food reintroduction identifies causative factors. Gastroenterology 142 : 1451-1459. e1 ; quiz e14-15, 2012.
 
7) Alexander ES, et al : Twin and family studies reveal strong environmental and weaker genetic cues explaining heritability of eosinophilic esophagitis. J Allergy Clin Immunol 134 : 1084-1092, e1, 2014.
 
8) Rothenberg ME, et al : Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet 42 : 289-291, 2010.
PubMed
9) Kottyan LC, et al : Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet 46 : 895-900, 2014.
PubMed
10) Shoda T, et al : Comparison of gene expression profiles in eosinophilic esophagitis (EoE) between Japanand Westerncountries. Allergol Int 64 : 260-265, 2015.
 
11) Furuta K, et al : Case-control study of association of eosinophilic gastrointestinal disorders with Helicobacter pylori infection in Japan. J Clin Biochem Nutr 53 : 60-62, 2013.
PubMed
12) Kinoshita Y, et al : Elevated plasma cytokines in Japanese patients with eosinophilic esophagitis and gastroenteritis. Digestion 86 : 238-243, 2012.
PubMed
13) Ishimura N, et al : Limited role of allergy testing in patients with eosinophilic gastrointestinal disorders. J Gastroenterol Hepatol 28 : 1306-1313, 2013.
PubMed
14) Wen T, et al : Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol 135 : 187-197, 2015.
PubMed
15) Vazquez-Elizondo G, et al : The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther 38 : 1312-1319, 2013.
PubMed
P.212 掲載の参考文献
1) Kaijser R : Zur Kenntnis der allergischen Affektionen des Verdauungskanals vom Standpunkt des Chirurgen aus. Arch Klin Chir 188 : 36-64, 1937.
 
2) 岩田繁雄 : 高度の好酸球増多症を伴った亜急性好酸球性腹膜炎の1治験例. 南大阪病医誌 7 : 159-161, 1959.
 
3) 木下芳一ほか : 好酸球性食道炎/好酸球性胃腸炎の疾患概念確立と治療指針作成のための臨床研究-平成21年度総括・分担研究報告書. 厚生労働科学研究費補助金難治性疾患克服研究事業, 2010.
 
4) 木下芳一ほか : 好酸球性胃腸炎の診断と治療. Gastroenterological Endoscopy 54 : 1797-1805, 2012.
 
5) Bischoff SC : Food allergy and eosinophilic gastroenteritis and colitis. Curr Opin Allergy Clin Immunol 10 : 238-245, 2010.
PubMed
6) Hogan SP, et al : A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. Nat Immunol 2 : 353-360, 2001.
PubMed
7) Raithel M, et al : Eosinophilic gastroenteritis with refractory ulcer disease and gastrointestinal bleeding as a rare manifestation of seronegative gastrointestinal food allergy. Nutr J 13 : 93, 2014.
PubMed
8) Talley NJ, et al : Eosinophilic gastroenteritis : a clinicopathological study of patients with disease of the mucosa muscle layer, and subserosal tissues. Gut 31 : 54-58, 1990.
PubMed
9) 木下芳一ほか : 好酸球性食道炎/好酸球性胃腸炎の疾患概念確立と治療指針作成のための臨床研究-平成23年度総括・分担研究報告書. 厚生労働科学研究費補助金難治性疾患克服研究事業, 2012.
 
10) 木下芳一ほか : 好酸球性消化管疾患の診断基準. 胃と腸 48 : 1853-1858, 2013.
 
11) 木下芳一ほか : 好酸球性消化管障害の診断と治療. 日消誌 110 : 953-964, 2013.
Medical*Online
12) 岡本浩之, 東馬智子 : 好酸球性胃腸炎の病勢評価指標としての便中EDN定量の有用性. アレルギーの臨床 34 (11) : 974-977, 2014.
 
13) Pinetonde Chambrun G, et al : Natural history of eosinophilic gastroenteritis. Clin Gastroenterol Hepatol 9 (11) : 950-956, 2011.
 
14) 新生児-乳児消化管アレルギー診断治療指針, 厚生労働省難治性疾患研究班作成. [http://nrichd.ncchd.go.jp/imal/FPIES/icho/pdf/fpies.pdf]
 
15) 野村伊知朗ほか : 小児における好酸球性消化管疾患の概念. 胃と腸 48 : 1897-1903, 2013.
 
P.217 掲載の参考文献
1) Albot G, et al : Les cholecystites a eosinophiles. Press Med 57 : 558-559, 1949.
PubMed
2) Leegaard M : Eosinophilic cholecystitis. Acta Chir Scand 146 : 295-296, 1980.
PubMed
3) Butler TW, et al : Eosinophilic cholangitis, lymphadenopathy, and peripheral eosinophilia : a case report. Am J Gastroenterol 80 : 572-574, 1985.
PubMed
4) Tenner S, et al : Eosinophilic cholangiopathy. Gastrointest Endosc 45 : 307-309, 1997.
PubMed
5) 木村佳人ほか : 明らかな胆管病変出現前の初期から原発性硬化性胆管炎類似の典型像に至るまでの経過を観察しえた好酸球性胆管炎の1例. 日消誌 110 : 271-281, 2013.
Medical*Online
6) 寺田忠史ほか : Eosinophilic cholecystitisの3例. 日消誌 84 : 2118-2122, 1987.
 
7) Dabbs DJ : Eosinophilic and lymphoeosinophilic cholecystitis. Am J Surg Pathol 17 : 494-501, 1993.
 
8) 岩室正也ほか : 好酸球性胆嚢炎と考えられた2例. 治療 91 : 1611-1614, 2009.
 
9) Nashed C, et al : Eosinophilic cholangitis and cholangiopathy : a sheep in wolves clothing. HPB Surg 2010 : 906496, 2010.
PubMed
10) Felman RH, et al : Eosinophilic cholecystitis, appendiceal inflammation, pericarditis, and cephalosporin-assosiated. Dig Dis Sci 30 : 418-422, 1994.
 
11) Miura F, et al : Resected case of eosinophilic cholangiopathy with secondary sclerosing cholangitis. World J Gastroenterol 15 : 1304-1307, 2009.
 
12) Horiuchi K, et al : Marked eosinophilia as the first manifestation of sclerosing cholangitis. Intern Med 48 : 1377-1382, 2009.
PubMed
13) Takikawa H, et al : Recent status of primary sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Surg 6 : 352-355, 1999.
PubMed
14) Iwamuro M, et al : Eosinophilic cholangitis with initial clinical features indistinguishable from IgG4-related cholangitis. Intern Med 48 : 1143-1147, 2009.
PubMed
15) Sussman DA, et al : Eosinophilic cholangiopathy with concurrent eosinophilic colitis in a patient with idiopathic hypereosinophilic syndrome. Eur J Gastroenterol Hepatol 20 : 574-577, 2008.
 
P.222 掲載の参考文献
1) Crofton JW, et al : Pulmonary eosinophilia. Thorax 7 : 1-35, 1952.
PubMed
2) Liebow AA, Carrington CB : The eosinophilic pneumonias. Medicine (Baltimore) 48 (4) : 251-285, 1969.
PubMed
3) Carrington CB, et al : Chronic eosinophilic pneumonia. N Engl J Med 280 (15) : 787-798, 1969.
PubMed
4) Allen JN, et al : Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 321 : 569-574, 1989.
PubMed
5) Badesch DB, et al : Acute eosinophilic pneumonia : a hypersensitivity phenomenon. Am Rev Respir Dis 139 : 249-252, 1989.
PubMed
6) Ricker DH, et al : Fatal pulmonary aspergillosis presenting as acute eosinophilic pneumonia in a previously healthy child. Chest 100 : 875-877, 1991.
 
7) Rhee CK, et al : Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. Eur Respir J 41 : 402-409, 2013.
PubMed
8) 吉田浩子, 山内広平 : 好酸球性肺炎. 呼吸 22 : 545-549, 2003.
Medical*Online
9) Philit F, et al : Idiopathic acute eosinophilic pneumonia : a study of 22 patients. Am J Respir Crit Care Med 166 : 1235-1239, 2002.
PubMed
10) Shorr AF, et al : Acute eosinophilic pneumonia among US Military personnel deployed in or near Iraq. JAMA 292 : 2997-3005, 2004.
PubMed
11) Uchiyama H, et al : Alterations in smoking habits are associated with acute eosinophilic pneumonia. Chest 133 : 1174-1180, 2008.
PubMed
12) Rom WN, et al : Acute eosinophilic pneumonia in a New York City firefighter exposed to World Trade Centerdust. Am J Respir Crit Care Med 166 : 797-800, 2002.
 
13) Hirai K, et al : Acute eosinophilic pneumonia associated with smoke from fireworks. Intern Med 39 : 401-403, 2000.
PubMed
14) 妹川史朗ほか : Trichosporon cutaneumと Trichoderma virideの沈降抗体が陽性の急性好酸球性肺炎の2例. 日胸疾患会誌 31 (3) : 352-359, 1993.
 
15) Kawayama T, et al : High concentrationof (1→3)-beta-D-glucanin BAL fluid in patients with acute eosinophilic pneumonia. Chest 123 : 1302-1307, 2003.
 
16) Watanabe K, et al : Acute eosinophilic pneumonia following cigarette smoking : a case report including cigarette-smoking challenge test. Intern Med 41 : 1016-1020, 2002.
PubMed
17) Allen JN, Davis WB : Eosinophilic lung diseases. Am J Respir Crit Care Med 150 : 1423-1438, 1994.
 
18) Cottin V, Cordier JF : Eosinophilic pneumonias. Allergy 60 : 841-857, 2005.
PubMed
19) Buddharaju VL, et al : Acute eosinophilic pneumonia associated with shock. Crit Care Med 27 (9) : 2014-2016, 1999.
PubMed
20) Daimon T, et al : Acute eosinophilic pneumonia : Thin-section CT findings in 29 patients. Eur J Radiol 65 (3) : 462-467, 2008.
PubMed
21) Daimon T, et al : KL-6 and surfactant proteins A and D in serum and bronchoalveolar lavage fluid in patients with acute eosinophilic pneumonia. Intern Med 44 : 811-817, 2005.
 
22) Janz DR, et al : Acute eosinophilic pneumonia : A case report and review of the literature. Crit Care Med 37 : 1470-1474, 2009.
PubMed
23) Fujimura M, et al : Bronchoalveolar lavage cell findings in three types of eosinophilic pneumonia : acute, chronic and drug-induced eosinophilic pneumonia. Respir Med 92 : 743-749, 1998.
PubMed
24) Nakahara Y, et al : Increased interleukin-5 levels in bronchoalveolar lavage fluid is a major factor for eosinophil accumulation in acute eosinophilic pneumonia. Respiration 68 : 389-395, 2001.
PubMed
25) Miyazaki E, et al : Circulating thymus- and activation-regulated chemokine/CCL17 is a useful biomarker for discriminating acute eosinophilic pneumonia from other causes of acute lung injury. Chest 131 : 1726-1734, 2007.
PubMed
26) Tazelaar HD, et al : Acute eosinophilic pneumonia : histopathologic findings in nine patients. Am J Respir Crit Care Med 155 : 296-302, 1997.
PubMed
27) 持丸博ほか : 急性好酸球性肺炎と慢性好酸球性肺炎の臨床病理学的相違. 日呼吸会誌 45 : 223-232, 2007.
 
P.227 掲載の参考文献
1) Carrington CB, et al : Chronic eosinophilic pneumonia. N Engl J Med 280 : 787-798, 1969.
PubMed
2) Marchand E, et al : Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. Medicine (Baltimore) 77 (5) : 299-312, 1998.
PubMed
3) Kita H, et al : Cytokine production at the site of disease in chronic eosinophilic pneumonia. Am J Respir Crit Care Med 153 : 1437-1441, 1996.
PubMed
4) Webb WR, et al : Chronic eosinophilic pneumonia. In : High-Resolution CT of the Lung, p389-391, Wolters Kluwer Health , Philadelphia, 2015.
 
5) Cordier JF, et al : Eosinophilic pneumonias. In : Interstitial Lung Diseases, p833-838, People's Medical Publishing House-USA, Shelton, 2010.
 
6) 望月吉郎ほか : 慢性好酸球性肺炎の予後の検討. 日呼吸会誌 40 : 851-855, 2002.
Medical*Online
P.230 掲載の参考文献
1) Fraser RS, et al : Eosinophilic lung disease. In : Diagnosis of Disease of the Chest, 4th ed, p1744, WB Saunders, Philadelphia, 1999.
 
2) Travis WD, et al : Non-neoplastic disorders of the lower respiratory tract. In : Atlas of Nontumor Pathology, p161, American Registoryof Pathology, Washington, DC, 2002.
 
3) 肺寄生虫症. 新呼吸器専門医テキスト (日本呼吸器学会編), p312, 南江堂, 2015.
 
4) Loffler W : Zur differential-Diagnosis der Lungeninliltrierungen. II. Uber fluchtige Suceedan-Infiltrate (mit Eosinohilie). Beitr Z Klind Tuberk 79 : 368-392, 1932.
 
5) Kim HY, et al : Transient pulumonary eosinophilia incidentally found on low-dose computed tomography : findings in 40 individuals. J Comput Assist Tomogr 32 : 101-107, 2008.
 
6) Kim SJ, et al : Simple pulmonary eosinophilia found on follow-up computed tomography of oncologic patients. Eur J Radiol 83 : 1977-1982, 2014.
PubMed
7) 佐藤哲夫ほか : 好酸球性肺炎. 医学と薬学 59 (5) : 713-718, 2008.
Medical*Online
8) Yasuda K, et al : Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci USA1 09 : 3451-3456, 2012.
 
9) 善本知広 : IL-33とアレルギー性炎症. 炎症と免疫 22 (2) : 65-71, 2014.
 
P.236 掲載の参考文献
1) Takayanagi N, et al : Chronic bronchiolitis with associated eosinophilic lung disease (eosinophilic bronchiolitis). Respiration 68 : 319-322, 2001.
PubMed
2) Cordier JF, et al : Hypereosinophilic obliterative bronchiolitis : a distinct, unrecognised syndrome. Eur Respir J 41 : 1126-1134, 2013.
PubMed
3) 中込一之ほか : 喘息様症状で発症し, びまん性小葉中心性陰影を呈した, 好酸球性細気管支炎・肺炎の1例. 日呼吸会誌 41 : 722-727, 2003.
Medical*Online
4) 永田忍彦ほか : 気管支喘息の経過中に発症した慢性好酸球性細気管支炎の1例. 日呼吸会誌 42 : 767-771, 2004.
Medical*Online
5) 森本耕三ほか : 好酸球性副鼻腔炎を合併した好酸球性細気管支炎の1例. 日呼吸会誌 44 : 980-984, 2006.
Medical*Online
6) 神谷周良, 福島康次 : 気管支喘息の治療経過中に好酸球性気管支炎・細気管支炎を発症した症例. International Reviewof Asthma 9 : 88-92, 2007.
 
7) Fukushima Y, et al : A patient with bronchial asthma in whom eosinophilic bronchitis and bronchiolitis developed during treatment. Allergol Int 59 : 87-91, 2010.
PubMed
8) Yanagitani N, et al : Eosinophilic bronchiolitis indicating eosinophilic airway disease with overexpression of carcinoembryonic antigen in sinus and bronchiole : case report. Biol Regul Homeost Agents 1 : 99-102, 2010.
PubMed
9) 伏屋芳紀ほか : 「アレルギーの臨床」に寄せる喘息症状を呈した好酸球性細気管支炎の一例. アレルギーの臨床 31 : 355-360, 2011.
 
10) 澤田千晴ほか : 著明なアトピー素因を背景にもつ好酸球性細気管支炎の1例. 日本胸部臨床 70 : 385-392, 2011.
Medical*Online
11) 磯部全ほか : 喘鳴を伴わずに発症した好酸球性細気管支炎の1例. 日呼吸会誌 2 : 607-611, 2013.
 
12) 諏訪陽子ほか : 遷延する鼻症状後に発症した好酸球性細気管支炎の1例. 日呼吸会誌 3 : 128-132, 2014.
 
13) Kobayashi T, et al : Hypereosinophilic obliterative bronchiolitis clinically mimicking diffuse panbronchiolitis : four-year follow-up. Intern Med 54 : 1091-1094, 2015.
PubMed
14) 東谷真実ほか : 顕著なアトピー素因をもつ好酸球性細気管支炎の1例. Therapeutic Research 35 : 509-510, 2014.
Medical*Online
15) 高柳昇 : 1. アレルギー性鼻炎, 好酸球性細気管支炎 2) 好酸球性細気管支炎. 日本胸部臨床 71 : S5119- S5124, 2012.
 
P.241 掲載の参考文献
1) Jennette JC, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 (1) : 1-11, 2013.
 
2) 厚生労働省難治性疾患克服研究事業 ANCA関連血管炎の診療ガイドライン (尾崎承一ほか編), 2011. (非売品, MindsのHPから参照可能) [http://minds.jcqhc.or.jp/n/medical_user_main.php]
 
3) Vaglio A, et al : Eosinophilic granulomatosis with polyangiitis (Churg- Strauss) : state of the art. Allergy 68 : 261-273, 2013.
PubMed
4) Pagnoux C, et al : Churg-Strauss syndrome. Curr Opin Rheumatol 19 (1) : 25-32, 2007.
 
5) Comarmond C, et al ; French Vasculitis Study Group : Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) : Clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Groupcohort. Arthritis Rheum 65 (1) : 270-281, 2013.
 
6) 谷口正実 : 好酸球性多発血管炎性肉芽腫症. リウマチ科 50 (4) : 450-457, 2013.
 
7) Weller PF, et al : The relationship of asthma therapy and Churg-Strauss syndrome : NIH workshop summary report. J Allergy Clin Immunol 108 (2) : 175-183, 2001.
PubMed
8) Healy B, et al : Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strausssyndrome. J Allergy Clin Immunol 131 (2) : 571-576, e1-6, 2013.
 
9) Kim S, et al : Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 125 (6) : 1336-1343, 2010.
PubMed
10) Saech J, et al : Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 69 (6) : 1254-1255, 2010.
 
11) 谷口正実ほか : 鼻茸・アスピリン喘息. 喘息 25 (1) : 45-53, 2012.
Medical*Online
12) 谷口正実, 石井豊太 : 好酸球性多発血管炎性肉芽腫症と鼻副鼻腔病変. JOHN S29 (5) : 867-870, 2013.
 
13) 厚生労働省難治性疾患克服研究事業 ANCA関連血管炎の診療ガイドライン 2014年改訂版 (非売品).
 
14) Sable-Fourtassou R, et al ; French Vasculitis Study Group : Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143 (9) : 632-638, 2005.
 
15) Sinico RA, et al : Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strausssyndrome. Arthritis Rheum 52 (9) : 2926-2935, 2005.
 
16) Guillevin L, Pagnoux C : Therapeutic strategies for systemic necrotizing vasculitides. Allergol Int 56 (2) : 105-111, 2007.
PubMed
17) 谷口正実 : 専門医のためのアレルギー学講座アレルギー・免疫疾患の新規治療薬と治療法Churg-Strauss Syndrome (アレルギー性肉芽腫性血管炎) の最近の治療免疫グロブリン大量療法を含めて. アレルギー 59 (8) : 923-930, 2010.
 
18) Cohen P, et al ; French Vasculitis Study Group : Churg-Strauss syndrome with poor-prognosis factors : A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57 (4) : 686-693, 2007.
PubMed
19) Taniguchi M, et al : Treatment for Churg-Strauss syndrome : induction of remission and efficacy of intravenous immunoglobulin therapy. Allergol Int 56 (2) : 97-103, 2007.
PubMed
20) 谷口正実 : IVIG療法. 呼吸 33 (6) : 581-590, 2014.
 
21) Koike H, et al ; Research Group for IVIg for EGPA/CSS in Japan : Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) : a multicenter, double-blindtrial. J Neurol 262 (3) : 752-759, 2015.
 
22) Fervenza FC : Rituximabin ANCA-associated vasculitis : fad or fact? Nephron Clin Pract 118 (2) : c182-188, 2011.
PubMed
23) Guillevin L, et al : Churg-Straus syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78 : 26-37, 1999.
 
24) Gayraud M, et al ; French Vasculitis Study Group : Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome : analysis of four prospective trials including 278 patients. Arthritis Rheum 44 (3) : 666-675, 2001.
 
25) Guillevin L, et al : The Five-Factor Score revised : assesment of prognosis of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 90 : 19-27, 2011.
 
26) Moosig F, et al : A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA) : monocentric experiences in 150 patients. Ann Rheum Dis 72 (6) : 1011-1017, 2013.
PubMed
P.246 掲載の参考文献
1) Agarwal R, et al : Allergic bronchopulmonary aspergillosis : review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 43 : 850-873, 2013.
PubMed
2) Greenberger PA : Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 110 : 685-692, 2002.
PubMed
3) Greenberger PA : When to suspect and work up allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 111 : 1-4, 2013.
PubMed
4) Knutsen AP, et al : Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 129 : 280-291 ; quiz92-93, 2012.
 
5) Chowdhary A, et al : Allergic bronchopulmonary mycosis due to fungi other than Aspergillus : a global overview. Crit Rev Microbiol 40 : 30-48, 2014.
PubMed
6) 福冨友馬ほか : 本邦における病院通院成人喘息患者の実態調査-国立病院機構ネットワーク共同研究-. アレルギー 59 : 37-46, 2010.
Medical*Online
7) Yoshida Y, et al : Development of allergic bronchopulmonary aspergillosis with central bronchiectasis over a 10-year period : the need to recheck allergens ensitization. Intern Med 52 : 2135-2138, 2013.
 
8) Gibson PG, et al : Induced sputum IL-8 gene expression, neutrophil influx and MMP-9 in allergic bronchopulmonary aspergillosis. Eur Respir J 21 : 582-588, 2003.
PubMed
9) Agbetile J, et al : Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV1. Clin Exp Allergy 42 : 782-791, 2012.
PubMed
10) Fairs A, et al : Isolation of Aspergillus fumigatus from sputum is associated with elevated airborne levels in homes of patients with asthma. Indoor Air 23 : 275-284, 2013.
PubMed
11) Chauhan B, et al : Evidence for the involvement of two different MHC class II regions in susceptibility or protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 106 : 723-729, 2000.
PubMed
12) Tanimoto H, et al : Molecular-based allergy diagnosis of allergic bronchopulmonary aspergillosis in Aspergillus fumigatus-sensitized Japanese patients. Clin Exp Allergy 2015 Jun 27. doi : 10.1111/cea.12590. [Epu bahead of print]
 
13) 「喘息予防・管理ガイドライン 2012」作成委員 : 喘息予防・管理ガイドライン 2012, 協和企画, 2012.
 
14) Wark PA, et al : Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev (3) : CD001108, 2004.
PubMed
15) Stevens DA, et al : A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 342 : 756-762, 2000.
PubMed
16) Wark PA, et al : Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis : a randomized controlled trial. J Allergy Clin Immunol 111 : 952-957, 2003.
PubMed
17) Tillie-Leblond I, et al : Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 66 : 1254-1256, 2011.
PubMed
P.251 掲載の参考文献
1) 宮地良樹 : 好酸球性膿疱性毛包炎. 最新皮膚科学体系 第6巻水疱症・膿疱症 (玉置邦彦総編集), p244-249, 中山書店, 2002.
 
2) 野村尚史ほか : 太藤病の病型. 皮膚病診療 35 : 129-136, 2013.
 
3) Katoh M, et al : Eosinophilic pustular folliculitis : a review of the Japanese published works. J Dermatol 40 : 15-20, 2013.
 
4) Yamamoto Y, et al : Clinical epidemiology of eosinophilic pustular folliculitis : results from a nationwide survey in Japan. Dermatology 230 : 87-92, 2015.
PubMed
5) Nomura T, et al : Eosinophilic pustular folliculitis : the transition in sex differences and interracial characteristics between 1965 and 2013. J Dermatol 42 : 343-352, 2015.
PubMed
6) Nervi DJ, et al : Eosinophilic pustular folliculitis : A 40 year retrospect. J Am Acad Dermatol 55 : 285-289, 2006.
 
7) Nakahigashi K, et al : PGD2 induces eotaxin-3 via PPARγ from sebocytes : a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol 129 : 536-543, 2012.
 
8) 野村尚史ほか : 好酸球性膿疱性毛包炎. 皮膚科の臨床 56 : 303-311, 2014.
 
9) Matsumura Y, et al : Atypical clinical appearance of eosinophilic pustular folliculitis of seborrheic areas of the face. Eur J Dermatol 22 : 658-662, 2012.
PubMed
10) 宮地良樹 : 好酸球性膿疱性毛包炎. 皮膚疾患最新の治療 2015-16 (渡辺晋一, 古川福実編), p128, 南江堂, 2015.
 
11) Kabashima K, et al : Treatment of eosinophilic pustular folliculitis (Ofuji's disease) with tacrolimus ointment. Br J Dermatol 151 : 949-950, 2004.
PubMed
12) Otsuka A, et al : Treatment of eosinophilic pustular folliculitis with ciclosporin : suppression of mRNA expression of IL-4 and IL-13. J Eur Acad Dermatol Venereol 24 : 1489-1491, 2010.
PubMed
P.256 掲載の参考文献
1) Shulman LE : Diffuse fasciitis with hypergammaglobulinemia and eosinophilia : a new syndrome? J Rheumatol 1 : 46, 1974.
 
2) Rodnan GP, et al : Proceedings : Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome. Arthritis Rheum 18 : 525, 1975.
PubMed
3) Peterson LS, et al : Classification of morphea (localized scleroderma). Mayo Clin Proc 70 : 1068-1076, 1995.
PubMed
4) 藤本学 : 好酸球性筋膜炎. 最新皮膚科学大系 9 膠原病 非感染性肉芽腫 (玉置邦彦ほか編), p124-127, 中山書店, 2002.
 
5) Pinal- Fernandez I, et al : Diagnosis and classification of eosinophilic fasciitis. Autoimmun Rev 13 : 379-382, 2014.
PubMed
6) Sillo P, et al : Eosinophilic Fasciitis associated with Mycoplasma arginini infection. J Clin Microbiol 50 : 1113-1117, 2012.
PubMed
7) Hashimoto Y, et al : Polymerase chain reaction of Borrelia burgdorferi flagellin gene in Shulman syndrome. Dermatology 192 : 136-139, 1996.
PubMed
8) Berianu F, et al : Eosinophilic fasciitis : clinical characteristics and response to methotrexate. Int J Rheum Dis 18 : 91-98, 2015.
PubMed
9) Lebeaux D, et al : Eosinophilic fasciitis (Shulman disease) : new insights into the therapeutic management from a series of 34 patients. Rheumatology (Oxford) 51 : 557-561, 2012.
PubMed
10) de Masson A, et al : Severe aplastic anemia associated with eosinophilic fasciitis : report of 4 cases and review of the literature. Medicine 92 : 69-81, 2013.
PubMed
11) Lebeaux D, Sene D : Eosinophilic fasciitis (Shulman disease). Best Pract Res Clin Rheumatol 26 : 449-458, 2012.
PubMed
12) Nashel J, Steen V : The use of an elevated aldolase in diagnosing and managing eosinophilic fasciitis. Clin Rheumatol 34 : 1481-1484, 2015.
PubMed
13) Fujimoto M, et al : Serum aldolase level is a useful indicator of disease activity in eosinophilic fasciitis. J Rheumatol 22 : 563-565, 1995.
PubMed
14) Bischoff L, Derk CT : Eosinophilic fasciitis : demographics, disease pattern and response to treatment : report of 12 cases and review of the literature. Int J Dermatol 47 : 29-35, 2008.
PubMed
15) Chun JH, et al : Two cases of eosinophilic fasciitis. Ann Dermatol 23 : 81-84, 2011.
PubMed
P.259 掲載の参考文献
1) Wells GC : Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc 57 : 46-56, 1971.
PubMed
2) Wells GC, Smith NP : Eosinophilic cellulitis. Br J Dermatol 100 : 101-109, 1979.
PubMed
3) 矢野正一郎ほか : Eosinophilic cellulitis (Wells症候群). 臨床皮膚科 52 : 206-211, 1998.
 
4) 三上正史ほか : 虫刺症に続発した Eosinophilic Cellulitisの1例. 皮膚科の臨床 46 : 1181-1184, 2004.
 
5) 高橋昇司ほか : 細菌感染が誘因と考えられた Eosinophilic Cellulitis (Wells' Syndrome). 皮膚科の臨床 37 : 492-493, 1995.
 
6) 飯塚万利子ほか : Eosinophilic Cellulitisの2例. 皮膚科の臨床 35 : 125-130, 1993.
 
7) 初道誠ほか : Eosinophilic cellulitisの1例. アレルギー 53 : 1079-1083, 2004.
Medical*Online
8) 山本都美ほか : 喘息患者にみられた Eosinophilic Cellulitisの1例. 皮膚科の臨床 49 : 933-936, 2007.
 
9) 足立孝司ほか : 強皮症患者にみられた Wells症候群 (Eosinophilic Cellulitis) の1例. 西日本皮膚科 72 : 577-580, 2010.
 
10) 太居英夫, 金子佳照 : 前立腺癌を合併した Eosinophilic Cellulitisの1例. 臨床皮膚科 40 : 221-224, 1986.
 
11) Peters MS, et al : Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome. Br J Dermatol 109 : 141-148, 1983.
PubMed
12) Espana A, et al : Wells' syndrome (eosinophilic cellulitis) : correlation between clinical activity, eosinophil levels, eosinophil cation protein and interleukin-5. Br J Dermatol 140 : 127-130, 1999.
PubMed
13) Stam-Westerveld EB, et al : Eosinophilic cellulitis (Wells' syndrome) : treatment with minocycline. Acta Drem Venereol 78 : 157, 1998.
 
14) 田宮紫穂ほか : Eosinophilic Cellulitisの1例. 皮膚科の臨床 43 : 1657-1660, 2001.
 
15) 三井田博ほか : ロキシスロマイシン内服が奏効したWells症候群の1例. 臨床皮膚科 59 : 849-852, 2005.
 
P.263 掲載の参考文献
1) Hughes PA, et al : Eosinophilic meningitis : a case series report and review of the literature. Mil Med 168 : 817-821, 2003.
PubMed
2) Lo Re V 3rd, et al : Eosinophilic meningitis. Am J Med 114 : 217-223, 2003.
PubMed
3) 當眞弘 : 広東住血線虫症. 臨床と微生物 41 : 379-384, 2014.
Medical*Online
4) 宮腰淑子 : 好酸球性髄膜炎を呈したドロレス顎口虫症の1例. Clinical Parasitology 21 : 73-76, 2011.
 
5) Umehara F, et al : MRI studies of spinal visceral larva migrans syndrome. J Neurol Sci 249 : 7-12, 2006.
PubMed
6) Osoegawa M, et al : Localized myelitis caused by visceral larva migrans due to Ascaris suum masquerading as an isolated spinal cord tumour. J Neurol Neurosurg Psychiatry 70 : 265-266, 2001.
PubMed
7) Fukae J, et al : Longitudinal myelitis caused by visceral larva migrans associated with Toxocara cati infection : case report. Clin Neurol Neurosurg 114 : 1091-1094, 2012.
PubMed
8) Fox AS, et al : Fatal eosinophilic meningoencephalitis and visceral larva migrans caused by the raccoon ascarid Baylisascaris procyonis. N Engl J Med 312 : 1619-1623, 1985.
PubMed
9) Ragland AS, et al : Eosinophilic pleocytosis in coccidioidal meningitis : frequency and significance. Am J Med 95 : 254-257, 1993.
PubMed
10) Drake KW, et al : Coccidioidal meningitis and brain abscesses : analysis of 71 cases at a referral center. Neurology 73 : 1780-1786, 2009.
 
11) Hollister D Jr, et al : Eosinophilic meningitis in Hodgkin's disease. Report of a case and review of the literature. Arch Intern Med 143 : 590-592, 1983.
PubMed
12) Dellagi K, et al : Fatal eosinophilic meningitis and bronchogenic carcinoma. Ann Pathol 4 : 391-392, 1984.
PubMed
13) 神原瑞樹ほか : シリコンアレルギーが引き起こした好酸球性髄膜炎に伴いシャント機能不全を繰り返した1例. Neurological Surgery 42 : 1125-1130, 2014.
 
14) Goldblum RM, et al : Antibodies to silicone elastomers and reactions to ventriculoperitoneal shunts. Lancet 340 : 510-513, 1992.
PubMed
15) Kaplan PW, et al : Reversible dementia with idiopathic hypereosinophilic syndrome. Neurology 39 : 1388-1391, 1989.
PubMed
16) Hirano K, et al : Eosinophilic meningitis caused by primary angiitis of the central nervous system. Intern Med 52 : 1393-1396, 2013.
PubMed
P.266 掲載の参考文献
1) Brown EW : Eosinophilic granuloma of the bladder. J Urol 83 : 665-668, 1960.
PubMed
2) Palubinskas AJ : Eosinophilic cystits : case report of eosinophilic infiltration of the urinary bladder. Radiology 75 : 589-591, 1960.
 
3) vanden Ouden D : Diagnosis and management of eosinophilic cystitis. Eur Urol 37 : 386-394, 2000.
 
4) 渡辺美穂ほか : トシル酸スプラタストで奏功を得た好酸球性膀胱炎の1例. 泌尿器科紀要 55 : 715-719, 2009.
 
5) Dubucquoi S, et al : Evidence for eosinophil activation in eosinophilic cystits. Eur Urol 25 : 254-258, 1994.
 
6) Hellstrom HR, et al : Eosinophilic cystitis : A study of 16 cases. Am J Clin Pathol 72 : 777-784, 1979.
PubMed
7) 前田純宏, 畑山忠 : 尿中好酸球により発見された好酸球性膀胱炎の1例. 泌尿器科紀要 48 : 633-635, 2002.
 
8) 倉本朋未ほか : トシル酸スプラタスト (IPD) 内服が有効であった好酸球性膀胱炎の1例. 泌尿器科紀要 60 : 447-450, 2014.
 
9) 山田哲夫ほか : 好酸球性膀胱炎. 日本臨牀 51 : 811-815, 1993.
Medical*Online
10) Wan Majdiah WM, et al : Association between Specific IgE Levels and Severity of Symptoms among Patients with Rhinitis in North East Malaysia. Int Med J 18 : 348-349, 2011.
 
P.273 掲載の参考文献
1) 木村哲二ほか : リンパ組織増生を伴う異常肉芽腫について, 特に他の類似変化の組織像との比較. 第11回東京病理集団会記事, p10-14, 1948.
 
2) 飯塚栄 : 好エオジン球性リンパ腺炎およびリンパ肉芽腫症-木村氏病の提唱-. 日大医誌 18 : 900-908, 1959.
 
3) 吉田誠 : 軟部好酸球肉芽腫 (木村病). 21世紀耳鼻咽喉科領域の臨床 No.18免疫・アレルギー疾患 (石川哮編), p287-290, 中山書店, 2001.
 
4) 石井正則 : 木村氏病について-4例の経験と本邦429例の統計的観察-. 耳鼻咽喉科展望 25 : 407-416, 1982.
 
5) 田制昭浩ほか : 柴朴湯が有効であった喉頭蓋木村病例. 耳鼻咽喉科臨床 96 : 999-1004, 2003.
 
6) 鈴木さおりほか : 当科における木村病6症例の検討. 頭頸部外科 13 : 47-54, 2003.
 
7) Nonaka M, et al : Anti- IgE therapy to Kimura's Disease : A pilot study. Auris Nasus Larynx 41 : 384-388, 2014.
PubMed
8) Sakitani E, et al : Increased expression of thymic stromal lymphoprotein and its receptor in Kimura's disease. ORL J Otorhinolaryngol Rerat Spec 77 : 44-54, 2015.
 
P.278 掲載の参考文献
1) Swerdlow SH, et al (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2008.
 
2) Valent P, et al : Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130 : 607-612, 2012.
PubMed
3) Noel P : Eosinophilic myeloid disorders. Semin Hematol 49 : 120-127, 2012.
PubMed
4) Crane MM, et al : Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 126 : 179-181, 2010.
 
5) Cools J, et al : A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 : 1201-1214, 2003.
PubMed
6) Gotlib J, et al : The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia : implications for diagnosis, classification, and management. Blood 103 : 2879-2891, 2004.
 
7) Tanaka H, et al : Pure red cell aplasia associated with imatinib-treated FIP1L1- PDGFRA positive chronic eosinophilic leukemia. Intern Med 49 : 1195-1200, 2010.
PubMed
8) Elling C, et al : Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117 : 2935-2943, 2011.
PubMed
9) Gotlib J : World Health Organization-defined eosinophilic disorders : 2014 update on diagnosis, risk stratification, and management. Am J Hematol 89 : 325-337, 2014.
PubMed
10) Pardanani A, et al : CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 : 3093-3096, 2003.
PubMed
11) Jovanovic JV, et al : Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 109 : 4635-4640, 2007.
PubMed
12) Legrand F, et al : The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia : New Insights Based on a Survey of 44 Cases. Medicine (Baltimore), 2013. [Epub ahead of print]
 
13) Hochhaus A, et al : Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia : analysis of the phase 2, open-label, single-arm A2101 study. J Cancer Res Clin Oncol 139 : 1985-1993, 2013.
PubMed
14) Jin Y, et al : Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα : roles of Mcl-1 and β-catenin. Mol Cancer 13 : 17, 2014.
 
15) Chen J, et al : PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA 101 : 14479-14484, 2004.
PubMed
P.284 掲載の参考文献
1) Valent P, et al : Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 130 : 607-612.e9, 2012.
 
2) 定明子, 松井利充 : 好酸球増加を伴う造血器腫瘍 (CBF白血病を除く) : 変わりゆくHES/CELの概念を中心に. 血液フロンテイア 24 : 37-47, 2014.
 
3) Bain BJ, Ahmad S : Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol 166 : 809-817, 2014.
PubMed
4) Samoszuk M : IgE in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 79 : 1518-1522, 1992.
PubMed
5) Grimaldi JC, Meeker TC : The t (5 ; 14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 73 : 2081-2085, 1989.
 
6) Pandit R, et al : Non-small-cell lung cancer associated with excessive eosinophilia and secretion of interleukin-5 as a paraneoplastic syndrome. Am J Hematol 82 : 234-237, 2007.
PubMed
7) Bain B, et al : Chronic eosinophilic leukemia, not otherwise specified. & Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In : WHO Classification of Tumours : Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed (ed by Swerdlow SH, et al), p51-53, 68-73, IARC Press, Lyon, 2008.
 
8) Simon HU, et al : Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 : 1112-1120, 1999.
PubMed
9) Koyasu S, Moro K : Th2-type innate immune responses mediated by natural helper cells. Ann N Y Acad Sci 1283 : 43-49, 2013.
PubMed
10) 定明子, 松井利充 : 本邦における慢性好酸球性白血病/特発性好酸球増多症候群の臨床像と治療. 臨床血液 51 : 515-525, 2010.
 
11) Klion AD, et al : Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosionophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenesss. Blood 101 : 4660-4666, 2003.
 
12) de Lavareille A, et al : High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 110 : 476-479, 2002.
PubMed
13) Montgomery ND, et al : Diagnostic complexities of eosinophilia. Arch Pathol Lab Med 137 : 259-269, 2013.
PubMed
14) Elling C, et al : Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 117 : 2935-2943, 2011.
PubMed
15) Roufosse F, et al : Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol 126 : 828-835. e3, 2010.
 
P.289 掲載の参考文献
1) Haenisch B, et al : Systemic mast cell activation disease : the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology 137 : 197-205, 2012.
PubMed
2) Lange M, et al : Clinical aspects of paediatric mastocytosis : a review of 101 cases. J Eur Acad Dermatol Venereol 27 : 97-102, 2013.
 
3) Heide R, et al : Clinical scoring of cutaneous mastocytosis. Acta Derm Venereol 81 : 273-276, 2001.
PubMed
4) Longley J, et al : The mast cell and mast cell disease. J Am Acad Dermatol 32 : 545-561, 1995.
PubMed
5) Van Doormaal JJ, et al : Prevalence of indolent systemic mastocytosis in a Dutchregion. J Allergy Clin Immunol 131 : 1429-1431, 2013.
 
6) Brockow K : Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am 34 : 283-295, 2014.
PubMed
7) Zappulla JP, et al : Mastocytosis in mice expressing human kit receptor with the activating Asp816Val mutation. J Exp Med 202 : 1635-1641, 2005.
PubMed
8) Carter MC, et al : Mastocytosis. Immunol Allergy Clin North Am 34 (1) : 181-196, 2014.
PubMed
9) Pardanani A : Systemic mastocytosis in adults : 2015 update on diagnosis, risk stratification, and management. Am J Hematol 90 : 250-262, 2015.
PubMed
10) Forster A, et al : Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells. Allergy 70 : 764-774, 2015.
 
11) 山本俊幸 : 色素性蕁麻疹. 病理と臨床 (臨時増刊) 33 : 321, 2015.
 
12) Arock M, et al : Current treatment options in patients with mastocytosis : status in 2015 and future perspectives. Eur J Haematol 94 : 474-490, 2015.
PubMed
13) Meni C, et al : Paediatric mastocytosis : a systematic review of 1747 cases. Br J Dermatol 172 : 642-651, 2015.
PubMed
14) Akin C, Valent P : Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am 34 : 207-218, 2014.
PubMed
15) Valent P, et al : Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol 156 : 119-127, 2011.
PubMed
P.294 掲載の参考文献
1) Ochi N, et al : A new type of hypersensitivity pneumonitis in Japan. In : Sarcoidosis and Other Granulomatous Diseases (ed by Williams WJ, Davies BH), p705-710, Alpha Omega, Wales, 1980.
 
2) Ando M, et al : Japanese summer-type hypersensitivity pneumonitis. Geographic distribution, home environment, and clinical characteristics of 621 cases. Am Rev Respir Dis 144 : 765-769, 1991.
PubMed
3) Shimazu K, et al : Hypersensitivity pneumonitis induced by Trichosporon cutaneum. Am Rev Respir Dis 130 : 407-411, 1984.
PubMed
4) Yoshida K, et al : Environmental mycological studies on the causative agent of summer-type hypersensitivity pneumonitis. J Allergy Clin Immunol 81 : 475-483, 1988.
PubMed
5) Ando M, et al : Serotype-related antigen of Trichosporon cutaneum in the induction of summer-type hypersensitivity pneumonitis : correlation between serotype of inhalation challenge-positive antigen and that of the isolates from patients' homes. J Allergy Clin Immunol 85 : 36-44, 1990.
 
6) Soda K, et al : Different classes of antibody activities to Trichosporon cutaneum antigen in summer-type hypersensitivity pneumonitis by enzyme-linked immunosorbent assay. Am Rev Respir Dis 133 : 83-87, 1986.
PubMed
7) Ando M : Summer-type hypersensitivity pneumonitis. In : Lung Disease in the Tropics (ed by Sharma OmP), p449-478, Marcel Dekker, New York, 1991.
 
8) Soda K, et al : C1q and C3 in bronchoalveolar lavage fluid from patients with summer-type hypersensitivity pneumonitis. Chest 93 : 76-80, 1988.
PubMed
9) Yoshida K, et al : Prevention of summer-type hypersensitivity pneumonitis : effect of elimination of Trichosporon cutaneum from the patients' homes. Arch Environ Health 44 : 317-322, 1989.
 
10) Ando M, et al : Difference in the phenotypes of bronchoalveolar lavage lymphocytes in patients with summer-type hypersensitivity pneumonitis, farmer's lung, ventilation pneumonitis, and bird fancier's lung : report of a nationwide epidemiologic studyin Japan. J Allergy Clin Immunol 87 : 1002-1009, 1991.
 
11) Yamasaki H, et al : Polarized type 1 cytokine profile in bronchoalveolar lavage T cells of patients with hypersensitivity pneumonitis. J Immunol 163 : 3516-3523, 1999.
PubMed
12) Ando M, et al : HLA-DQw3 in Japanese summer-type hypersensitivity pneumonitis induced by Trichosporon cutaneum. Am Rev Respir Dis 140 : 948-950, 1989.
PubMed
13) Arima K, et al : Effect of cigarette smoking on prevalence of summer-type hypersensitivity pneumonitis caused by Trichosporon cutaneum. Arch Environ Health 47 : 274, 1992.
PubMed
14) Yoshizawa Y, et al : Chronic hypersensitivity pneumonitis in Japan : a nationwide epidemiologic survey. J Allergy Clin Immunol 103 : 315-320, 1999.
PubMed
P.300 掲載の参考文献
1) Ando M, et al : Difference in the phenotypes in of bronchoalveolar lavage lymphocytes in patients with summer-type hypersensitivity pneumonitis, farmer's lung, ventilation pneumonitis, and bird fancier's lung ; Report of a nationwide epidemiologic study in Japan. J Allergy Clin Immunol 87 (5) : 1002-1009, 1991.
PubMed
2) 菅守隆 : 夏型過敏性肺炎とその周辺. 日本胸部臨床 62 (2) : 97-106, 2003.
Medical*Online
3) 小原秋穂 : 農夫肺起因抗原に対する抗体陽性酪農従事者の肺胞リンパ球の活性化に関する研究. 岩手医学雑誌 44 (4) : 483-492, 1992.
 
4) 守義明 : interleukin-1及びtumor necrosis factorα注入による実験的肺肉芽腫形成. 岩手医学雑誌 45 (3) : 251-260, 1993.
 
5) 鹿内俊樹, 富地信和 : 肉芽腫性肺疾患における肺組織内浸潤リンパ球免疫組織学的研究. 岩手医学雑誌 44 (4) : 431-441, 1992.
 
6) Barrowcliff DF, et al : Farmer's lung : a study of an early acute fatal case. Thorax 23 : 490-500, 1968.
PubMed
7) Mouri T, et al : Hypersensitivity pneumonitis caused by spores of Japanese mushrooms. 19th annual conference of the European Respiratory Society, abstract p1023, Sep, 2009, Vienna.
 
8) 青木悠ほか : シイタケ栽培による過敏性肺炎の2例. 日職業・環境アレルギー会誌 15 (2) : 37-42, 2008.
Medical*Online
9) 毛利孝ほか : 農夫肺長期観察例の胸部CT所見. 臨床放射線 49 (1) : 178-184, 2004.
 
10) Pan LH, et al : Inhibition of binding between E- and P-selectin to sialyl-Lewis X molecule suppresses the inflmatory responses in hypersensitivity peumonitis in mice. Am J Respir Crit Care Med 161 : 1689-1697, 2000.
 
11) Mouri T, et al : KL-6, SP-A and SP-D in BALF and serum in patients with interstitial lung disorders. In : Bronchology and Bronchoesophagology : State of the Art (ed by Yoshimura H, et al), p338-340, Elsevier Science BV, 2001.
 
P.308 掲載の参考文献
1) Yoshizawa Y, et al : Chronic hypersensitivity pneumonitis in Japan : a nationwide epidemiologic survey. J Allergy Clin Immunol 103 : 315-320, 1999.
PubMed
2) Ohtani Y, et al : Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol 90 : 604-610, 2003.
 
3) Miyazaki Y, et al : Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 134 : 1265-1270, 2008.
PubMed
4) Xaubet A, et al : Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 21 : 64-70, 2004.
PubMed
5) Terho EO : Work-related respiratory disorders among Finnish farmers. Am J Ind Med 18 : 269-272, 1990.
PubMed
6) Madsen D, et al : The prevalence of farmer's lung in an agricultural population. Am Rev Respir Dis 113 : 171-174, 1976.
 
7) Lacasse Y, et al : Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med 168 : 952-958, 2003.
PubMed
8) Okamoto T, et al : A nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51 : 191-199, 2013.
PubMed
9) 宮崎泰成, 稲瀬直彦 : 【間質性肺炎のパラダイムシフト】慢性過敏性肺炎と特発性間質性肺炎. 呼吸器内科 27 : 118-124, 2015.
 
10) Agostini C, et al : New aspects of hypersensitivity pneumonitis. Curr Opin Pulm Med 10 : 378-382, 2004.
PubMed
11) Edwards J, et al : Antigens in pigeon breeders' disease. Immunology 19 : 729-735, 1970.
 
12) Lympany PA, du Bois RM : Diffuse lung disease : product of genetic susceptibility and environmental encounters. Thorax 52 : 92-94, 1997.
PubMed
13) Bourke SJ, et al : Hypersensitivity pneumonitis : current concepts. Eur Respir J 32 : 81s-92s, 2001.
 
14) Kishi M, et al : Pathogenesis of cBFL in common with IPF? Correlation of IP-10/TARC ratio with histological patterns. Thorax 63 : 810-816, 2008.
PubMed
15) Belperio J, et al : The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J Immunol 173 : 4692-4698, 2004.
PubMed
16) Ishizuka M, et al : Validation of inhalation provocation test in chronic bird-related hypersensitivity pneumonitis and new prediction score. Ann Am Thorac Soc 12 : 167-173, 2015.
PubMed
17) Ohtani Y, et al : Chronic bird fancier's lung : histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 60 : 665-671, 2005.
PubMed
18) Kuramochi J, et al : Lung cancer in chronic hypersensitivity pneumonitis. Respiration 82 : 263-267, 2011.
PubMed
P.313 掲載の参考文献
1) Fink JN : Hypersensitivity pneumonitis. J Allergy Clin Immunol 74 : 1-10, 1984.
PubMed
2) Yoshizawa Y, et al : Chronic hypersensitivity pneumonitis in Japan : a nationwide epidemiologic survey. J Allergy Clin Immunol 103 : 315-320, 1999.
PubMed
3) Ohtani Y, et al : Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol 90 : 604-610, 2003.
 
4) Reed CE, Barbee RA : Pigeon-breeders' lung : A newly observed interstitial pulmonary disease. JAMA 193 : 261-265, 1965.
PubMed
5) Caldwell JR, et al : Immunologic mechanisms in hypersensitivity pneumonitis. I. Evidence for cell-mediated immunity and complement fixation in pigeon breeders' disease. J Allergy Clin Immunol 52 : 225-230, 1973.
PubMed
6) Okamoto T, et al : Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 51 : 191-199, 2013.
PubMed
7) Inase N, et al : A clinical study of hypersensitivity pneumonitis presumably caused by feather duvets. Ann Allergy Asthma Immunol 96 : 98-104, 2006.
PubMed
8) Mitaka K, et al : Th2-biased immune responses are important in a murine model of chronic hypersensitivity pneumonitis. Int Arch Allergy Immunol 154 : 264-274, 2011.
 
9) 土屋公威, 稲瀬直彦 : 鳥飼病. 内科 109 : 1149-1152, 2012.
 
10) Suhara K, et al : Utility of immunological tests for bird-related hypersensitivity pneumonitis. Respir Investig 53 : 13-21, 2015.
PubMed
11) Ishizuka M, et al : Validation of inhalation provocation test in chronic bird-related hypersensitivity pneumonitis and new prediction score. Ann Am Thorac Soc 12 : 167-173, 2015.
PubMed
12) Ohtani Y, et al : Chronic bird fancier's lung : histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 60 : 665-671, 2005.
PubMed
13) Takemura T, et al : Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology 61 : 1026-1035, 2012.
PubMed
14) 稲瀬直彦 : 過敏性肺炎と特発性肺線維症の関係とは? Modern Physician 35 : 779-782, 2015.
 
15) Miyazaki Y, et al : Clinical predictors and histologic appearance of acute exacerbations in chronic hypersensitivity pneumonitis. Chest 134 : 1265-1270, 2008.
PubMed
P.320 掲載の参考文献
1) 海老澤元宏ほか : 食物アレルギー委員会報告 第2報 食物アレルギーの定義と分類について. 日小児アレルギー会誌 17 : 558-559, 2003.
 
2) 日本小児アレルギー学会 食物アレルギー委員会 (宇理須厚雄, 近藤直実監修) : 食物アレルギー診療ガイドライン 2012, 協和企画, 2011.
 
3) 厚生労働科学研究班「食物アレルギーの診療の手引き2014」検討委員会 (主任研究者海老澤元宏) : 食物アレルギーの診療の手引き 2014. [http://www.foodallergy.jp/manual2014.pdf]
 
4) Hitomi Y, et al : Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J Allergy Clin Immunol 124 : 779-785, 2009.
PubMed
5) Lack G, et al : Factors associated with the development of peanut allergy in childhood. N Engl J Med 348 : 977-985, 2003.
PubMed
6) Horimukai K, et al : Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 134 (4) : 824-830, 2014.
PubMed
7) Du Toit G, et al : Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 372 (9) : 803-813, 2015.
PubMed
8) Debra JP, et al : Early regular egg exposure in infants with eczema : A randomized controlled trial. J Allergy Clin Immunol 132 : 387-392, 2013.
 
9) Wood RA, et al : The natural history of milk allergy in an observational cohort. J Allergy Clin Immunol 131 : 805-812, 2013.
 
10) Sicherer SH, et al : The natural history of egg allergy in an observational cohort. J Allergy Clin Immunol 133 : 492-499, 2014.
 
11) 緒方美佳ほか : 乳児アトピー性皮膚炎におけるBirfurcated Needleを用いた皮膚プリックテストの食物アレルギーの診断における有用性 (第1報) -鶏卵アレルギー-. アレルギー 57 : 843-852, 2008.
 
12) Komata T, et al : The predictive relationship of food-specific serum IgE concentrations to challenge outcomes for egg and milk varies by patient age. J Allergy Clin Immunol 119 : 1272-1274, 2007.
 
13) Sato S, et al : Utility of the peripheral blood basophil histamine release test in the diagnosis of hen's egg, cow's milk, and wheat allergy in children. Int Arch Allergy Immunol 155 : 96-103, 2011.
 
14) Anaphlylaxis対策特別委員会 : アナフィラキシーガイドライン, 一般社団法人日本アレルギー学会, 2014.
 
15) Burks AW, et al : Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 367 (3) : 233-243, 2012.
PubMed
16) 海老澤元宏ほか : 経口免疫療法の実際と問題点. アレルギー 64 (6) : 809-815, 2015.
Medical*Online
P.323 掲載の参考文献
1) Benhamou AH, et al : State of the art and new horizons in the diagnosis and management of egg allergy. Allergy 65 : 283-289, 2010.
PubMed
2) Urisu A, et al : Allergenic activity of heated and ovomucoid depleted egg white. J Allergy Clin Immunol 100 : 171-176, 1997.
PubMed
3) Bernhisel-Broadbent J, et al : Allergenicity and antigenicity of chicken egg ovomucoid (Gald III) compared with ovalbumin (Gal d I) in children with egg allergy and in mice. J Allergy Clin Immunol 93 : 1047-1059, 1994.
 
4) Jarvinen KM, et al : Specificity of IgE antibodies to sequential epitopes of hen's egg ovomucoid as a marker for persistence of egg allergy. Allergy 62 : 758-765, 2007.
 
5) Escudero C, et al : Egg white proteins as inhalant allergens associated with baker's asthma. Allergy 58 : 616-620, 2003.
 
6) Quirce S, et al : Chicken serum albumin (Gal d 5) is a partially heat-labile inhalant and food allergen implicated in the bird-egg syndrome. Allergy 56 : 754-762, 2001.
 
7) Caubet J C, et al : Molecular diagnosis of egg allergy. Curr Opin Allergy Clin Immunol 11 : 210-215, 2011.
PubMed
8) Boyano-Martinez T, et al : Prediction of tolerance on the basis of quantification of egg white-specific IgE antibodies in children with egg allergy. J Allergy Clin Immunol 110 : 304-309, 2002.
PubMed
9) Montesinos E, et al : Egg white specific IgE levels in serum as clinical reactivity predictorsin the course of egg allergy follow-up. Pediatr Allergy Immunol 21 : 634-639, 2010.
PubMed
10) 池松かおりほか : 乳児期発症食物アレルギーに関する検討 (第2報) -卵・牛乳・小麦・大豆アレルギーの3歳までの経年的変化-. アレルギー 55 : 533-541, 2006.
Medical*Online
11) Savage JH, et al : The natural history of egg allergy. J Allergy Clin Immunol 120 : 1413-1417, 2007.
PubMed
12) Hamilton RG, et al : Extension of food allergen specific IgE ranges from the Immuno CAP to the IMMULITE systems. Ann Allergy Asthma Immunol 107 : 139-144, 2011.
 
13) Ando H, et al : Utility of ovomucoid-specific IgE concentrations in predicting symptomatic egg allergy. J Allergy Clin Immunol 122 : 583-588, 2008.
PubMed
14) Urisu A, et al : Clinical significance of IgE-binding activity to enzymatic digests of ovomucoid in the diagnosis and the prediction of the outgrowing of egg white hypersensitivity. Int Arch Allergy Immunol 120 : 192-198, 1999.
PubMed
15) Yamada K, et al : IgE-binding activity to enzyme-digested ovomucoid distinguishes between patients with contact urticaria to egg with and without overt symptoms on ingestion. Allergy 55 : 565-569, 2000.
PubMed
16) 坂井堅太郎ほか : ゆで卵の作成と放置に伴うオボムコイドの卵黄への浸透. アレルギー 47 (11) : 1176-1181, 1998.
Medical*Online
17) Kato Y, et al : Decrease in antigenic and allergenic potentials of ovomucoid by heating in the presence of wheat flour : dependence on wheat variety and intermolecular disulfide bridges. J Agric Food Chem 49 : 3661-3665, 2001.
 
18) Lemon- Mule H, et al : Immunologic changes in children with egg allergy ingesting extensively heatedegg. J Allergy Clin Immunol 122 : 977-983, 2008.
 
P.328 掲載の参考文献
1) 「食物アレルギーの診療の手引き 2014」検討委員会 : 疫学. 食物アレルギー診療の手引き 2014 (海老澤元宏), p4, 2014.
 
2) 中野泰至ほか : 牛乳アレルギー患者におけるカゼイン, βラクトグロブリン感作に関する研究. アレルギー 59 : 117-122, 2010.
Medical*Online
3) Shek LPC, et al : Humoral and cellular responses to cow milk proteins in patients wit milk-induced IgE-mediatedand non-IgE-mediated disorders. Allergy 60 : 912-919, 2005.
 
4) 伊藤靖典ほか : 日本人牛乳アレルギー児における好塩基球活性化試験を用いたβ-カゼインの即時型アレルゲン性についての検討. アレルギー 63 : 1330-1337, 2014.
Medical*Online
5) 木村光明 : 食物アレルギーのin vitro診断. 日小児アレルギー会誌 28 : 193-200, 2014.
Medical*Online
6) 今井孝成 : ミルクアレルギー児におけるビオチン欠乏症の問題. アレルギー 60 : 1614-1620, 2011.
Medical*Online
7) 高柳正樹 : カルニチンの臨床. 生物試料分析 35 : 281-292, 2012.
Medical*Online
8) 日本小児アレルギー学会食物アレルギー委員会 : 新生児・乳児消化管アレルギー. 食物アレルギー診療ガイドライン 2012 (宇理須厚雄, 近藤直実監修), p82-87, 協和企画, 2012.
 
9) 木村光明ほか : 消化管症状を主とする乳児の牛乳アレルギーの臨床像と検査値について. 日児誌 112 : 1787-1793, 2008.
 
10) Kimura M, et al : Usefulness of lymphocyte stimulation test for the diagnosis of intestinal cow's milk allergy in infants. Int Arch Allergy Immunol 157 : 58-64, 2012.
PubMed
11) 木村光明ほか : 牛乳蛋白による新生児・乳児の消化管アレルギー患者における好酸球とCRP値との関係. 日児誌 115 : 777-781, 2011.
 
12) Powell GK : Milk- and soy-induced enterocolitis of infancy. Clinical features and standardization of challenge. J Pediatr 93 : 553-560, 1978.
PubMed
13) 木村光明ほか : 牛乳蛋白による消化管アレルギー患者の予後についての研究. 日児誌 115 : 1301-1306, 2011.
 
14) Saito M, et al : Infantile hepatic dysfunction improved by elimination of cow's milk formulas. Pediatr Allergy Immunol 16 : 445-448, 2005.
PubMed
15) 小尾真喜子ほか : SLE様症状を呈したIgE抗体非依存性牛乳アレルギーの一例. 日児誌 108 : 1222-1225, 2004.
 
P.333 掲載の参考文献
1) 厚生労働科学研究班による食物アレルギーの診療の手引き 2014.
 
2) 日本小児アレルギー学会食物アレルギー委員会 : 食物アレルギー診療ガイドライン, 協和企画, 2012.
 
3) Young E, et al : A population study of food intolerance. Lancet 343 : 1127-1130, 1994.
 
4) 池松かおりほか : 乳児期発症食物アレルギーに関する検討 (第2報) -卵・牛乳・小麦・大豆アレルギーの3歳までの経年的変化. アレルギー 55 : 533-541, 2006.
Medical*Online
5) Keet CA, et al : The natural history of wheat allergy. Ann Allergy Asthma Immunol 102 (5) : 410-415, 2009.
PubMed
6) Morita E, et al : Fast omega-5 gliadin is a major allergen in wheat-dependent exercise-induced anaphylaxis. J Dermatol Sci 33 : 99-104, 2003.
 
7) Palosuo K, et al : Wheat omega-5 gliadin is a major allergen in children with immediate allergy to ingested wheat. J Allergy Clin Immunol 108 : 634-638, 2001.
 
8) Cianferoni A, et al : Oral food challenge to wheat : a near-fatal anaphylaxis and review of 93 food challenges in children. World Allergy Organ J 6 : 14, 2013.
 
9) Ebisawa M, et al : Clinical utility of IgE antibodies to ω-5gliadin in the diagnosis of wheat allergy : a pediatric multicenter challenge study. Int Arch Allergy Immunol 158 (1) : 71-76, 2012.
 
10) 厚生労働科学研究班による食物アレルギーの栄養指導の手引き 2014.
 
11) Sicherer SH : Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 108 : 881-890, 2001.
PubMed
12) Jones SM, et al : Immunologic cross-reactivity among cereal grains and grasses in children with food hypersensitivity. J Allergy Clin Immunol 96 : 341-351, 1995.
PubMed
13) 藤野歩, 栗原和幸 : アナフィラキシー型小麦アレルギーに対する急速特異的経口耐性誘導の2例. アレルギー 59 : 1580-1584, 2010.
Medical*Online
14) 楳村春江ほか : タンパク質換算を用いた小麦アレルギー患者への除去解除指導 (第4報). 日小児アレルギー会誌 27 : 710-720, 2013.
Medical*Online
15) Sato S, et al : Clinical studies in oral allergen-specific immunotherapy : differences among allergens. Int Arch Allergy Immunol 164 (1) : 1-9, 2014.
PubMed
P.339 掲載の参考文献
1) 農林水産省 : 大豆のまめ知識. [http://www.maff.go.jp/j/seisan/ryutu/daizu]
 
2) 林典子ほか : 大豆, 豆類. 食物アレルギーの栄養指導 (海老澤元宏編), p32-34, 医歯薬出版, 2012.
 
3) Ballmer-Weber BK, Vieths S : Soy allergy in perspective. Curr Opin Allergy Clin Immunol 8 : 270-275, 2008.
PubMed
4) 「食物アレルギーの診療の手引き 2011」検討委員会 : 厚生労働科学研究班による食物アレルギーの診療の手引き 2011, p3.
 
5) 「食物アレルギーの診療の手引き 2014」検討委員会 : 厚生労働科学研究班による食物アレルギーの診療の手引き 2014, p4.
 
6) 日本小児アレルギー学会食物アレルギー委員会 : 食物アレルギー診療ガイドライン 2012, p17-57, 協和企画, 2011.
 
7) 日本アレルギー学会 Anaphylaxis対策特別委員会 : アナフィラキシーガイドライン 2014, p1-24, 2014. [http://www.jsaweb.jp/]
 
8) Taramarcaz P, et al : Soy anaphylaxis. Allergy 56 : 792, 2001.
PubMed
9) 「特殊型食物アレルギーの診療の手引き 2015」作成委員会 : 特殊型食物アレルギーの診療の手引き 2015, p2-7.
 
10) Holzhauser T, et al : Soybean (Glycine max) allergy in Europe : Gly m 5 (beta-conglycinin) and Gly m 6 (glycinin) are potential diagnostic markers for severe allergic reactions to soy. J Allergy Clin Immunol 123 : 452-458, 2009.
 
11) Canonica GW, et al : A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J 6 (1) : 17, 2013.
PubMed
12) Mittag D, et al : Soybean allergy in patients allergic to birch pollen : clinical investigation and molecular characterization of allergens. J Allergy Clin Immunol 113 : 148-154, 2004.
PubMed
13) Kleine-Tebbe J, et al : Severe oral allergy syndrome and anaphylactic reactions caused by a Bet v 1-related PR-10 protein in soybean, SAM22. J Allergy Clin Immunol 110 : 797-804, 2002.
 
14) Wang T, et al : Advances of research on glycinin and beta-conglycinin : a review of two major soybean allergenic proteins. Crit Rev Food Sci Nutr 54 : 850-862, 2014.
PubMed
15) Ito K, et al : IgE to Gly m 5 and Gly m 6 is associated with severe allergic reactions to soybean in Japanese children. J Allergy Clin Immunol 128 : 673-675, 2011.
 
16) Adachi A, et al : Soybean beta-conglycinin as the main allergen in a patient with food-dependent exercise-induced anaphylaxis by tofu : food processing alters pepsin resistance. Clin Exp Allergy 39 : 167-173, 2009.
 
17) Ebisawa M, et al : Gly m 2S albumin is a major allergen with a high diagnostic value in soybean-allergic children. J Allergy Clin Immunol 132 : 976-978 e1-5, 2013.
 
18) Klemans RJ, et al : Components in soy allergy diagnostics : Gly m 2S albumin has the best diagnostic value in adults. Allergy 68 : 1396-1402, 2013.
PubMed
19) Inomata N, et al : Late-onset anaphylaxis to Bacillus natto-fermented soybeans (natto). J Allergy Clin Immunol 113 : 998-1000, 2004.
PubMed
20) 佐藤美紀 : 大豆アレルギー. 矢山晶子, 松永佳世子 : 豆乳アレルギー. 猪又直子 : 納豆アナフィラキシー. 症例を通して学ぶ年代別食物アレルギーのすべて (海老澤元宏編), p142-143, p218-221, 南山堂, 2013.
 
21) Komata T, et al : Usefulness of wheat and soybean specific IgE antibody titers for the diagnosis of food allergy. Allergol Int 58 : 599-603, 2009.
PubMed
22) 日本アレルギー学会食物アレルギー委員会経口負荷試験標準化ワーキンググループ : 食物アレルギー経口負荷試験ガイドライン 2009, p17-55, 協和企画, 2009.
 
23) Cochico SG : Propofol allergy : assessing for patient risks. AORN J 96 : 398-405, quiz 406-408, 2012.
 
24) Zhang T, et al : Therapeutic effects of a fermented soy product on peanut hypersensitivity is associated with modulation of T-helper type 1 and T-helper type 2 responses. Clin Exp Allergy 38 : 1808-1818, 2008.
 
25) Savage JH, et al : The natural history of soy allergy. J Allergy Clin Immunol 125 : 683-686, 2010.
PubMed
P.344 掲載の参考文献
1) Smith HL : Buckwheat-poisoning with report of a case in man. Arch Int Med 3 : 350-359, 1909.
 
2) Blumstein GI : Buckwheat allergy-An investigation of asthma associated with flour substitutes used in the baking industry. (Reprint from the South African Journal, p737-739, Capetimes Limited, Cape Town, 1947.)
 
3) 三沢敬義 : アレルギー性疾患. 日内会誌 25 : 133-262, 1937.
 
4) 松村龍ほか : 小児気管支喘息のアレルゲン診断と特異療法に関する研究, 枕のそばがらに付着しているそば粉による吸入性喘息. アレルギー 18 : 902-911, 1969.
 
5) 中村晋, 室久敏三郎 : 気管支喘息の研究, 第5報, そばアレルギーについて. アレルギー 19 : 702-717, 1970.
Medical*Online
6) 中村晋, 山口道也 : そばアレルギー症の研究 第2報 そばアレルギー症に関する全国調査成績. アレルギー 23 : 554-560, 1974.
Medical*Online
7) 高橋由利子ほか : 横浜市の小学校9万人を対象としたそばアレルギー罹患率調査. アレルギー 47 : 26-33, 1998.
 
8) 日本小児アレルギーガイドライン委員会 : 疫学. 食物アレルギー診療ガイドライン 2012 (字理須厚雄・近藤直美監), p20-25, 協和企画, 2012.
 
9) 渡辺一彦ほか : そばアレルギー37例の臨床的検討. 小児科臨床 50 : 2029-2034, 1997.
Medical*Online
10) 田中和子ほか : そばアレルギー. アレルギー・免疫 10 : 722-728, 2003.
 
11) Tanaka K, et al : Pepsin-resistant 16-k Dbuckwheat protein is associated with immediate hypersensitivity reaction in patients with buckwheat allergy. Int Arch Allergy Immunol 129 : 49-56, 2002.
 
12) 柳田紀之ほか : そば負荷試験252例から作成したプロバビリティーカーブ. アレルギー 62 : 1326, 2013.
 
P.349 掲載の参考文献
1) 永倉顕一, 宿谷明紀 : ピーナッツアレルギー. 小児科 55 (増刊号) : 721-728, 2014.
 
2) Mc Gowan EC, Keet CA : Prevalence of self-reported food allergy in the National Health and Nutrition Examination Survey (NHANES) 2007-2010. J Allergy Clin Immunol 132 (5) : 1216-1219. e5, 2013.
 
3) Peters RL, et al : Natural history of peanut allergy and predictors of resolution in the first 4 years of life : A population-based assessment. J Allergy Clin Immunol 135 (5) : 1257-1266.e1-2, 2015.
 
4) Du Toit G, et al : Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. J Allergy Clin Immunol 122 (5) : 984-991, 2008.
PubMed
5) Du Toit G, et al ; LEAP Study Team : Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 372 (9) : 803-813, 2015.
 
6) Brough HA, et al : Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. J Allergy Clin Immunol 135 (1) : 164-170, 2015.
PubMed
7) Brown SJ, et al : Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 127 (3) : 661-667, 2011.
PubMed
8) Sicherer SH, et al : Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics 102 (1) : e6, 1998.
PubMed
9) Bock SA, et al : Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 107 (1) : 191-193, 2001.
PubMed
10) Blom WM, et al : Threshold dose distributions for 5 major allergenic foods in children. J Allergy Clin Immunol 131 (1) : 172-179, 2013.
 
11) Beyer K, et al : Effects of cooking methods on peanut allergenicity. J Allergy Clin Immunol 107 (6) : 1077-1081, 2001.
PubMed
12) Maloney JM, et al : The use of serum-specific IgE measurements for the diagnosis of peanut, tree nut, and seed allergy. J Allergy Clin Immunol 122 (1) : 145-151, 2008.
PubMed
13) Skolnick HS, et al : The natural history of peanut allergy. J Allergy Clin Immunol 107 (2) : 367-374, 2001.
PubMed
14) Anagnostou K, Clark A : Peanut immunotherapy. Clin Transl Allergy 4 : 30, 2014.
PubMed
15) Neuman-Sunshine DL, et al : The natural history of persistent peanut allergy. Ann Allergy Asthma Immunol 108 (5) : 326-331. e3, 2012.
 
P.353 掲載の参考文献
1) 小倉由紀子, 小倉英郎 : アトピー性皮膚炎における食物アレルギーの頻度 第2報. アレルギー 58 : 1269 (抄録), 2009.
 
2) 小倉由紀子, 小倉英郎 : アトピー性皮膚炎における食物アレルギーの頻度. アレルギー 50 : 621-628, 2001.
Medical*Online
3) 小倉由紀子, 小倉英郎 : アトピー性皮膚炎の原因食物抗原診断におけるCAP-RASTの有用性と限界について 第2報. アレルギー 59 : 438 (抄録), 2010.
 
4) 小倉英郎ほか : アトピー性皮膚炎に対するアクチナーゼ処理米 (ファインライス(R)) の臨床効果とその使用方法について. アレルギーの臨床 13 : 566 -571, 1993.
 
5) 小倉英郎, 小倉由紀子 : アトピッ子のお料理ブック, 女子栄養大学出版部, 2003.
 
6) 小倉英郎, 小倉由紀子 : アトピッ子のお料理ブック 2, 女子栄養大学出版部, 2008.
 
P.360 掲載の参考文献
1) Feng C, et al : Histamine (Scombroid) Fish Poisoning : a Comprehensive Review. Clin Rev Allergy Immunol, 2015. [Epub ahead of print]
 
2) Pawankar R, et al : Allergic diseases as a global public health issue. In : WAO White Book on Allergy, WAO, Milwaukee, 2011.
 
3) Pawankar R : Allergic diseases and asthma : a global public health concern and a call to action. World Allergy Organ J 7 (1) : 12, 2014.
 
4) Hajeb P, Selamat J : A contemporary review of seafood allergy. Clin Rev Allergy Immunol 42 (3) :365-385, 2012.
PubMed
5) 「食物アレルギーの診療の手引き 2014」検討委員会 : 厚生労働科学研究班による食物アレルギーの診療の手引き 2014, p4.
 
6) 「特殊型食物アレルギーの診療の手引き 2015」作成委員会 : 特殊型食物アレルギーの診療の手引き 2015, p2-7.
 
7) 日本アレルギー学会Anaphylaxis対策特別委員会 : アナフィラキシーガイドライン 2014, p1-24. 2014.[http://www.jsaweb.jp/]
 
8) Wang J, et al : Correlation of specific IgE to shrimp with cockroach and dust mite exposure and sensitization in an inner-city population. J Allergy Clin Immunol 128 (4) : 834-837. 2011.
 
9) Sicherer SH, Sampson HA : Food allergy : Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol 133 (2) : 291-307, 2014.
PubMed
10) Tsabouri S, et al : Fish and shellfish allergy in children : review of a persistent food allergy. Pediatr Allergy Immunol 23 (7) : 608-615, 2012.
PubMed
11) Leung NY, et al : Current immunological and molecular biological perspectives on seafood allergy : a comprehensive review. Clin Rev Allergy Immunol 46 (3) : 180-197, 2014.
PubMed
12) Canonica GW, et al : A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J 6 (1) : 17, 2013.
PubMed
13) 塩見一雄 : 魚類, 甲殻類・軟体動物 (頭足類, 貝類). 食物アレルギー A to Z (中村丁次編), p50-57, 第一出版, 2010.
 
14) Kobayashi A, et al : Comparison of allergenicity and allergens between fish white and dark muscles. Allergy 61 (3) : 357-363, 2006.
PubMed
15) Kuehn A, et al : Fish allergens at a glance : variable allergenicity of parvalbumins, the major fish allergens. Front Immunol 5 : 179, 2014.
 
16) 富川盛光 : 甲殻類アレルギー. 永倉顕一 : 軟体類アレルギー. 中村陽一 : 甲殻類アレルギー, 貝アレルギー. 南崇史, 福富友馬 : アニサキスアレルギー. 症例を通して学ぶ年代別食物アレルギーのすべて (海老澤元宏編), p 160-163, 206-211, 南山堂, 2013.
 
17) Sampson HA : Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 107 (5) : 891-896, 2001.
PubMed
18) Ayuso R, et al : Greater epitope recognition of shrimp allergens by children than by adults suggests that shrimp sensitization decreases with age. J Allergy Clin Immunol 125 (6) : 1286-1293 e1283, 2001.
 
19) 日本小児アレルギー学会食物アレルギー委員会 : 食物アレルギー診療ガイドライン 2012, p17-57, 協和企画, 2011.
 
20) 日本アレルギー学会食物アレルギー委員会経口負荷試験標準化ワーキンググループ : 食物アレルギー経口負荷試験ガイドライン 2009, p22-25, 協和企画, 2009.
 
21) 「食物アレルギーの栄養指導の手引き2011」検討委員会 : 厚生労働科学研究班による食物アレルギーの栄養指導の手引き2011. p10.
 
P.365 掲載の参考文献
1) 海老澤元宏編 : 厚生労働科学研究班による食物アレルギーの診療の手引き, p3, 2008.
 
2) 海老澤元宏編 : 厚生労働科学研究班による食物アレルギーの診療の手引き, p4, 2014.
 
3) 穐山浩ほか : 食物アレルゲン (ピーナッツ, 魚卵). 臨床免疫・アレルギー科 46 : 592, 2006.
 
4) 原彰彦 : 魚類の卵形成と雌特異蛋白質ビテロジェニン. 化学と生物 39 : 29-36, 2001.
 
5) Ueda H, et al : Changes in serum concentrations of steroid hormones, thyroxine, and vitellogenin during spawning migration the chum salmon, Oncorhynchus keta. Gen Comp Endcrinol 53 : 203-211, 1984.
PubMed
6) Finn RN : Vertebrate yolk complexes and the functional implications of phosvitins and other subdomains in vitellogenins. Biol Reprod 76 : 926-935, 2007.
PubMed
7) Shimizu Y, et al : Major allergen and its IgE cross-reactivity among salmonid fish roe allergy. J Agric Food Chem 57 : 2314-2319, 2009.
PubMed
8) 清水裕, 佐伯宏樹 : 魚卵アレルゲンの本体と性状. 魚介類アレルゲンの科学 (塩見一雄, 佐伯宏樹編), p47-59, 恒星社厚生閣, 2010.
 
9) Shimizu Y, et al : Molecular and immunological characterization of β'-component (Onc k 5), a major IgE-binding protein in chum salmon roe. Int Immunol 26 : 139-147, 2014.
 
10) Fujita S, et al : In vitro digestion of major allergen in salmon roe and its peptide portion with proteolytic resistance. Food Chem 130 : 644-650, 2012.
 
11) Kondo Y, et al : IgE Cross-reactivity between Fish Roe (Salmon, Herring and Pollock) and Chicken Egg in Patients Anaphylactic to Salmon Roe. Allergol Int 54 : 317-323, 2005.
 
12) 千貫祐子ほか : 牛肉アレルギー患者20例の臨床的および血清学的解析. 日皮会誌 123 : 1807-1814, 2013.
 
13) Gonzalez-de-Olano D, et al : Allergy to Red Caviar. J Investig Allergol Clin Immunol 21 : 491-495, 2011.
 
14) 渡辺一彦 : 主要抗原とこれによるアレルギーの特徴, 症状, 診断, 対応 7.魚介類最新食物アレルギー (中村晋, 飯倉洋治編), p253, 永井書店, 2002.
 
P.371 掲載の参考文献
1) 宇理須厚雄, 近藤直実 ; 日本小児アレルギー学会食物アレルギー委員会 : 食物アレルギー診療ガイドライン 2012. 協和企画, 2012.
 
2) Zuidmeer L, et al : The prevalence of plant food allergies : a systematic review. J Allergy Clin Immunol 121 : 1210-1218, e4, 2008.
 
3) Burney P, et al : Prevalence and distribution of sensitization to foods in the European Community Respiratory Health Survey : a EuroPrevall analysis. Allergy 65 : 1182-1188, 2010.
PubMed
4) Caliskaner Z, et al : Risk factors for oral allergy syndrome in patients with seasonal allergic rhinitis. Med Oral Patol Oral Cir Bucal 16 : e312-316, 2011.
PubMed
5) 厚生労働科学研究班 : 食物アレルギーの診療の手引き 2014, 2015.
 
6) 海老澤元宏 : 食物アレルギーの診療の手引き 2011. 厚生労働科学研究費補助金 免疫アレルギー疾患等予防・治療研究事業 食物アレルギーの発症要因の解明および耐性化に関する研究, 2011.
 
7) Pacios LF, et al : Mimotope mapping as a complementary strategy to define allergen IgE-epitopes : peach Pru p 3 allergen as a model. Mol Immunol 45 : 2269-2276, 2008.
 
8) Fernandez-Rivas M, et al : Allergy to Rosaceae fruits without related pollinosis. J Allergy Clin Immunol 100 : 728 -733, 1997.
 
9) Inomata N, et al : Identification of peamaclein as a marker allergen related to systemic reactions in peach allergy. Ann Allergy Asthma Immunol 112 : 175-177, e3, 2014.
 
10) Ono R, et al : A case of food -dependent exercise-induced anaphylaxis caused by ingestion of orange. Arerugi 64 : 149-155, 2015.
PubMed
11) Breiteneder H, Radauer C : A classification of plant food allergens. J Allergy Clin Immunol 113 : 821-830, quiz 31, 2004.
 
12) Scheurer S, et al : Strong allergenicity of Pru av 3, the lipid transfer protein from cherry, is related to high stability against thermal processing and digestion. J Allergy Clin Immunol 114 : 900-907, 2004.
PubMed
13) Bohle B, et al : Cooking birch pollen-related food : divergent consequences for IgE-and T cell-mediated reactivity in vitro and in vivo. J Allergy Clin Immunol 118 : 242-249, 2006.
 
14) Scheurer S, et al : Cross-reactivity within the profilin panallergen family investigated by comparison of recombinant profilins from pear (Pyr c 4), cherry (Pru av 4) and celery (Api g 4) with birch pollen profilin Bet v 2. J Chromatogr B Biomedi Sci Appl 756 : 315-325, 2001.
 
15) Radauer C, et al : Cross-reactive and species-specific immunoglobulin E epitopes of plant profilins : an experimental and structure-based analysis. Clin Exp Allergy 36 : 920-929, 2006.
PubMed
16) Puehringer HM. et al : MdAP, a novel protein in apple. is associated with the major allergen Mai d 1. Gene 321 : 173-183, 2003.
 
17) Gaier S, et al : Purification and structural stability of the peach allergens Pru p 1 and Pru p 3. Mol Nutr Food Res 52 (Suppl 2) : S220-229, 2008.
 
18) Ebner C, et al : Common epitopes of birch pollen and apples-studies by western and northern blot. J Allergy Clin Immunol 88 : 588-594, 1991.
PubMed
19) Ebner C, et al : Identification of allergens in fruits and vegetables : IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 95 : 962-969, 1995.
 
20) Scheurer S, et al : Cross-reactivity and epitope analysis of Pru a 1, the major cherry allergen. Molecular Immunol 36 : 155-167, 1999.
PubMed
21) Lombardero M, et al : Prevalence of sensitization to Artemisia allergens Art v 1, Art v 3 and Art v 60kDa. Cross-reactivity among Art v 3 and other relevant lipid-transfer protein allergens. Clin Exp Allergy 34 : 1415-1421, 2004.
 
22) Pastorello EA, Robino AM : Clinical role of lipid transfer proteins in food allergy. Mol Nutr Food Res 48 : 356-362, 2004.
PubMed
23) Salcedo G, et al : Plant non-specific lipid transfer proteins as food and pollen allergens. Clin Exp Allergy 34 : 1336-1341, 2004.
PubMed
24) Fernandez-Rivas M, Cuevas M : Peels of Rosaceae fruits have a higher allergenicity than pulps. Clin Exp Allergy 29 : 1239-1247, 1999.
PubMed
25) Borges JP, et al : The lipid transfer proteins (LTP) essentially concentrate in the skin of Rosaceae fruits as cell surface exposed allergens. Plant Physiol Biochem 44 : 535-542, 2006.
PubMed
26) Ortolani C, et al : Comparison of results of skin prick tests (with fresh foods and commercial food extracts) and RAST in 100 patients with oral allergy syndrome. J Allergy Clin Immunol 83 : 683 -690, 1989.
 
27) 徳田玲子ほか : 果物・野菜アレルギー診断における好塩基球活性化マーカーCD203c発現定量の有用性. 日本ラテックスアレルギー研究会会誌 15 : 57-64, 2011.
Medical*Online
28) Guhsl EE, et al : IgE, IgG4 and IgA specific to Bet v 1 -related food allergens do not predict oral allergy syndrome. Allergy 70 : 59-66, 2015.
 
29) 宇理須厚雄 (監修) : 食物アレルギーの基礎と対応. 薬理学的活性物質 (仮性アレルゲン), (株) みらい. 2011.
 
30) Okamoto Y, Kurihara K : A case of oral allergy syndrome whose symptoms were dramatically improved after rush subcutaneous injection immunotherapy with pollen extracts of birch. Arerugi 61 : 652-658, 2012.
PubMed
31) Pereira C, et al : Specific sublingual immunotherapy with peach LTP (Pru p 3). One year treatment : a case report Cases J 2 : 6553, 2009.
PubMed
32) Cox L, et al : Allergen immunotherapy : a practice parameter third update. J Allergy Clin Immunol 127 : S1-55. 2011.
PubMed
P.378 掲載の参考文献
1) 食品添加物表示について (PDF). 消費者庁ホームページ食品表示食品添加物表示に関する情報.
 
2) Young E, et al : The prevalence of reaction to food additives in a survey population. J R Coll Physicians Lond 21 : 241-247. 1987.
 
3) Fuglsang G, et al : Prevalence of intolerance to food additives among Danish school children. Pediatr Allergy Immunol 4 : 123 -129, 1993.
 
4) 食品表示・考 FOOCOM.NET. [http://www.foocom.net]
 
5) アレルギー物質の食品表示. ぜん息予防のためのよくわかる食物アレルギーの基礎知識2012年改訂版, 独立行政法人環境再生保全機構 (宇理須厚雄総監修), 2013.
 
6) Juhlin L : Recurrent urticaria, clinical investigation of 330 patients. Br J Dermatol 104 : 369-381, 1981.
PubMed
7) Mikkelsen H, et al : Hypersensitivity reactions to food colours with special reference to the natural colour annatto extract (butter colour). Arch Toxicol 1 : 141-143. 1978.
 
8) Hariparsad D, et al : Oral Tartrazine challenge in childhood asthma : effect on bronchial reactivity. Clin Allergy 14 : 81-85, 1984.
PubMed
9) Rowe KS, Rowe KJ : Synthetic food coloring and behavior : a dose response effect in a double-blind, placebo-controlled, repeated-measures study. J Pediatr 125 (5 Pt 1) : 691-698, 1994.
 
10) Bush RK. et al : Prevalence of sensitivity to sulfiting agents in asthmatic patients. Am J Med 81 : 816-820, 1986.
PubMed
11) Schwartz HJ, Chester EH : Bronchospastic responses to aerosolized metabisulfite in asthmatic subjects : potential mechanisms and clinical implications. J Allergy Clin Immunol 74 : 511-513, 1984.
PubMed
12) Tarlo SM, Broder I : Tartrazine and benzoate challenge and dietary avoidance in chronic asthma. Clin Allergy 12 : 303-312, 1982.
PubMed
13) 栗原和幸ほか : ブリックテスト陰性, 皮内テスト陽性のエリストールによるアナフィラキシーの5歳男児例. アレルギー 62 : 1534-1540, 2013.
 
14) 海老澤元宏 : エリストール (甘味料) 等の摂取による即時型アレルギーの全国調査. 第25回日本アレルギー学会春季臨床大会, 横浜. 2013年5月11-12日.
 
15) 穐山浩 : 低分子化合物の食物アレルギー. 第50回日本小児アレルギー学会, 横浜. 2013年10月19-20日.
 
16) Randhawa S, Bahna SL : Hypersensitivity reactions to food additives. Curr Opin Allergy Clin Immunol 9 : 278-283, 2009.
PubMed
17) Pacor ML et al : Efficacy of leukotriene receptor antagonist in chronic urticaria : a double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 31 : 1607-1614, 2001.
PubMed
P.382 掲載の参考文献
1) 手島玲子 : 医薬品添加物等の安全確保に関する研究, 平成22-23年度厚生労働科学研究総合研究報告書, p5-6, 2012.
 
2) Murphy A, et al : Allergic reactions to protofol in egg-allergic children. Anesth Analg 113 : 140-144, 2011.
 
3) 消費者庁次長 : 別添アレルゲンを含む食品に関する表示 (最終改正/平成27年6月1日 消食表第276号). [http://www.caa.go.jp/foods/pdf/150601_tuchi-togo.pdf]
 
4) Artesani MC, et al : Egg sensitization caused by immediate hypersensitivity reaction to drug-containing lysozyme. Ann Allergy Asthma Immunol 101 : 105, 2008.
PubMed
5) 消費者庁食品表示課 : アレルギー物質を含む食品に関する表示 Q&A [http://www.caa.go.jp/foods/df/syokuhin1088.pdf]
 
6) 酒井信夫ほか : 医薬品添加物に含まれる食物アレルゲンタンパク質に関する研究. 国立医薬品食品衛生研究所報告 130 : 58-65, 2012.
 
7) Nowak-Wegrzyn A, et al : Contamination of dry powder inhales for asthma with milk proteins containing actose. J Allergy Clin Immunol 113 : 558-560, 2004.
 
8) Eda A, et al : Acute allergic reaction due to milk proteins contaminating lactose added to corticosteroid for injection. Allergol Int 58 : 137-139, 2009.
PubMed
9) 岡藤郁夫ほか : 大豆油を含む成分栄養剤で症状が悪化した慢性下痢症の2例. 日小児会誌 107 : 489-494, 2003.
 
10) 緒方千秋 : 漢方薬の服薬指導. ファルマシア 44 : 127-129, 2008.
 
11) Chung CH, et al : Cetukimab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 : 1109-1117, 2008.
PubMed
12) Commins SP, Platts-Mills TA : Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. J Allergy Clin Immunol 124 : 652-657, 2009.
PubMed
13) 千貫祐子ほか : 牛肉アレルギー患者20例の臨床的および血清学的解析. 日皮膚会誌 123 : 1807-1814, 2013.
 
14) Girard JP, Gamba L : Radiologic contrast media. In : Allergic Reactions to Drugs (ed by de Weck AL, Bundgaard H), Handb Exp Pharm 63, p717-725, Springer-Verlag, Berlin, 1983.
 
P.388 掲載の参考文献
1) 一般社団法人日本アレルギー学会アトピー性皮膚炎ガイドライン専門部会 : アトピー性皮膚炎診療ガイドライン 2015 (片山一朗監修), 協和企画, 2015.
 
2) 池松かおりほか : 乳児期発症食物アレルギーに関する検討 (第2報) 卵・牛乳・小麦・大豆アレルギーの3歳までの経年的変化. アレルギー 55 : 533 -541, 2006.
 
3) Lack G : Epidemiologic risks for food allergy. J Allergy Clin Immunol 121 : 1331-1336, 2008.
PubMed
4) Alan D, et al : Filaggrin Mutations Associated with Skin and Allergic Diseases. N Engl J Med 365 : 1315-1327, 2011.
 
5) Martin PE, et al : Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy 45 : 255-264, 2015.
PubMed
6) 日本小児アレルギー学会食物アレルギー委員会 : 食物アレルギー診療ガイドライン 2012 (宇理須厚雄監修), 協和企画. 2012.
 
P.395 掲載の参考文献
1) 厚生労働省難治性疾患研究班 : 新生児-乳児消化管アレルギー診断治療指針.[http://nrichd.ncchd.go.jp/imal/FPIES/icho/pdf/fpies.pdf]
 
1) Nomura I, et al : Four distinct subtypes of non-IgE-mediated gastrointestinal food allergies in neonates and infants, distinguished by their initial symptoms. J Allergy Clin Immunol 127 : 685-688, e8, 2011.
 
2) Nowak-Wgrzyn A, et al : Non-IgE-mediated gastrointestinal food allergy. J Allergy Clin Immunol 135 : 1114-1124, 2015.
PubMed
2) 厚生労働省, 難病情報センターホームページ, 好酸球性消化管疾患 (新生児-乳児食物蛋白誘発胃腸炎) .[http://www.nanbyou.or.jp/entry/3931] (注意 ; 食物蛋白誘発胃腸炎は消化管アレルギーと同義, 即時型アレルギーとの混同を防ぐための行政上の用語)
 
3) Berin MC : Immunopathophysiology of food protein-induced enterocolitis syndrome. J Allergy Clin Immunol 135 : 1108-1113, 2015.
PubMed
4) Kimura M, et al : Usefulness of lymphocyte stimulation test for the diagnosis of intestinal cow's milk allergy in infants. Int Arch Allergy Immunol 157 : 58-64, 2012.
PubMed
5) Morita H, et al : Antigen-specific T-cell responses in patients with non-IgE-mediated gastrointestinal food allergy are predominantly skewed to T (H) 2. J Allergy Clin Immunol 131 : 590-592, e1-6, 2013.
 
P.399 掲載の参考文献
1) 特殊型食物アレルギーの診療の手引き 2015. 厚生労働省科学研究補助金「難治性疾患等実用化研究事業 (免疫アレルギー疾患等実用化研究事業免疫アレルギー疾患実用化研究分野) 研究事業, 生命予後に関わる重篤な食物アレルギーの実態調査・新規治療法の開発および治療指針の策定.
 
2) Tanaka S, et al : An epidemiological study on food-dependent exercise-induced anaphylaxis in kindergartners, schoolchildren, and junior-high-school students. Asia-Pacific J Publ Health 7 : 26-30, 1994.
 
3) Aihara Y, et al : Frequency of food -dependent exercise-induced anaphylaxis in Japanese junior-high-school students. J Allergy Clin Immunol 108 : 1035-1039, 2001.
PubMed
4) Morita E, et al : Prevalence of wheat allergy in Japanese adults. Allergol Int 61 : 101-105, 2012.
PubMed
5) Chinuki Y, Morita E : Wheat-dependent exercise-induced anaphylaxis sensitized with hydrolyzed wheat protein in soap. Allergol Int 61 : 529-537, 2012.
PubMed
6) Morita E, et al : Food-dependent exercise-induced anaphylaxis. J Dermatol Sci 47 : 109-117, 2007.
PubMed
7) Matsuo H, et al : Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. Clin Exp Allergy 35 : 461-466, 2005.
PubMed
8) Morita E, et al : Food-dependent exercise-induced anaphylaxis-importance of omega-5 gliadin and HMW-glutenin as causative antigens for wheat-dependent exercise-induced anaphylaxis-. Allergol Int 58 : 493 -498, 2009.
 
9) 森田栄伸 : コリン性蕁麻疹. 日常皮膚診療における私の工夫 (宮地良樹編), p 210-104. 全日本病院出版会. 2007.
 
P.405 掲載の参考文献
1) Amlot PL, et al : Oral allergy syndrome (OAS) : symptoms of IgE-mediated hypersensitivity to foods. Clin Allergy 17 : 33-42, 1987.
PubMed
2) Ortolani C, et al : The oral allergy syndrome. Ann Allergy 61 (6 Pt 2) : 47-52, 1988.
 
3) 猪又直子 : 皮膚科臨床アセッ ト16「じんましん・血管性浮腫」39. 口腔アレルギー症候群と蕁麻疹, 中山書店, 2013.
 
4) Mari A, et al : The oral allergy syndrome : improved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol 5 : 267-273, 2005.
PubMed
5) 猪又直子ほか : 植物性食物による口腔アレルギー症候群 63例の検討-原因食物ごとの皮膚試験と特異IgE測定における陽性率の比較及び花粉感作状況について. アレルギー 56 : 1276-1284, 2007.
 
6) 猪又直子 : 口腔アレルギー症候群. J Environ Dermatol Cutan Allergol 4 : 125-136, 2010.
Medical*Online
7) 森田栄伸 : 特殊型食物アレルギーの診療の手引き. [http://www.med.shimane-u.ac.jp/dermatology/FAguideline2015.pdf].
 
8) 守田亜希子ほか : 横浜近郊における, ハンノキ花粉感作と植物性食物による口腔アレルギー症候群の関連について. アレルギー 57 : 138-146, 2008.
Medical*Online
9) Maeda N, et al : Correlation of oral allergy syndrome due to plant-derived fods with pollen sensitization in Japan. Ann Allergy Asthma Immunol 104 : 205-210, 2010.
 
10) 猪又直子ほか : 成人の食物アレルギーの特徴, 原因食物, 自然史. Visual Dermatology 11 : 272-279, 2012.
 
11) Hasegawa M, et al : Clinical features of four cases with cashew nut allergy and cross-reactivity between cashew nut and pistachio. Allergol Int 58 : 209-215, 2009.
PubMed
12) Tuppo L, et al : Peamaclein-a new peach allergenic protein : similarities, differences and misleading features compared to Pru p 3. Clin Exp Allergy 43 : 128-140, 2013.
PubMed
13) Inomata N, et al : Identification of peamaclein as a marker allergen related to systemic reactions in peach allergy. Ann Allergy Asthma Immunol 112 : 175-177, 2014.
PubMed
14) Hotta A, et al : Case of food-dependent exercise-induced anaphylaxis due to peach with Pru p 7 sensitization. J Dermatol, 2015. [Epub ahead of print]
 
P.409 掲載の参考文献
1) 赤澤晃, 松永佳世子 (監) : ラテックスアレルギー安全対策ガイドライン 2013, 協和企画, 2013.
 
2) 井上徳浩ほか : 当院におけるラテックスアレルギー患者の特徴と追跡調査. 日本ラテックスアレルギー研究会誌 9 : 54-63, 2005.
 
3) Wagner S, Breiteneder H : The latex-fruit syndrome. Biochem Soc Trans 30 : 935 -940, 2002.
 
4) Blanco C, et al : Latex allergy : clinical features and cross-reactivity with fruits. Ann Allergy 73 (4) : 277-281, 1994.
 
5) Scott H : Clinical implications of cross-reactive food allergens. J Allergy Clin Immunol 108 : 881-890, 2001.
 
6) Hamilton RG, et al : Diagnostic performance of FDA-cleared serological assays for natural rubber latex specific IgE antibody. J Allergy Clin Immunol 103 : 925-930, 1999.
PubMed
7) Banerjee B, et al : IgE from latex allergic patients binds to cloned and expressed B cell epitopes of prohevein. J Immunol 159 : 5724-5732, 1997.
PubMed
P.414 掲載の参考文献
1) Millins RJ, et al : Breastfeeding anaphylaxis. Lancet 338 (8777) : 1279-1280, 1991.
 
2) MacDonell JW, Ito S : Breastfeeding anaphylaxis case study. J Hum Lact 14 : 243-244, 1998.
PubMed
3) McKinney KK, Scranton SE : A case report of breastfeeding anaphylaxis : successful prophylaxis with oral antihistamines. Allergy 66 : 435-436, 2011.
PubMed
4) Villalta D, Martelli P : A case of breastfeeding anaphylaxis. Eur Ann Allergy Clin Immunol 39 : 26-27, 2007.
 
5) Shank JJ, et al : Recurrent postpartum anaphylaxis with breast-feeding. Obstet Gynecol 114 : 415-416, 2009.
PubMed
6) 堀川達弥ほか : Breast feeding anaphylaxis.アレルギー 62 : 442, 2013.
Medical*Online
7) Aihara M, et al : Food-dependent excerise-induced anaphylaxis : influence of concurrent aspirin administration on skin testing and provocation. Br J Dermatol 146 : 466-472, 2002.
 
8) Fukunaga A, et al : Limited influence of aspirin intake on mast cell activation in patients with food-dependent exercise-induced anaphylaxis : comparison using skin prick and histamine release test. Acta Derm Venereol 92 : 480-483, 2012.
PubMed
9) Matsuo H, et al : Aspirin augments IgE-mediated histamine release from human peripheral basophils via Syk kinase activation. Allergol Int 62 : 503-511, 2013.
PubMed
P.419 掲載の参考文献
1) Charpin D, et al : Prevalence of allergy to hymenoptera stings in different samples of the general population. J Allergy Clin Immunol 90 : 331-334, 1992.
PubMed
2) Freeman T : Bee, yellow jacket wasp, and other Hymenoptera stings : Reaction types and acute management. In : UpToDate. (ed by Golden D, Felweg A), p1-7, Wolters Kluwer, Alphen aan den Rijn, the Netherlands, 2015.
 
3) Bilo BM, et al : Diagnosis of Hymenoptera venom allergy. Allergy 60 : 1339-1349, 2005.
PubMed
4) Hayashi Y, et al : Epidemiologic investigation of hornet and paper wasp stings in forest workers and electrical facility field workers in Japan. Allergol Int 63 : 21-26, 2014.
PubMed
5) Sturm GJ, et al : Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare. J Allergy Clin Immunol 133 : 1635-1643, 2014.
PubMed
6) Tracy J : Diagnosis of Hymenoptera venom allergy. In : UpToDate. (ed by Golden D, Felweg A), pl-14, Wolters Kluwer, Alphen aan den Rijn, the Netherlands, 2015.
 
7) Rueff F, et al : Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy : importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 124 : 1047-1054, 2009.
PubMed
8) Pravettoni V, et al : Basal platelet-activating factor acetylhydrolase : prognostic marker of severe Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 133 : 1218-1220, 2014.
PubMed
9) Golden DB, et al : Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 123 : 1371 -1375, 2009.
 
10) Golden DB, et al : Stinging insect hypersensitivity : a practice parameter update 2011. J Allergy Clin Immunol 127 : 852 -854, 2011.
 
11) Graft DF : Hymenoptera venom immunotherapy : Efficacy, indication. and mechanism of action. In : UpToDate (ed by Golden D, Felweg A), p1-14, Wolters Kluwer, Alphen aan den Rijn, the Netherlands, 2015.
 
12) Gonzalez FJ, et al : Hymenoptera venom allergy : characteristics, tolerance and efficacy of immunotherapy in the paediatric population. Allergol Immunopathol (Madr) 37 : 111-115, 2009.
PubMed
13) Xia JB, et al : Efficacy analysis of methylprednisolone plus adrenaline to treat wasp sting injury. Saudi Med J 30 : 1272-1275, 2009.
PubMed
14) deShazo RD, et al : Stings of imported fire ants : Clinical manifestations, diagnosis, and treatment In : UpToDate (ed by Golden D, Felweg A), p1-14, Wolters Kluwer, Alphen aan den Rijn, the Netherlands, 2015.
 
15) Asada H, et al : CD4+ T-lymphocyte-induced Epstein-Barr virus reactivation in a patient with severe hypersensitivity to mosquito bites and Epstein-Barr virus-infected NK cell lymphocytosis. Arch Dermatol 139 : 1601-1607, 2003.
 
16) Asada H, et al : Mosquito salivary gland exiracts induce EBV-infected NK cell oncogenesis via CD4 T cells in patients with hypersensitivity to mosquito bites. J Invest Dermatol 125 : 956-961, 2005.
PubMed
17) Komase Y, et al : IgE antibodies against midge and moth found in Japanese asthmatic subjects and comparison of allergenicity between these insects. Allergy 52 : 75-81, 1997.
PubMed
18) 奥田稔ほか : アレルギー性鼻炎における昆虫アレルギーの全国調査. 日耳鼻 105 : 1181-1188, 2002.
 
19) Sarinho E, et al : There are more asthmatics in homes with high cockroach infestation. Braz J Med Biol Res 37 : 503-510. 2004.
PubMed
20) Donohue KM, et al : Anti-cockroach and anti-mouse IgE are associated with early wheeze and atopy in an inner-city birth cohort. J Allergy Clin Immunol 122 : 914-920, 2008.
 
21) Portnoy J, et al : Environmental assessment and exposure reduction of cockroaches : a practice parameter. J Allergy Clin Immunol 132 : 802-808, e1-25, 2013.
 
22) Page K et al : Early immunological response to German cockroach frass exposure induces a Th2/Th17 environment. J Innate Immun 3 : 167-179, 2011.
PubMed
23) Kino T, Oshima S : Allergy to insects in Japan. II. The reaginic sensitivity to silkworm moth in patients with bronchial asthma. J Allergy Clin Immunol 64 : 131-138, 1979.
PubMed
24) 金谷邦夫ほか : 養蚕関係者にみられた過敏性肺臓炎と思われる1例. アレルギー 25 : 732-737, 1976.
Medical*Online
P.425 掲載の参考文献
1) 一般社団法人ペットフード協会 : 平成26年 (2014年) 全国犬猫飼育実態調査. Available from : [http://www.petfood.or.jp/]
 
2) 瀬野悟史ほか : ペットアレルギー, 和歌山県における疫学調査より. 日耳鼻 106 : 750-753, 2003.
 
3) World Health Organization and International Union of Immunological Societies Allergen Nomenclature Sub-committee : Allergen Nomenclature. cited 2015 26/9 ; Available from : [http://www.aJlergen.org/]
 
4) Ohman JL Jr, et al : Allergens of mammalian origin. III. Properties of a major feline allergen. J Immunol 113 (6) : 1668-1677, 1974.
 
5) Ichikawa K, et al : High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats. Clin Exp Allergy 29 (6) : 754-761, 1999..
PubMed
6) Custovic A, et al : House dust mite and cat allergen in different indoor environments. Clin Exp Allergy 24 (12) : 1164-1168, 1994.
PubMed
7) Kilburn S, et al : Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev 2003 (1) : CD002989.
PubMed
8) Couroux P, et al : Fel d 1-derived synthetic peptide imrmino-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy 45 (5) : 974-981, 2015.
 
9) Senti G, et al : Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 129 (5) : 1290-1296. 2012.
PubMed
10) Lodrup Carlsen KC, et al ; group GWPBCw : Does pet ownership in infancy lead to asthma or allergy at school age? Pooled analysis of individual participant data from 11 European birth cohorts. PLoS One 7 (8) : e43214, 2012.
PubMed
11) Pelucchi C, et al : Pet exposure and risk of atopic dermatitis at the pediatric age : a meta-analysis of birth cohort studies. J Allergy Clin Immunol 132 (3) : 616-622, e7, 2013.
 
P.430 掲載の参考文献
1) 安枝浩 : ダニアレルゲンの免疫生物学とアレルギー疾患. アレルギー 57 : 807-816, 2008.
Medical*Online
2) Erben AM, et al : Anaphylaxis after ingestion of beignets contaminated with Dermatophagoides farina. J Allergy Clin Immunol 92 : 846-849, 1993.
 
3) Sanchez-Borges M, et al : Anaphylaxis from ingestion of mites : Pancake anaphylaxis. J Allergy Clin Immunol 131 : 31-35, 2013.
PubMed
4) Takahashi K, et al : Oral mite anaphylaxis caused by mite-contaminated okonomiyaki/pancake-mix in Japan : 8 case reports and a review of 28 reported cases. Allergology International 63 : 51-56, 2014.
 
5) 磯崎淳ほか : 貯蔵庫ダニ (storage mite) 摂取によるアナフィラキシーと診断した1例-本邦報告例のまとめ-. 臨床免疫・アレルギー科 55 : 378-382, 2011.
 
6) 大石拓ほか : たこ焼き粉に繁殖したコナヒョウヒダニが原因と考えられたアナフィラキシーの1例-過去の報告例の検討. 日小皮会誌 33 : 69-73, 2014.
 
7) 稲葉弥寿子ほか : お好み焼き粉に繁殖したダニによる即時型アレルギーの2例-Inhibition immunoblot法による原因抗原の検討と粉の種類によるダニ数およびダニ抗原増加の検討-. 日皮会誌 120 : 1893 -1900, 2010.
 
8) Sanchez-Borges M, et al : An update on oral anaphylaxis from mite ingestion. Ann Allergy Asthma Immunol 94 : 216-220, 2005.
PubMed
9) 野口佳恵ほか : お好み焼き粉に混入したダニによるアナフィラキシーショックの1例. 皮膚科の臨床 53 : 427-430, 2011.
 
10) Matsumoto T, Satoh A : The occurrence of mite-containing wheat flour. Pediatr Allergy Immunol 15 : 469-471, 2004.
PubMed
11) 松本知明ほか : ダニ繁殖小麦粉食品によるアナフィラキシーとその対策. 小児科 45 : 1458-1464, 2004.
 
12) 長尾佳樹ほか : ミックス粉に繁殖するダニによるアナフィラキシーの3例とアンケート結果について. 日小児アレルギー会誌 28 : 226-231. 2014.
Medical*Online
13) 日本小児アレルギー学会食物アレルギー委員会 : 食物アレルギー診療ガイドライン 2012, p46-57, 協和企画, 2011.
 
14) 日本アレルギー学会「ダニアレルギーにおけるアレルゲン免疫療法の手引」作成委員会 : ダニアレルギーにおけるダニアレルゲン免疫療法の手引き, p 16-25, 日本アレルギー学会, 2015.
 
15) 日本アレルギー学会Anaphylaxis対策特別委員会 : アナフィラキシーガイドライン, p 13-21, 日本アレルギー学会, 2014.
 
P.437 掲載の参考文献
1) 鈴木加余子ほか : ジャパニーズスタンダードアレルゲン (2008) の陽性率2010年-2012年の推移. J Environ Dermatol Cutan Allergol 9 : 101-109, 2015.
Medical*Online
2) Shanon J : Pseudo-atopic dermatitis. Contact dermatitis due to chrome sensitivity simulating atopic dermatitis. Dermatologica 131 : 176-190, 1965.
PubMed
3) 足立厚子, 堀川達弥 : 全身型金属アレルギー食餌制限の有効性について. 臨皮 46 : 883-889, 1994.
 
4) 長橋捷, 和田攻 : ニッケル. 環境汚染物質の生体への影響 3, ニッケル (米国研究協議会編), p1, 東京化学同人. 1977.
 
5) Fisher AA : Systemic contact-type dermatitis. In : Contact Dermatitis 3rd ed (ed by Fisher AA), p 119-130, Lea & Febiger, Philadelphia, 1986.
 
6) Veien NK, et al : Oral challenge with metal salts. (I) vesicular patch-test-negative hand eczema. Contact Dermatitis 9 : 402 -406. 1983.
 
7) Adachi A, et al : Mercury-induced nummular dermatitis. J Am Acad Dermatol 43 : 383-385, 2000.
PubMed
8) Adachi A, Horikawa T : The significance, problem and method of oral provocation test in metal allergy. Environ Dermatol 6 : 74 -82, 1999.
 
9) Nierlsen GD, et al : Nickel-sensitive patients with vesicular hand eczema, oral challenge with a diet naturally high in nickel. Br J Dermatol 122 : 299-308, 1990.
 
10) Cederbrant K, et al : In vitro lymphocyte proliferation as compared to patch test using gold, palladium and nickel. Int Arch Allergy Immunol 112 : 212-217, 1997.
PubMed
11) 鷲尾文郎ほか : ビタミンB12製剤による薬疹臨床的特徴およびコバルトアレルギーの関与について. 皮膚病診療 16 : 597-600, 1994.
 
12) Medeiros LM, et al : Complementary and alternative remedies : an additional source of potential systemic nickel exposure. Contact Dermatitis 58 : 97-100, 2008.
PubMed
13) 北崎祐之ほか : 各種金属アレルゲンにおける対応. GPのための金属アレルギー臨床 (井上昌幸ほか編), p 118-121, デンタルダイアモンド社, 2003.
 
14) Sicilia A, et al : Titanium allergy in dental implant payients : a clinical study on 1500 consecutive patients. Clin Oral Impl Res 19 : 823-835, 2008.
 
15) Ekqvist S, et al : A correlation found between gold concentration in blood and patch test reactions in patients with coronary stents. Contact Dermatitis 59 : 137-142, 2008.
PubMed
16) 川上泰弘ほか : 人工膝関節患者における金属アレルギーの検討. 日人工関節会誌 43 : 729-730, 2013.
 
P.441 掲載の参考文献
1) 松永佳世子, 早川律子 : 化粧品によるかぶれ. 皮膚科の臨床 30 : 885-904, 1988.
 
2) Fukutomi Y, et al : Rhinoconjunctival sensitization to hydrolyzed wheat protein in facial soap can induce wheat-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol 127 : 531-533, 2011.
PubMed
3) Nakamura M, et al : A new reliable method for detecting specific IgE antibodies in the patients with immediate type wheat allergy due to hydrolyzed wheat protein : Correlation of its titer and clinical severity. Allergol Int 63 : 243 -249, 2014.
 
4) Lachapelle JM, Maibach HI (ed) : Patch testing methodology. In : Patch Testing and Prick Testing, p33-70, Springer-Verlag, Berlin, Heidelberg, 2009.
 
5) 松永佳世子 : 日本皮膚アレルギー・接触皮膚炎学会の歴史. J Environ Dermatol Cutan Allergol 2 : 427-442, 2008.
Medical*Online
6) 鈴木加余子, 松永佳世子 : これだけは知っておきたい接触皮膚炎の基礎知識ジャパニーズスタンダードアレルゲンと陽性率の推移 (解説). 日皮会誌 122 : 3115-3117, 2012.
 
7) パッチテスト反応アトラス : 日本接触皮膚炎学会, 松永佳世子発行, 春恒社 (東京都), 2005.
 
8) Wahlberg JE, Lindberg M : Patch testing. In : Contact Dermatitis, 4th ed (ed by Frosch PJ, et al), p 366-386, Springer, Germany, 2005.
 
9) De Groot AC : Patch Testing, 3th ed, Elsevier, Netherland, 2008.
 
10) Gohara M, et al : Allergic contact dermatitis caused by phenylethyl resorcinol [4- (1-phenylethyl) -1,3-benzenediol], a skin-lightening agent in cosmetics. Contact Dermatitis 69 (5) : 319-320, 2013.
PubMed
11) Yagami A, et al : Allergic contact dermatitis caused by 3-o-ethyl-1-ascorbic acid (vitamin C ethyl). Contact Dermatitis 70 (6) : 376-377, 2014.
 
12) 鈴木加余子ほか : ジャパニーズスタンダードアレルゲン2007年度陽性率とジャパニーズスタンダードアレルゲン (2008) の2009年度陽性率. J Environ Dermatol Cutan Allergol 6 : 67-84, 2012.
 
13)鈴木加余子, 松永佳世子 : ジャパニーズスタンダードアレルゲンの陽性率. WHAT'S NEW in皮膚科学 2014-2015 (宮地良樹). p48-49, メディカルレビュー社, 2014.
 
P.446 掲載の参考文献
1) Heiner DC, Sears JW : Chronic respiratory disease associated with multiple circulating precipitins to cow's milk. Am J Dis Child 100 : 500-502, 1960.
 
2) Boat TF, et al : Hyperactivity to cow milk in young children with pulmonary hemosiderosis and cor pulmonale secondary to nasopharyngeal obstruction. J Pediatr 87 : 23-29, 1975.
 
3) Lee SK, et al : Cow's milk induced pulmonary disease in children. Adv Pediatr 25 : 39-57, 1978.
PubMed
4) Fossati G, et al : Pulmonary hemosiderosis induced by cow's milk proteins : a discussion of clinical case. Pediatr Med Chir 14 : 203-207, 1997.
 
5) Moissidis I, et al : Milk-induced pulmonary disease in infants (Heiner syndrome). Pediatr Allergy Immunol 16 : 545-552, 2005.
PubMed
6) 高橋耕一ほか : 特発性肺ヘモジデローシスの全国調査一九九四-その発症状況と予後因子について-. 日本医事新報 3710 : 30-34, 1995.
 
7) Simon G : Pulmonary Hemorrhage/Hemoptysisin Children. Pediatr Pulmonol 37 : 476-484, 2004.
 
8) Epstein CE, et al : Time course of hemosiderin production by alveolar macrophages in a murine model. Chest 20 : 2013-2020, 2001.
 
9) 手塚純一郎 : ミルクアレルギーによる肺出血 (Heiner症候群). 呼吸 27 (1) : 1075-1080, 2008.
 
10) 新見彰男ほか : 特発性肺ヘモジデローシスの2症例-CT所見を中心に-. 日胸疾会誌 30 (9) : 1749-1755, 1992.
 
11) Saeed MM, et al : Prognosis in pediatric idiopathic pulmonary hemosiderosis. Chest Perspect (3) : 721-725, 1999.
 
12) Kiper N, et al : Long-term clinical course of patients with idiopathic pulmonary haemosiderosis (1979-1994) : prolonged survival with low-dose corticosteroid therapy. Pediatr Pulmonol 27 : 180-184, 1999.
PubMed
P.450 掲載の参考文献
1) Hopkins IJ, Shield LK : Poliomyelitis-like illness associated with asthma in childhood. Lancet 303 (7860) : 760, 1974.
 
2) Hopkins IJ : A new syndrome : poliomyelitis-like illness associated with acute asthma in childhood. Aust Paediatr J 10 : 273-276, 1974.
PubMed
3) Kira J, et al : Acute myelitis associated with hyperIgEemia and atopic dermatitis. J Neurol Sci 148 : 199-203, 1997.
PubMed
4) Horiuchi I, et al : Acute myelitis after asthma attacks with onset after puberty. J Neurol Neurosurg Psychiatry 68 : 665-668, 2000.
PubMed
5) 黒川智美ほか : 気管支喘息発作の度ごとに単麻痺を呈した再発性脊髄症の1成人例. 福岡医学雑誌 91 : 85-89, 2000.
 
6) Kira J : Atopy and neural damage. Intern Med 41 : 169-174, 2002.
PubMed
7) 菅谷ことこほか : エンテロウイルス71感染の関与が考えられた Hopkins症候群の1例. 日児誌 117 : 1125-1128, 2013.
 
8) 錫村明生 : Hopkins症候群の免疫学的機序. 神経内科 56 : 41-44, 2002.
 
9) Manson JI, Thong YH : Immunological abnormalities in the syndrome of poliomyelitis-like illness associated with acute bronchial asthma (Hopkin's syndrome). Arch Dis Child 55 : 26-32, 1980.
 
10) Arita J, et al : Hopkins syndrome : T2-weighted high intensity of anterior horn on spinal MR imaging. Pediatr Neurol 13 : 263-265, 1995.
PubMed
11) Liedholm LJ, et al : Acute postasthmatic amyotrophy (Hopkins' syndrome). Muscle Nerve 17 : 769-772, 1994.
PubMed
12) Mizuno Y, et al : Poliomyelitis-like illness after acute asthma (Hopkins syndrome) : a histological study of biopsied muscle in a case. Brain Dev 17 : 126-129, 1995.
 
13) Cohen HA, et al : Poliomyelitis-like syndrome following asthmatic attack (Hopkins' syndrome) recovery associated with i.v. gamma globulin treatment. Infection 26 : 247-249, 1998.
 
14) Yeung SC, et al : Flaccid paralysis of the limbs after an asthmatic attack. Pediatr Neurol 42 : 133-136, 2010.
PubMed
15) Cantarin- Extremera V, et al : Immune-mediated mechanisms in the pathogenesis of Hopkins syndrome. Pediatr Neurol 47 : 373-374, 2012.
PubMed
P.454 掲載の参考文献
1) Speer F : The allergic tension-fatigue syndrome. Pediatr Clin North Am 1 : 1029-1037, 1954.
 
2) Baker S : Fatigue in school Children. Educ Rev 15 : 34, 1898.
 
3) 牛山允ほか : The Allergic Tension- Fatigue Syndrome (1). 小児の精神と神経 16 : 231-239, 1976.
 
4) 富田和巳ほか : アレルギー性緊張・弛緩症候群と考えられた1例. 小児科臨床 48 : 2426-2429, 1995.
 
5) 姫野友美, 木原令夫 : 食物負荷試験により乳酸とヒスタミンの上昇をみたthe Allergic Tension-Fatigue Syndrome (ATFS) の1例. アレルギーの臨床 17 : 679-683, 1997.
 
6) 篠田紳司ほか : 食物アレルギーが関与する疾患と症状 4) 神経系. 小児科臨床 53 : 538-542, 2000.
Medical*Online
7) 黒梅恭芳 : Allergic tension fatigue syndromeはアレルギーで本当におこるのか. 小児科診療 51 : 2069-2070, 1988.
 
8) 千葉友幸 : アレルギー性緊張・弛緩症候群 (AFTS). 小児内科 23 : 159-163, 1991.
 
9) Fukutomi O, et al : Abnormal response of the autonomic nervous systems in food-dependent exercise-induced anaphylaxis. Ann Allergy 68 : 438-445, 1992.
PubMed
10) 星野孝ほか : アレルギーと神経・精神・内分泌系との接点. アレルギーの領域 1 : 1227-1236, 1994.
 
11) 近藤直実ほか : 食餌抗原によるリンパ球幼若化反応が有用であったアレルギー性緊張弛緩症候群. アレルギーの臨床 7 : 122-125, 1987.
 
12) 近藤直実ほか : 食物アレルギーにおける食物負荷試験-特に, double-blind, placebo-controlled food challengeの実際とその位置づけ-. 小児科臨床 46 : 6-12, 1993.
Medical*Online
P.457 掲載の参考文献
1) Hompes S, et al : Provoking allergens and treatment of anaphylaxis in children and adolescents-data from the anaphylaxis registry of German-speaking countries. Pediatr Allergy Immunol 22 : 568-574, 2011.
PubMed
2) Matsuo H, et al : Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. Clin Exp Allergy 35 : 461-466, 2005.
PubMed
3) 井手康二ほか : 運動誘発アナフィラキシー-最適運動強度によるトレーニング療法が奏効した1例. アレルギー 54 : 338, 2005.
Medical*Online
4) 井手康二ほか : スポーツ選手における食物依存性運動誘発アナフィラキシー-症例を通して適切な運動負荷試験の検討. アレルギー 57 : 431, 2008.
Medical*Online
P.461 掲載の参考文献
1) Randolph TG : Ecologic mental illness : psychiatry exteriorized. J Lab Clin Med 54 : 936, 1959.
 
2) Cullen MR : The worker with multiple chemical sensitivities : an overview. Occup Med 2 : 655-661, 1987.
PubMed
3) 石川哲ほか : 化学物質過敏症診断基準について. 日本医事新報 3857 : 25-29, 1998.
 
4) Azuma K, et al : Prevalence and characteristics of chemical intolerance : a Japanese population-based study. Arch Environ Occup Health , 2014. [Epub ahead of print]
 
5) Meggs WJ : Mechanism of allergy and chemical sensitivity. Toxicol Ind Health 15 : 331-338, 1999.
PubMed
6) Hojo S, et al : Subjective and objective characteristics of patients with multiple chemical sensitivity in Japan. Jpn J Clin Ecol 16 : 104- Perspect , 2007.
 
7) Graveling RA, et al : A review of multiple chemical sensitivity. Occup Environ Med 56 : 73-75, 1999.
PubMed
8) Ojima M, et al : Odor perception in patients with multiple chemical sensitivity. Tohoku J Exp Med 198 : 163-173, 2002.
PubMed
9) Hillert L, et al : Odor processing in multiple chemical sensitivity. Hum Brain Mapp 28 : 172-182, 2007.
PubMed
10) Gilbert ME : Does the kindling model of epilepsy contribute to our understsnding of multiple chemical sensitivity? Ann N Y Acad Sci 933 : 68-91, 2001.
PubMed
11) Hojo S, et al : Clinical characteristics of physician-diagnosed patients with multiple chemical sensitivity in Japan. Int J Hyg Environ Health 211 : 682-689, 2008.
PubMed
12) Anonymous : Multiple chemical sensitivity : a 1999 consensus. Arch Environ Health 54 : 147-149, 1999.
 
13) Miller CS, Prihoda TJ : The environmental exposure sensitivity inventory (EESI) : a standardized approach for measuring chemical intolerances for research and clinical applications. Toxicol Ind Health 15 : 370-385, 1999.
PubMed
14) Azuma K, et al : Assesment of cerebral blood flow in patients with multiple chemical sensitivity using near-infrared spectroscopy-recovery after olfactory stimulation : a case-control study. Environ Health Prev Med 20 (3) : 185-194, 2015.
 
15) 坂部貢ほか : 化学物質過敏症-免疫学的側面から-. アレルギーの臨床 33 (8) : 23-27, 2013.
 
16) Bascom R, et al : Neurogenic ibflammation : With additional discussion of central and perceptual integration of nonneurogenic inflammation. Environ Health Perspect 105 (Suppl 2) : 531-537, 1997.
 
17) Delgado M, et al : VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. Ann N Y Acad Sci 921 : 68-78, 2000.
PubMed
P.467 掲載の参考文献
1) 早崎峯夫 : 寄生虫と免疫. 比較臨床血液研究会誌 1 : 24-28, 1988.
 
2) Eddens T, et al : Eosinophils Contribute to Early Clearance of Pneumocystis murina Infection. J Immunol 195 (1) : 185-193, 2015.
PubMed
3) Carretero R, et al : Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8 (+) T cells. Nat Immunol 16 (6) : 609-617, 2015.
PubMed
4) Kobayashi S, et al : Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases. Allergy 57 (10) : 950-956, 2002.
PubMed
5) Okada R, et al : The severity of peripheral blood eosinophilia indicates an eosinophilia-associated disease corresponding to its level. Allergol Intern 2015. (in print)
 
6) Bocquet H, et al : Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms : DRESS). Semin Cutan Med Surg 15 (4) : 250-257, 1996.
PubMed
7) Tohyama M, et al : Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 134 (9) : 1113-1117, 1998.
PubMed
8) Suzuki Y, et al : Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 134 (9) : 1108-1112, 1998.
PubMed
9) Bocquet H, et al : Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) syndrome associated with azithromycin presenting like septic shock : a case report. J Med Case Rep 8 : 332, 2014.
 
10) Kardaun SH, et al : Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms : does a DRESS syndrome really exist? Br J Dermatol 156 (3) : 609-611, 2007.
PubMed
11) 厚生労働省ホームページ. [http://www.mhlw.go.jp/shingi/2007/03/dl/s0322-10b.pdf]
 
12) Drago F, et al : A retrospective study of cutaneous drug reactions in an outpatient population. Int J Clin Pharm, 2015. [Epub ahead of print]
 
13) Sanchez-Borges M, et al : Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. World Allergy Organ J 6 (1) : 18, 2013.
PubMed
14) Ferrusquia J, et al : Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity. World J Gastroenterol 21 (13) : 4069-4077, 2015.
PubMed
15) Ideguchi H, et al : Cisplatin-induced eosinophilic pneumonia. Case Rep Pulmonol 2014 : 209732, 2014.
PubMed
16) Evison M, et al : Olanzapine-induced eosinophilic pleuritis. Respir Med Case Rep 14 : 24-26, 2015.
PubMed
17) Michaud CJ, et al : Diagnosis of exclusion : a case report of probable glatiramer acetate-induced eosinophilic myocarditis. Case Rep Neurol Med 2014 : 786342, 2014.
PubMed
18) Jenks CL, et al : Drug hypersensitivity causing organizing eosinophilic pneumonia in a pediatric patient. Heart Lung 44 (3) : 243-245, 2015.
 
19) Edston E : Accumulation of eosinophils, mast cells, and basophils in the spleen in anaphylactic deaths. Forensic Sci Med Pathol 9 (4) : 496-500, 2013.
PubMed
20) Reggiani Bonetti L, et al : Splenic hypereosinophilia in anaphylaxis-related death : different assessments depending on different types of allergens? Int J Legal Med 129 (1) : 97-103, 2015.
PubMed
21) Steinke JW, et al : Aspirin activation of eosinophils and mast cells : implications in the pathogenesis of aspirin-exacerbated respiratory disease. J Immunol 193 (1) : 41-47, 2014.
PubMed
22) Kurai J, et al : Acute eosinophilic pneumonia caused by calcium stearate, an additive agent for an oral antihistaminic medication. Intern Med 45 (17) : 1011-1016, 2006.
PubMed
23) 大西香絵ほか : SASPにより重度の有害事象を呈したRAの4例. 日本アレルギー学会誌 61 : 537, 2012.
 
24) Hirata S, et al : Lymphocyte transformation test is not helpful for the diagnosis of methotrexate-induced pneumonitis in patients with rheumatoid arthritis. Clin Chim Acta 407 (1-2) : 25-29, 2009.
 
25) Phatharacharukul P, Klaewsongkram J : A Case of Sulfasalazine-Induced Hypersensitivity Syndrome Confirmed by Enzyme-Linked Immunospot Assay. Allergy Asthma Immunol Res 5 (6) : 415-417, 2013.
PubMed
P.473 掲載の参考文献
1) Kemp SF, Lockey RF : Anaphylaxis : a review of causes and mechanisms. J Allergy Clin Immunol 110 (3) : 341-348, 2002.
PubMed
2) Executive summary of disease management of drug hypersensitivity : a practice parameter. Joint Task Forceon Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American Academyof Allergy, Asthma and Immunology, andthe Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 83 (6 Pt 3) : 665-700, 1999.
 
3) 海老澤元宏ほか : アナフィラキシー対策とエピペン. アレルギー 62 (2) : 144-154, 2013.
Medical*Online
4) 村中正治, 山口正雄 : 薬物アレルギー. 臨床アレルギー学, 改訂第3版 (宮本昭正監修), p410-423, 南江堂, 2007.
 
5) 中川武正ほか : 薬物アレルギーとその対処法. メディカル・サイエンス・インターナショナル, 2001.
 
6) Celik GE, et al : Drug allergy. In : Middleton's Allergy : Principles and practice, 8th ed (ed by Adkinson NF Jr, et al), p1274-1295, Mosby-Year Book, Philadelphia, 2013.
 
7) Solensky R : Allergy to β-lactam antibiotics. J Allergy Clin Immunol 130 (6) : 1442, e1-5, 2012.
 
8) Khan FS, Weiss ME : Skin testing for β-lactam antibiotics : impact of the availability of a major determinant. Curr Allergy Asthma Rep 13 (1) : 64-71, 2013.
 
9) Blanca-Lopez N, et al : Hypersensitivity reactions to quinolones. Curr Opin Allergy Clin Immunol 11 (4) : 285-291, 2011.
PubMed
10) 日本アレルギー学会Anaphylaxis対策特別委員会 (編) : アナフィラキシーガイドライン. メディカルレビュー社, 2014年11月.
 
11) 松村行雄ほか : 抗生物質皮膚テストの再検討. アレルギー 39 : 696-700, 1990.
Medical*Online
12) Apter AJ, et al : Clinical and genetic risk factors of self-reported penicillin allergy. J Allergy Clin Immunol 122 (1) : 152-158, 2008.
PubMed
13) 日本医療安全調査機構 HP : 警鐘事例 No.2薬剤性アナフィラキシーの発現防止と早期対応. [http://www.medsafe.jp/activ_alarm/activ_alarm_002.pdf]
 
P.476 掲載の参考文献
1) Johansson SG, et al : Revised nomenclature for allergy for global use : Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113 : 832-836, 2004.
PubMed
2) Katayama H, et al : Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology 175 : 621-628, 1990.
PubMed
3) Morcos SK : Review article : Acute serious and fatal reactions to contrast media : our current understanding. Br J Radiol 78 : 686-693, 2005.
PubMed
4) Wysowski DK, Nourjah P : Deaths attributed to X-ray contrast media on U. S. death certificates. AJR Am J Roentgenol 186 : 613-615, 2006.
 
5) Niendorf HP, et al : Safety and risk of Gadolinium-DTPA : extended clinical experience after more than 69 million applications. In : (ed by Felix R, et al) Magnevist Monograph 5th, revised edition. p29-37, Blackwell Publishing Limited, Oxford, 2007.
 
6) Li A, et al : Acute adverse reactions to magnetic resonance contrast media-gadolinium chelates. Br J Radiol 79 : 368-371, 2006.
PubMed
7) 鳴海善文, 中村仁信 : 非イオン性ヨード造影剤およびガドリニウム造影剤の重症副作用および死亡例の頻度調査. 日医学放射線会誌 65 : 300-301, 2005.
 
8) 日本アレルギー学会 : アナフィラキシーガイドライン. メディカルレビュー社, 2014年11月1日.
 
9) Brockow K, Ring J : Classification and pathophysiology of radiocontrast media hypersensitivity. Chem Immunol Allergy 95 : 157-169, 2010.
PubMed
10) ACR Manual on Contrast Media Version 9. 2013 (Accessed at [http://www.acr.org/quality-safety/resources/contrast-manual] ).
 
11) Davenport MS, et al : Repeat contrast medium reactions in premedicated patients : frequency and severity. Radiology 253 : 372-379, 2009.
PubMed
12) Dillman JR, et al : Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine premedication. AJR Am J Roentgenol 190 : 187-190, 2008.
PubMed
13) Simons FE, et al : 2012 Update : World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 12 : 389-399, 2012.
 
14) Lightfoot CB, et al : Survey of radiologists' knowledge regarding the management of severe contrast material-induced allergic reactions. Radiology 251 : 691-696, 2009.
PubMed
P.482 掲載の参考文献
1) 堀池典生ほか : 薬物性肝障害の実態-全国集計-. 薬物性肝障害の実態 (恩地森一編), p1-10, 中外医学社, 2008.
 
2) 佐田通夫ほか : 痩せ薬・健康食品による薬物性肝障害二次全国調査集計結果. 肝臓 45 : 96-108, 2004.
 
3) de Abajo FJ, et al : Acute and clinically relevant drug-induced liver injury : a population based case-control study. Br J Clin Pharmacol 58 : 71-80, 2004.
PubMed
4) Lammert C, et al : Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury : search for signals. Hepatology 47 : 2003-2009. 2008.
PubMed
5) Lucena MI, et al : Phenotypic characterization of idiosyncratic drug-induced liver injury : the influence of age and sex. Hepatology 49 : 2001-2009, 2009.
PubMed
6) Lammert C, et al : Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 51 : 615-620, 2010.
PubMed
7) Russmann S, et al : Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16 : 3041-3053, 2009.
PubMed
8) 滝川一ほか : DDW-J 2004ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005.
 
P.487 掲載の参考文献
1) Pichler WJ : Adverse side-effects to biological agents. Allergy 61 : 912-920, 2006.
PubMed
2) Aubin F, et al : The complexity of adverse side-effects to biological agents. J Crohns Colitis 7 : 257-262, 2013.
PubMed
3) Boyman O, et al : Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 10 : 612-627, 2014.
PubMed
4) 山口由衣, 相原道子 : 生物学的製剤による過敏症. アレルギー・免疫 20 : 77-84, 2013.
 
5) Matucci A, et al : Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to iniximab. Clin Exp Allergy 43 : 659-664, 2013.
PubMed
6) Okuyama A, et al : Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 70 : 299-304, 2011.
 
7) Chung CH, et al : Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 : 1109-1117, 2008.
PubMed
8) 千貫祐子ほか : がん治療薬と食物アレルギー. 静脈経腸栄養 28 : 615-618, 2013.
 
9) Ramos-Casals M, et al : Autoimmune diseases induced by biological agents : a double-edged sword? Autoimmun Rev 9 : 188-193, 2010.
PubMed
10) 松倉節子, 相原道子 : 分子標的治療薬による注意を要する皮膚反応. 皮膚アレルギーフロンティア 10 : 111-117, 2012.
Medical*Online
11) De Gannes GC, et al : Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 143 : 223-231, 2007.
 
12) Costa MF, et al : Drug induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum 37 : 381-387, 2008.
PubMed
13) Kreamer KM : Immune Checkpoint Blockade : A New Paradigm in Treating Advanced Cancer. J Adv Pract Oncol 5 : 418-431, 2014.
 
14) 山口由衣 : 分子標的薬の基礎知識-皮膚科医が知っておくべき皮膚障害-. 日皮会誌 125 : 1401-1407, 2015.
 
15) 山口由衣, 相原道子 : 分子標的治療薬によるよくみる皮膚障害, 皮膚アレルギーフロンティア 10 : 37-42, 2012.
 
P.491 掲載の参考文献
1) 北見周ほか : Stevens-Johnson症候群ならびに中毒性表皮壊死症の全国疫学調査-平成20年度厚生労働科学研究費補助金 (難治性疾患克服研究事業) 重症多形滲出性紅斑に関する調査研究. 日皮会誌 121 : 2467-2487, 2011.
 
2) Chen P, et al : Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364 : 1126-1133, 2011.
PubMed
3) Ozeki T, et al : Genome-wide association study identifies HLS-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20 : 1034-1041, 2011.
 
4) Pichler WJ, et al : Drug hypersensitivity : flare-up reactions, cross-reactivity and multiple drug hypersensitivity. J Dermatol 38 : 216-221, 2011.
PubMed
5) Illing PT, et al : Immune self-reactivity triggered by drug-modified HLA-peptide repertoire. Nature 486 : 554-558, 2012.
PubMed
6) Takahashi R, et al : Defective regulatory T cells in patients with severe drug eruptions : timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182 : 8071-8079, 2009.
PubMed
7) Heng MC, Allen SG : Efficacy of cyclophosphamide in toxic epidermal necrolysis-Clinical and pathophysiologic aspects. J Am Acad Dermatol 25 : 778-786, 1991.
PubMed
8) Saito N, et al : An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med 6 : 245ra95, 2014.
PubMed
P.496 掲載の参考文献
1) Lyell A : Toxic epidermal necrolysis. An eruption resembling scalding of the skin. Br J Dermatol 68 : 355-361, 1956.
PubMed
2) Stevens AM, Johnson FC : A new eruptive fever associated with stomatitis and ophthalmia : Report of two cases in children. Am J Dis Child 24 : 526-533, 1922.
 
3) Bastuji-Garin S, et al : Clinical classification of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129 : 92-96, 1993.
PubMed
4) 北見周ほか : Stevens-Johnson症候群ならびに中毒性表皮壊死症の全国疫学調査. 日皮会誌 121 : 2467-2482, 2011.
 
5) Chung WH, et al : A marker for Sevens-Johnson syndrome. Nature 428 : 486, 2004.
 
6) Hung SI, et al : HLA-B*5801 allele as genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102 : 4134-4139, 2005.
PubMed
7) Chen P, et al : Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364 : 1126-1133, 2011.
PubMed
8) Ozeki T, et al : Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Human Mol Genet 20 : 1034-1041, 2011.
PubMed
9) Lyell A : A review of toxic epidermal necrolysis in Britain. Br J Dermatol 79 : 662-671, 1967.
PubMed
10) Takahashi R, et al : Defective regulatory T cells in patients with sever drug eruptions : timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182 : 8071-8079, 2009.
PubMed
11) Hosaka H, et al : Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis : frozen-section diagnosis. J Dermatol 37 : 407-412, 2010.
PubMed
12) Saito N, et al : An annexin A1-FPR1 interaction contributes to necroptosis of keratinocytes in severe cutaneous adverse drug reactions. Sci Transl Med 6 : 245ra95, 2014.
PubMed
13) Abe R, et al : Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol 162 : 1515-1520, 2003.
PubMed
14) Abe R, et al : granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 151 : 514-515, 2009.
PubMed
15) Bastuji-Garin S, et al : SCORTEN : a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115 : 149-153, 2000.
PubMed
P.500 掲載の参考文献
1) Shiohara T, et al : Drug-induced hypersensitivity syndrome : Recent Advances in the Diagnosis, Pathogenesis and Management. In : Adverse Cutaneous Drug Eruptions (ed by French LE), Chem Immunol Allergy vol 97, Karger, Basal, p 122-138, 2012.
 
2) Takahashi R, et al : Defective regulatory T cells in patients with severe drug eruptions : timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182 : 8071-8079, 2009.
PubMed
3) Aota N, Shiohara T : Viral connection between drug rashes and autoimmune disease : how autoimmune responses are generated after resolution of drug rashes. Autoimmun Rev 8 : 488-494, 2009.
PubMed
P.504 掲載の参考文献
1) Roujeau JC, et al : Acute generalized exanthematous pustulosis. Analysis of 63 cases. Arch Dermatol 127 : 1333-1338, 1991.
PubMed
2) Huilaja L, et al : Acute localized exanthematous pustulosis on inguinal area secondary to piperacillin/tazobactam. Acta Derm Venereol 94 : 106-107, 2014.
PubMed
3) Hotz C, et al : Systemic involvement of acute generalized exanthematous pustulosis : a retrospective study on 58 patients. Br J Dermatol 169 : 1223-1232, 2013.
PubMed
4) Ingen-Housz-Oro S, et al : Acute generalized exanthematous pustulosis : a retrospective audit of practice between 1994 and 2011 at a single center. Br J Dermatol 172 : 1455-1457, 2015.
 
5) Pretel M, et al : Acute generalized exanthematous pustulosis induced by sorafenib. JAMA Dermatol 150 : 664-666, 2014.
PubMed
6) Britschgi M, et al : Acute generalized exanthematous pustulosis : a clue to neutrophil-mediated inflammatory processes orchestrated by T cells. Curr Opin Allergy Clin Immunol 2 : 325-331, 2002.
 
7) Kabashima K, et al : Increased circulating Th17 frequencies and serum IL-22 levels in patients with acute generalized exanthematous pustulosis. J Euro Acad Dermatol Venereol 25 : 485-488, 2011.
 
8) Nakai N, et al : Acute generalized exanthematous pustulosis caused by dihydrocodeine phosphate in a patient with psoriasis vulgaris and a heterozygous IL36RN mutation. JAMA Dermatol 151 : 311-315, 2015.
 
9) 堀田隆之ほか : フロモキセフナトリウムによるacute generalized exanthematous pustulosis の1例-発症における溶連菌感染関与の可能性-. 皮膚科の臨床 44 : 1405-1409, 2002.
 
10) Sidoroff A, et al : Acute generalized exanthematous pustulosis (AGEP) -a clinical reaction pattern. J Cutan Pathol 28 : 113-119, 2001.
PubMed
11) van Hattem S, et al : Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN) -like features : does overlap between AGEP and TEN exist? Clinical report and review of the literature. Br J Dermatol 171 : 1539-1545, 2014.
PubMed
12) Bouvresse S, et al : Tpxic epidermal necrolysis. DRESS, AGEP : Do overlap cases exist? Orphanet J Rare Dis 7 : 72, 2012.
PubMed
13) Krishna S, et al : A rapidly progressive and fatal atypical acute generalized exanthematous pustulosis. J Am Acad Dermatol 71 : e89-90, 2014.
 
P.509 掲載の参考文献
1) 医薬品医療機器総合機構ホームページ. [http://www.pmda.go.jp/guide/outline/report/report_25.html]
 
2) アナフィラキシーガイドライン (一般社団法人日本アレルギー学会監修, Anaphylaxis対策特別委員会編集) , メディカルレビュー社. 2014.
 
3) 山口正雄 : 抗菌薬によるアナフィラキシー. アレルギー・免疫 20 : 16-21, 2013.
 
4) 森田栄仲 : 蕁麻疹・血管性浮腫・アナフィラキシーを起す薬剤. 皮膚科臨床アセット2薬疹診療のフロントライン (古江増隆総編集, 相原道子専門編集), p 176-178,中山書店. 2011.
 
5) 森田栄伸ほか : 蕁麻疹・血管性浮腫型薬疹. MB Derma 198 : 65-69, 2012.
 
6) Chung CH, et al : Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358 : 1109-1117, 2008.
PubMed
7) Commlns SP, et al : Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol 123 : 426-433, 2009.
 
8) Commins SP, et al : The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose. J Allergy Clin Immunol 127 : 1286-1293, 2011.
 
9) 千貫祐子ほか : 牛肉アレルギー患者20例の臨床的および血清学的解析. 日皮会誌 123 : 1807-1814, 2013.
 
10) 千貫祐子ほか : セツキシマブによるアナフィラキシーショックの4例-α-gal特異的IgE検出による回避の可能性. 日皮会誌 124 : 179-183, 2014.
 
P.516 掲載の参考文献
1) 職業性アレルギー疾患診療ガイドライン2013作成委員会 : 職業性アレルギー疾患診療ガイドライン2013, 協和企画, 2013.
 
2) 中村晋ほか : 職業アレルギー-新しいアレルギー診療と社会医学の原点, 永井書店, 2011.
 
3) 職業アレルギー研究会 : 職業アレルギー, 文永堂, 1983.
 
4) 職業アレルギー研究会 : 職業性喘息, 朝倉書店, 1973.
 
5) 勝谷隆 : ホヤ喘息. 日本職業・環境アレルギー学会雑誌 12 : 1-15, 2005.
Medical*Online
6) 小埜和久 : 喘息の化学-ホヤ・ダニアレルゲンの構造と減感作治療. 化学と生物 34 (3) : 153-160, 1996.
 
7) Le Moual N, et al : Occupational exposures and uncontrolled adult-onset asthma in Hie European Community Respiratory Health Survey II. Eur Respir J 43 (2) : 374-386, 2014.
 
8) Committee GS : The 2015 update of the Global Strategy for Asthma Management and Prevention 2015 ; GINA Available from : (http://www.ginasthma.org/local/uploads/files/GINA_Report_2015.pdf.]
 
9) Yi ES : Hypersensitivity pneumonitis. Crit Rev Clin Lab Sci 39 (6) : 581-629, 2002.
PubMed
10) Pal TM, et al : The clinical spectrum of humidifier disease in synthetic fiber plants. Am J Ind Med 31 (6) : 682-692. 1997.
PubMed
11) Hodgson MJ, et al : Hypersensitivity pneumonitis in a metal-working environment Am J Ind Med 39 (6) : 616-628, 2001.
 
12) Dumas O, et al : Do young adults with childhood asthma avoid occupational exposures at first hire? Eur Respir J 37 (5) : 1043-1049, 2011.
 
13) Mazurek JM, et al : Is childhood asthma associated with educational level and longest-held occupation? Am J Epidemiol 175 (4) : 279-288. 2012.
PubMed
14) Tagiyeva N, et al : Parental occupation is a risk factor for childhood wheeze and asthma. Eur Respir J 35 (5) : 987-993, 2010.
PubMed
15) Tarlo SM, et al; Fourth Jack Pepys Workshop on Asthma in the Workplace Participants : An official American Thoracic Society proceedings : work-related asthma and airway diseases. Presentations and discussion from the Fourth Jack Pepys Workshop on Asthma in the Workplace. Ann Am Thorac Soc 10 (4) : S17-24, 2013.
 
16) Tarlo SM, Lemiere C : Occupational asthma. N Engl J Med 370 (7) : 640-649, 2014.
PubMed
P.521 掲載の参考文献
1) 職業性アレルギー疾患診療ガイドライン2013. 日本職業・環境アレルギー学会監修, 協和企画, 2013.
 
2) Tarlo SM, et al : Diagnosis and management of work-related asthma : American College Of Chest Physicians Consensus Statement Chest 134 (3 Suppl) : 1S-41S, 2008.
 
3) Nicholson PJ, et al : Evidence based guidelines for the prevention. identification, and management of occupational asthma. Occup Environ Med 62 (5) : 290-299, 2005.
PubMed
4) Mapp CE, et al : Occupational asthma. Am J Respir Crit Care Med 172 (3) : 280-305, 2005.
PubMed
5) Tarlo SM, Lemiere C : Occupational asthma. N Engl J Med 370 (7) : 640-649, 2015.
 
6) Anees W, et al : Effect of peak expiratory flow data quantity on diagnostic sensitivity and specificity in occupational asthma. Eur Respir J 23 (5) : 730-734, 2004.
PubMed
7) Burge CB, et al : Diagnosis of occupational asthma from time point differences in serial PEF measurements. Thorax 64 (12) : 1032-1036, 2009.
PubMed
8) Allard C, et al : Occupational asthma due to various agents. Absence of clinical and functional improvement at an interval of four or more years after cessation of exposure. Chest 96 (5) : 1046-1049, 1989.
PubMed
9) Rachiotis G, et al : Outcome of occupational asthma after cessation of exposure : a systematic review. Thorax. 62 (2) : 147-152, 2007.
PubMed
10) Beach J, et al : Diagnosis and management of work-related asthma. Evid Rep Technol Assess (Summ) (129) : 1-8, 2005.
PubMed
11) 喘息予防・管理ガイドライン 2015. 日本アレルギー学会喘息ガイドライン専門部会監修, 協和企画, 2015.
 
12) Malo JL, et al : Influence of inhaled steroids on recovery from occupational asthma after cessation of exposure : an 18-month double-blind crossover study. Am J Respir Crit Care Med 153 (3) : 953-960, 1996.
PubMed
13) Maestrelli P, et al : Effects of inhaled beclomethasone on airway responsiveness in occupational asthma. Placebo-controlled study of subjects sensitized to toluene diisocyanale. Am Rev Respir Dis 148 (2) : 407-412, 1993.
PubMed
14) Olivieri M, et al : Omalizumab in persistent severe bakers' asthma. Allergy 63 (6) : 790-791, 2008.
PubMed
15) 土橋邦夫 : 職業性喘息の新しい概念.呼吸器科 9 : 564-576, 2006.
 
16) Sastre J, Quirce S : Immunotherapy : an option in the management of occupational asthma? Curr Opin Allergy Clin Immunol 6 (2) : 96-100, 2006.
PubMed
17) Leynadier F, et al : Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 106 (3) : 585-590, 2000.
PubMed
18) Sastre J, et al : Specific immunotherapy with a standardized latex extract in allergic workers : a double-blind. placebo-controlled study. J Allergy Clin Immunol 111 (5) : 985-994, 2003.
PubMed
19) Vandenplas O, et al : Occupational asthma caused by natural rubber lateX : outcome according to cessation or reduction of exposure. J Allergy Clin Immunol 109 (1) : 125-130, 2002.
PubMed
P.527 掲載の参考文献
1) Campbell JM : Acute symptoms following work with hay. Br Med J 2 : 1143-1144, 1932.
 
2) Pepys J, et al : Farmer's lung. Thermophilic actinomycetes as a source of "farmer's lung hay" antigen. Lancet 2 : 607-611, 1963.
PubMed
3) Lalancette M, et al : Farmer's lung. Long-term outcome and lack of predictive value of bronchoalveolar lavage fibrosing factors. Am Rev Respir Dis 148 : 216-221, 1993.
PubMed
4) Yoshida K, et al : Occupational hypersensitivity pneumonitis in Japan : data on a nationwide epidemiological study. Occup Environ Med 52 : 570-574, 1995.
PubMed
5) 稲瀬直彦, 吉澤靖之 : 塗装工肺. 日本胸部臨床 64 : 610-616, 2005.
Medical*Online
6) Akizuki N, et al : Hypersensitivity pneumonitis among workers cultivating Tricholoma conglobatum (shimeji). Respiration 66 : 273-278, 1999.
PubMed
7) 浜口玲央ほか : バラビニールハウス栽培従事者に発症した Aspergillus nigerによる過敏性肺臓炎の1例. 日呼吸会誌 47 : 205-211, 2009.
Medical*Online
8) Bernstein DI, et al : Machine operator's lung. A hypersensitivity pneumonitis disorder associated with exposure to met alworking fluid aerosols. Chest 108 : 636-641, 1995.
 
9) 土屋公威, 稲瀬直彦 : 職業・環境と過敏性肺炎. アレルギー・免疫 19 : 1226-1233, 2012.
 
10) 吉村信行ほか : 環境暴露1カ月後に症状が顕在化するイソシアネートによる慢性過敏性肺炎の1例. 日呼吸会誌 36 : 627-632, 1998.
Medical*Online
11) Yoshizawa Y, et al : Hypersensitivity pneumonitis induced by toluene diisocyanate : sequelae of continuous exposure. Ann Intern Med 110 : 31-34, 1989.
PubMed
12) 日本職業・環境アレルギー学会ガイドライン専門部会 : 職業性アレルギー疾患診療ガイドライン, p110-143, 協和企画, 2013.
 
13) 酒井珠美ほか : イソシアネートによる過敏性肺炎と気管支喘息発作を併発した1例. 日呼吸会誌 1 : 114-118, 2012.
 
14) Monkare S : Influence of corticosteroid treatment on the course of farmer's lung. Eur J Respir Dis 64 : 283-293, 1983.
PubMed
15) Kokkarinen JI, et al : Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 145 : 3-5, 1992.
PubMed
P.532 掲載の参考文献
1) Moscato G, et al : EAACI position paper on occupational rhinitis. Respir Res 10 : 16, 2009.
PubMed
2) Leynaert B, et al : Perennial rhinitis : Anindependent risk factor for asthma in nonatopic subjects : results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 104 (2 Pt 1) : 301-304, 1999.
 
3) Siracusa A, et al : Epidemiology of occupational rhinitis : prevalence, aetiology and determinants. Clin Exp Allergy 30 : 1519-1534, 2000.
PubMed
4) Stevens WW, Grammer LC 3rd : Occupational rhinitis : an update. Curr Allergy Asthma Rep 15 : 487-492, 2015.
PubMed
5) 藤枝重治 : 職業性鼻炎. 耳鼻咽喉科展望 51 : 420-435, 2008.
 
6) Hox V, et al : Occupational upper airway disease : how work affects the nose. Allergy 69 : 282-291, 2014.
PubMed
7) Walusiak J, et al : Respiratory allergy in apprentice bakers : do occupational allergies follow the allergic march? Allergy 59 : 442-450, 2004.
PubMed
8) Baraniuk JN, Kaliner MA : Functional activity of upper-airway nerves. In : Asthma and Rhinitis (ed by Busse W, et al), p652-667, Blackwell Scientific, Cambridge, 1995.
 
9) Castano R, Theriault G : Defining and classifying occupational rhinitis. J Laryngol Otol 120 : 812-817, 2006.
PubMed
10) Hox V, et al : Crucial role of transient receptor potential ankyrin 1 and mast cells in induction of nonallergic airway hyperreactivity in mice. Am J Respir Crit Care Med 187 : 486-493, 2013.
PubMed
11) Silver WL, Finger TE : The anatomical and electrophysiological basis of peripheral nasal trigeminal chemoreception. Ann N Y Acad Sci 1170 : 202-205, 2009.
PubMed
12) Tizzano M, et al : Nasal chemosensory cells use bitter taste signaling to detect irritants and bacterial signals. Proc Natl Acad Sci U S A 107 : 3210-3215, 2010.
PubMed
13) Sublett JW, Bernstein DI : Occupational rhinitis. Immunol Allergy Clin North Am 31 : 787-796, 2011.
PubMed
14) 許容濃度の勧告 (2014年度). 産業衛誌 56 : 162-188, 2014.
 
15) Okubo K, et al : Japanese Guideline for Allergic Rhinitis 2014. Allergol Int 63 : 357-375, 2014
 
P.539 掲載の参考文献
1) 「職業性アレルギー疾患診療ガイドライン 2013」作成委員 : 職業性アレルギー疾患診療ガイドライン 2013, p63-109, 協和企画.
 
2) 日本ラテックスアレルギー研究会, ラテックスアレルギー安全対策ガイドライン作成委員会 : ラテックスアレルギー完全対策ガイド 2013, p15-16.
 
3) 高山かおるほか : 接触皮膚炎診療ガイドライン. 日皮会 119 (9) : 1757-1793, 2009.
 
P.543 掲載の参考文献
1) World Health Organization : Indoor air pollutants, exposure and health effects assessment. Euro-reports and studies No.78, World Health Organization Regional Officefor Europe. Copenhagen, 1983.
 
2) 井上浩利ほか : シックハウス症候群の眼症状の臨床的・アレルギー学的解析. 臨床眼科 62 : 719-722, 2008.
 
3) 内尾英一, 大野重昭 : アレルギー眼疾患における最近の話題. 日本醫事新報 3757 : 16-21, 1996.
Medical*Online
4) 大野重昭ほか : アレルギー性結膜疾患の新しい臨床評価基準と重症度分類. 医薬ジャーナル 37 : 1341-1349, 2001.
 
5) 厚生労働科学研究 (健康安全・危機管理対策総合研究事業) : シックハウス症候群診療マニュアル, 厚生労働省, 2009.
 
P.548 掲載の参考文献
1) 日本アレルギー学会 (監修) : アナフィラキシーガイドライン, クニメディア, 2014.
 
2) 日本職業・環境アレルギー学会ガイドライン専門部会 (監修) : 職業性アレルギー疾患診療ガイドライン, 協和企画, 2013.
 
3) Siracusa A, et al : Occupational anaphylaxis-an EAACI task force consensus statement. Allergy 70 (2) : 141-152, 2015.
PubMed
4) Joint Task Forceon Practice Parameters ; American Academy of Allergy, Asthma and Immunology ; American Collegeof Allergy, Asthma and Immunology ; Joint Councilof Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis : an updated practice parameter. J Allergy Clin Immunol 115 (3 Suppl 2) : S483-523, 2005. Erratum in : J Allergy Clin Immunol 122 (1) : 68, 2008.
 
5) 厚生労働省 : 人口動態統計「死亡数, 性・死因 (死因基本分類) 別」.
 
6) 松浦誠 : 蜂の生態と蜂毒. 皮膚 32 : 1-5, 1990.
 
7) Mauriello PM, et al : Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 74 (4 Pt 1) : 494-498, 1984.
 
8) 生井聖一郎, 牧野荘平 : 昆虫アレルギー 2 : 野生ハチアレルギーの頻度と実状. アレルギーの臨床 88 : 21-26, 1988.
 
9) 平田博国ほか : 典型的アレルギー疾患における免疫療法-ハチアレルギー-. 喘息 24 (1) : 28-35, 2011.
Medical*Online
10) Hirata H, et al : Efficacy and safety of rush immunotherapy in patients with Hymenoptera allergy in Japan. Asian Pac J Allergy Immunol 21 : : 89-94, 2003.
PubMed
11) Bonifazi F, et al : EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy : guidelines for clinical practice. Allergy 60 (12) : 1459-1470, 2005.
PubMed
12) Golden DB, et al : Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 351 : 668-674, 2004.
PubMed
13) 松永佳世子, 矢上晶子 : ラテックスアレルギー安全対策ガイドライン. 日本ラテックスアレルギー研究会会誌 10 (1) : 32-40, 2006.
Medical*Online
14) Sussman GL, Beeshold D : Allergy to latex rubber. Ann Intern Med 122 : 43-46, 1995.
 
15) Tarlo SM, et al : Occupational asthma caused by latex in a surgical glove manufacturing plant. J Allergy Clin Immunol 35 : 626-631, 1990.
 
16) 日本ラテックスアレルギー研究会 (編) : ラテックスアレルギー安全対策ガイドライン 2009, 協和企画, 2009年12月5日.
 
17) Jeebhay MF, et al : Occupational seafood allergy : a review. Occup Environ Med 58 (9) : 553-562, 2001.
PubMed
18) Choi IS, et al : Beta-lactam antibiotic sensitization and its relationship to allergic diseases in tertiary hospital nurses. Allergy Asthma Immunol Res 2 (2) : 114-122, 2010.
PubMed
19) Cetinkaya F, et al : Penicillin sensitivity among hospital nurses without a history of penicillin allergy. J Adv Nurs 58 (2) : 126-129, 2007.
PubMed
20) Nam YH, et al : Identifying genetic susceptibility to sensitization to cephalosporins in health care workers. J Korean Med Sci 27 (11) : 1292-1299, 2012.
PubMed
21) Tadokoro K, et al : Cefotiam-induced IgE-mediated occupational contact anaphylaxis of nurses ; case reports, RAST analysis, and a review of the literature. Clin Exp Allergy 24 (2) : 127-133, 1994.
 
22) Mizutani H, et al : Anaphylaxis from cefotiam hexetil hydrochloride (CTM-HE) in an atopic nurse. Clin Exp Dermatol 21 (3) : 246, 1996.
 
23) Kim JE, et al : Detection of specific IgE antibodies to cefotiam-HSA conjugate by ELISA in a nurse with occupational anaphylaxis. Allergy 65 (6) : 791-792, 2010.
 
24) Rudzki E, Rebandel P : Occupational contact urticaria from penicillin. Contact Dermatitis 13 : 192, 1985.
PubMed
25) Sussman GL, Dorian W : Psyllium anaphylaxis. Allergy Proc 11 (5) : 241-242, 1990.
PubMed
26) Khalili B, et al : Psyllium-associated anaphylaxis and death : a case report and review of the literature. Ann Allergy Asthma Immunol 91 (6) : 579-584, 2003.
 
27) Newman MJ, Goel P : An anesthesiologist with an allergy to multiple neuromuscular blocking drugs : a new occupational hazard. Anesth Analg 110 (2) : 601-602, 2010.
PubMed
28) Bandino ML, Tankersley MS : Anaphylaxis in an allergy immunotherapy extract-compounding technician after an extract needle stick. J Allergy Clin Immunol 129 (1) : 250-251, 2012.
 
29) Acero S, et al : Anaphylaxis due to a tick bite. Allergy 58 (8) : 824-825, 2003.
PubMed
30) Kleine-Tebbe J, et al : Bites of the European pigeon tick (Argas reflexus) : Risk of IgE-mediated sensitizations and anaphylactic reactions. J Allergy Clin Immunol 17 (1) : 190-195, 2006.
 
31) Vega J, et al : Occupational immunologic contact urticaria from pine processionary caterpillar (Thaumetopoea pityocampa) : experience in 30 cases. Contact Dermatitis 50 (2) : 60-64, 2004.
PubMed
32) Stevens WJ, et al : Anaphylactic reaction after bites by Glossina morsitans (tsetse fly) in a laboratory worker. J Allergy Clin Immunol 98 (3) : 700-701, 1996.
 
33) Teasdale EL, et al : Anaphylaxis after bites by rodents. Br Med J (Clin Res Ed) 286 (6376) : 1480, 1983.
PubMed
34) Hesford JD, et al : Anaphylaxis after laboratory rat bite : an occupational hazard. J Emerg Med 3 : 765-768, 1995.
 
35) Rankin TJ, et al : Anaphylactic reaction after a laboratory rat bite. Am J Emerg Med 25 : 985, 2007.
 
36) Torres JA, et al : Anodorant-binding protein as a new allergen from Siberian hamster (Phodopus sungorus). Int Arch Allergy Immunol 157 : 109-112, 2012.
PubMed
37) Watt AD, Mc Sharry CP : Laboratory animal allergy : anaphylaxis from a needle injury. Occup Environ Med 53 : 573-574, 1996.
PubMed
38) Acero S, et al : Occupational asthma and food allergy due to carmine. Allergy 53 (9) : 897-901, 1998.
PubMed
39) de Medeiros CR, et al : Anaphylactic reaction secondary to Bothrops snakebite. Allergy 63 : 242-243, 2008.
PubMed
40) de Medeiros CR, et al : Predictors of Bothrops jararaca venom allergy in snake handlers and snake venom handlers. Toxicon 51 (4) : 672-680, 2008.
PubMed
41) Nishioka SA, et al : Occupational injuries with captive lance-headed vipers (Bothrops moojeni) : experience from a snake farm in Brazil. Trop Med Int Health 5 : 507-510, 2000.
PubMed
42) 福冨友馬ほか : ヘアートリートメント液中の加水分解コムギに対する職業性経気道的感作が発症原因と思われた小麦依存性運動誘発アナフィラキシーの美容師の1例. 日職業環境アレルギー会誌 17 (1) : 41, 2009.
 
43) 原田晋ほか : 美容師に生じた, ヘアトリートメント製剤中の羊毛加水分解ケラチンによるアナフィラキシーの1例. 皮膚科の臨床 56 (1) : 71-75, 2014.
 
44) 笛木真ほか : 介護老人福祉施設での介護業務中に起きたアナフィラキシーの1例. 職業・環境アレルギー誌 11 (2) : 29-32, 2004.
 
45) Wittczak T, et al : Chlorhexidine-still an underestimated allergic hazard for health care professionals. Occup Med (Lond) 63 (4) : 301-305, 2013.
PubMed
46) Moller DR, et al : Delayed anaphylactoid reaction in a worker exposed to chromium. J Allergy Clin Immunol 77 (3) : 451-456, 1986.
 
47) Bergman A, et al : Contact urticaria with anaphylactic reactions caused by occupational exposure to iridium salt. Contact Dermatitis 32 (1) : 14-17, 1995.
PubMed
48) Krecisz B, et al : Cobalt-induced anaphylaxis, contact urticaria, and delayed allergy in a ceramics decorator. Contact Dermatitis 60 (3) : 173-174, 2009.
 
P.557 掲載の参考文献
1) Guarnieri M, Balmes JR : Outdoor air pollution and asthma. Lancet 383 (9928) : 1581-1592, 2014.
PubMed
2) 独立行政法人環境再生保全機構ホームページ. Available from : [http://www.erca.go.jp/]
 
3) Devalia JL, et al : Effect of nitrogen dioxide and sulphur dioxide on airway response of mild asthmatic patients to allergen inhalation. Lancet 344 (8938) : 1668-1671, 1994.
PubMed
4) Young MT, et al : Ambient air pollution exposure and incident adult asthma in a nationwide cohort of U. S. women. Am J Respir Crit Care Med 190 (8) : 914-921, 2014.
 
5) 石井康 : わが国におけるPM2.5の最新状況. 呼吸器内科 25 (6) : 540-548, 2014.
 
6) 乾俊ほか : 【大気汚染と呼吸器疾患】大気汚染と喘息. 呼吸器内科 25 (6) : 489-496, 2014.
 
7) Brandt EB, et al : Diesel exhaust particle induction of IL-17A contributes to severe asthma. J Allergy Clin Immunol 132 (5) : 1194-1204e2, 2013.
PubMed
8) Ohtoshi T, et al : Diesel exhaust particles stimulate human airway epithelial cells to produce cytokines relevant to airway inflammation in vitro. J Allergy Clin Immunol 101 (6 Pt 1) : 778-785, 1998.
 
9) Dockery DW, et al : An association between air pollution and mortality in six U.S. cities. N Engl J Med 329 (24) : 1753-1759, 1993.
PubMed
10) Downs SH, et al : Reduced exposure to PM10 and attenuated age-related decline in lung function. N Engl J Med 357 (23) : 2338-2347, 2007.
PubMed
11) Balmes JR, et al : Exposure to traffic : lung function and health status in adults with asthma. J Allergy Clin Immunol 123 (3) : 626-631, 2009.
PubMed
12) Stieb DM, et al : Air pollution and emergency department visits for cardiac and respiratory conditions : a multi-city time-seriesanalysis. Environ Health 8 : 25, 2009.
PubMed
13) Wenzel SE : Asthma phenotypes : the evolution from clinical to molecular approaches. Nat Med 18 (5) : 716-725, 2012.
PubMed
14) Hashimoto S, et al : Diesel exhaust particles activate p38 MAP kinase to produce interleukin 8 and RANTES by human bronchial epithelial cells and N-acetylcysteine attenuates p38 MAP kinase activation. Am J Respir Crit Care Med 161 (1) : 280-285, 2000.
 
15) Takizawa H, et al : Diesel exhaust particles induce NF-kappa B activation in human bronchial epithelial cells in vitro : importance in cytokine transcription. J Immunol 162 (8) : 4705-4711, 1999.
PubMed
P.562 掲載の参考文献
1) 溝畑朗 : 粒子状物質汚染における自動車の寄与, 第26回大気汚染学会講演要旨集, p133, 1985.
 
2) 高藤繁ほか : 大気汚染との関係-DFPとIgE産生からみて-. アレルギー疾患は増えているか調査結果と原因 (宮本昭正編), p78-81, 国際医学出版, 1987.
 
3) Zelikoff JT, et al : Arole for associated trasition metals in the immunotoxicity of inhaled ambient particulate matter. Environ Health Perspect 110 (Suppl 5) : 871-875, 2002.
 
4) Harrod KS, et al : Inhaled diesel engine emissions reduce bacterial clearance and exacerbate lung disease to Pseudomonas aeruginosa infection in vivo. Toxicol Sc 83 : 155-165, 2005.
 
5) Gavett SH, et al : Metal composition of ambient PM2.5 influences severity of allergic airways disease in mice. Environ Health Perspect 111 : 1471-1477, 2003.
PubMed
6) 小田嶋博 : 大気汚染との関連-気管支喘息に関して-. アレルギー疾患は増えているか調査結果と原因 (宮本昭正編), p46-49, 国際医学出版, 1987.
 
7) 小田嶋博ほか : 大気汚染物質 (浮遊粒子状物質, 二酸化窒素) と気管支喘息発作入院数との関連. アレルギー 44 : 160-169, 1995.
Medical*Online
8) Lin M, et al : The influence of ambient coarse particulate matter on asthma hospitalization in children : case-crossover and time-series analyses. Environ Health Perspect 110 : 575-581, 2002.
PubMed
9) Odajima H, et al : Decline in peak expiratory flow according to hourly short-term concentration of particulate matter in asthmatic children. Inhal Toxicol 20 : 1-10, 2008.
PubMed
10) Therese F, et al : Exhaled nitric oxide in children with asthma and short-term PM2.5 exposure in Seattle. Environ Health Perspect 113 : 1791-1794, 2005.
 
11) Ueda K, et al : The effects of weather, air pollutants, and Asian dust on hospitalization for asthma in Fukuoka. Environ Health Perev Med 15 : 350-357, 2010.
 
12) Kim HS, et al : Relationship between mortality and fine particles during Asian dust, smog-Asian dust, and smog days in Korea. Int J Environment Health Researth 22 : 518-530, 2012.
 
13) Delfino RJ, et al : Personal and ambient air pollution expusures and lung function decrements in children with asthma. Environ Health Perspect Perspect : 550-558, 2008.
PubMed
14) Patel MM, et al : Traffic-related air pollutants and exhaled markers of airway inflammation and oxidative stress in New York City adolescents. Environ Res 121 : 71-78, 2013.
PubMed
15) Yamazaki S, et al : Effect of hourly concentration of particulate matter on peak expiratory flow in hospitalized children : a panel study. Environ Health 10 : 15, 2011.
PubMed
P.567 掲載の参考文献
1) 西川雅高ほか : 東アジアにおける黄砂現象とその化学的特徴. 地球環境Global Environ mental Research 2 : 181-186, 2002.
 
2) He M, et al : Airborne Asian sand dust enhances murine lung eosinophilia. Inhal Toxicol 22 : 1012-1025, 2010.
PubMed
3) 国立環境研究所 : 環境省黄砂飛来情報. [http://soramame.taiki.go.jp/dss/kosa]
 
4) 国立環境研究所 : 東アジア域の黄砂・大気汚染物質分布予測. [http://www-cfors.nies.go.jp/~cfors/index-j.html].
 
5) 竹村俊彦 : エアロゾルの気候影響に関するモデル研究 (2013年度日本気象学会賞受賞記念講演). 天気 61 : 759-775, 2014.
 
6) 佐藤達明 : 黄砂現象時のアレルギー性鼻炎症状の変化. 耳鼻臨床 102 : 831-839, 2009.
 
7) 佐藤達明 : 島根県における黄砂現象に関するアンケート調査. 耳鼻臨床 105 : 331-337, 2012.
 
8) Kanatani K, et al : Desert dust exposure is associated with increased risk of asthma hospitalization in children. Am J Respir Crit Care Med 182 : 1475-1481, 2010.
PubMed
9) Kanatani K, et al : Indoor particle counts during Asian dust events under everyday conditions at an apartment in Japan. Environ Health Prev Med 19 : 81-88, 2014.
 
10) Watanabe M, et al : Correlation between Asian dust storms and worsening asthma in Western Japan. Allegol Int 60 : 267-275, 2011.
PubMed
11) Hong YC, et al : Asian Dust Storm and pulmonary function of school children in Seoul. Sci Total Environ 408 : 754-759, 2010.
PubMed
12) Onishi K, et al : Adverse health effects of Asian dust particles and heavy metals in Japan. Asia Pac J Public Health 27 : 1719-1726, 2015.
 
13) 岸川禮子ほか : 若い年齢層に及ぼす黄砂の影響-2008年調査結果-. アレルギー・免疫 19 : 102-111, 2012.
 
14) 岸川禮子ほか : 福岡県北九州市における黄砂を含む越境性微量粒子が健康に及ぼす影響調査. 職業・環境アレルギー誌 20 : 37-48, 2013.
 
15) Ichinose T, et al : Effects of Asian sand dust, Arizona sand dust, amorphous silica and aluminum oxide on allergic inflammation in the murine lung. Inhal Toxicol 20 : 685-694, 2008.
PubMed
16) Ichinose T, et al : Asian sand dust aggravates allergic rhinitis in gunea pigs insuced by Japanese cedar pollen. Inhal Toxicol 21 : 985-993, 2009.
 
17) He M, et al : Aggrevating effects of Asian sand dust on lung eosinophilia in mice immunized beforehand by ovalbumin. Inhal Toxicol 24 : 751-761, 2012.
 
18) Watanabe M, et al : Effects on asthma and induction of interleukin-8 caused by Asian dust particles collected in western Japan. J Asthma 51 : 595-602, 2014.
PubMed

VI 続発性免疫不全症候群 - 各種疾患・病態にみられる免疫異常 -

P.577 掲載の参考文献
1) How AIDS Changed Everything. Fact Sheet : 2014 Global Statistics- [http://www.unaids.org/sites/default/files/media_asset/20150714_FS_MDG6_Report_en.pdf]
 
2) 2014年エイズ発生動向. [http://api-netjfap.or.jp/status/2014/14nenpo/h26gaiyo.pdf]
 
3) Berger EA, et al : Chemokine receptors as HIV-1 coreceptors : roles in viral entry, tropism, and disease. Ann Rev Immunol 17 : 657-700, 1999.
 
4) Ramratnam B, et al : The decay of Hie latent reservoir of replication-competent HIV-1 is inversely correlated with the exlent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 6 : 82-85, 2000.
 
5) Finzi DJ, et al : Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5 : 512-517, 1999.
 
6) Cohen MS, et al : Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 365 : 493-505, 2011.
PubMed
7) Allers K, et al : Evidence for the cure of HIV infection by CCR5 Δ32/Δ32 stem cell transplantation. Blood 117 : 2791-2799. 2011.
 
P.583 掲載の参考文献
1) 厚生労働省科学研究費補助金エイズ対策研究事業「ART早期化と長期化に伴う日和見感染症への対処に関する研究」班平成25年度総括・分担研究報告書.
 
2) Djawe K, et al : Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-infected Persons-San Francisco, 1981-2012. J Infect Dis. 2015 Jun 3. pii : jiv 235. [Epub ahead of print].
 
3) Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents. Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.[http://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/0]
 
4) 厚生労働省科学研究費補助金エイズ対策研究事業「HIV感染症及びその合併症の課題を克服する研究」班 : 抗HIV治療ガイドライン.
 
5) 厚生労働省科学研究費補助金エイズ対策研究事業「日和見感染症の診断/治療およびそれを端緒とするHIV感染者の早期発見に関する研究」班 : 免疫再構築症候群診療のポイントVer 3.
 
P.595 掲載の参考文献
1) Panel on AntiretroviraJ Guidelines for Adults and Adolescents : Guidelines for the use of antiretroviral agents in HIV-l-infected adults and adolescents. Department of Health and Human Services. 2015.4.8. Available at [http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf]
 
2) Huldrych F, et al : Antiretroviral Treatment of Adult HIV Infection 2014 Recommendations of the International Antiviral Society-USA Panel JAMA 312 (4) : 410-425, 2014.
 
3) European AIDS Clinical Society : EACS Treatment Guidelines 7.1. 2014. Nov.[http://www.eacsociety.org/files/guidelines-7.1-english.pdf]
 
4) 平成25年度厚生労働科学研究費補助金エイズ対策研究事業「HIV感染症及びその合併症の課題を克服する研究班 (研究分担者鯉渕智彦)」 : 抗HIV治療ガイドライン. 2015年3月.
 
5) 日本エイズ学会HIV感染症治療委員会 : HIV感染症「治療の手引き」第18版-2014年12月.
 
6) Sanford Guide to HIV/AIDS Therapy. Antimicrobial Therapy, Inc. (2015.7.22).
 
7) McKellar MS, et al; Duke-Unc Acute HIV Infection Consortium : Acute HIV-1 infection in the Southeastern United States : a cohort study. AIDS Res Hum Retroviruses 29 (1) : 121-128, 2013.
PubMed
8) 山本直樹, 宮澤幸久 : 診療におけるHIV-1/2感染症の診断ガイドライン 2008.日本エイズ学会誌 11 (1) : 70-72, 2009.
 
9) Busch MP1. Satten GA : Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 102 (5B) : 117-124; discussion 125-126, 1997.
 
10) Crossley KM, Brew BJ : Neurological Complications in Controlled HIV Infection. Curr Infect Dis Rep 15 : 564-568, 2013.
PubMed
11) 厚生労働省 : 身体障害者手帳の概要身体障害者障害程度等級の解説 (身体障害認定基準). 平成15年1月10日. [http://www.mhlw.go.jp/file/06-Seisakujouhou-12200000-Shakaiengokyoku-shougaihokenfukushibu/001_1.pdf]
 
12) The INSIGHT START Study Group : Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. July 20, 2015DOI : 10.1056/NEJMoal506816.
 
13) Centers for Disease Control and Prevention : HIV/AIDS Surveillance Report 2007. Vol 19. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta. [http://www.cdc.gov/hiv/topics/surveillance/resources/reports/table2.html]
 
14) Shelburne SA, et al : Immune reconstitution inflammatory syndrome : more answers, more questions. J Antimicrob Chemother 57 (2) : 167-170. 2006.
PubMed
15) Achenbach CJ, et al : Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 54 : 424, 2012.
PubMed
16) Boulware DR et al ; COAT Trial Team : Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 370 (26) : 2487-2498, 2014.
PubMed
17) Grant RM, et al; iPrEx Study Team : Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363 (27) : 2587-2599, 2010.
 
18) CDC : Interim guidance for clinicians considering the use of preexposure prophykxis for the prevention of HIV infection in hetero sexually active adults. MMWR Morb Mortal Wkly Rep 61 : 586-589, 2012.
PubMed
19) Chen A, Dowdy DW : Clinical Effectiveness and Cost-Effectiveness of HIV Pre-Exposure Prophylaxis in Men Who Have Sex with Men : Risk Calculators for Real-World Decision-Making. PLoS ONE 9 (10) : e108742, 2014.
PubMed
20) HIV Prevention The Basics of HIV Prevention. Key Points, [https://aidsinfo.nih.gov/education-materials/fact-sheets/20/48/the-basics-of-hiv-prevention]
 
P.599 掲載の参考文献
1) Pfaller MA et al : Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005 : an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 45 : 1735-1745, 2007.
PubMed
2) Takakura S, et al : National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 53 : 283-289, 2004.
PubMed
3) Yamaguchi H, et al : Species distribution and in vitro susceptibility to three antifungal triazoles of clinical Candida isolates from a five-year nationwide survey in Japan. Med Mycol Res 3 : 17-26, 2012.
 
4) Pappas PG, et al : Clinical practice guidelines for the management of candidiasis : 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48 : 503-535, 2009.
 
5) Bertagnolio S, et al : Hospital-acquired candidemia in HIV-infected patients. Incidence, risk factors and predictors of outcome. J Chemother 16 : 172-178, 2004.
PubMed
6) Casado JL, et al : Candidal meningitis in HIV-infected patients : analysis of 14 cases. Clin Infect Dis 25 : 673-676, 1997.
PubMed
7) Kauffman CA, et al : Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Disease Mycoses Study Group. Clin Infect Dis 30 : 14-18, 2000.
 
8) Goldman M, et al : A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis : AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis 41 : 1473-1480, 2005.
 
9) Wilcox CM, et al : Fluconazole compared with endoscopy for human immunodeficiency virusinfected patients with esophageal symptoms. Gastroenterology 110:1803-1809, 1996.
PubMed
10) Pappas PG, et al : A prospective observational study of candidemia : epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 37 : 634-643, 2003.
PubMed
P.604 掲載の参考文献
1) 安岡彰 : HIV感染症に合併する日和見感染症の現状. 日内会誌 47 : 561-570, 2009.
 
2) Sloan DJ, et al : CryptococcaJ meningitis : epidemiology and therapeutic options. Clin Epidemiol 6 : 169-182, 2014.
PubMed
3) Charlier C, et al : Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformance. Infect Immun 77 (1) : 120-127, 2009.
 
4) Center for Disease Control and Prevention : Emergence of Cryptococcus gattL Pacific North West, 2004-2010. MMWR 59 (28) : 865-868, 2010.
 
5) 亀井克彦 : 増えている輸入真菌症. 日内会誌 99 : 31-37, 2010.
 
6) Tjia TL, et al : Cryptococcal meningitis. J Neurol Neurosurg Psychiatry 48 (9) : 853-858, 1985.
PubMed
7) Kauffman CA, et al : Detection of cryptococcal antigen. Comparison of two latex agglutination tests. Am J Clin Pathol 75 (1) : 106-109, 1981.
PubMed
8) Miszkiel KA, et al : The spectrum of MRI findings in CNS cryptococcosis in AIDS. Clin Radiol 51 : 842-850, 1996.
PubMed
9) Perfect JR, et al : Clinical practice guidelines for the management of cryptococcal disease : 2010 update by the infectious diseases society in america. Clin Infect Dis 50 : 291-322, 2010.
PubMed
10) Saag MS, et al : Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 326 (2) : 83-89, 1992.
 
11) van der Horst CM, et al : Treatment of cryptococcal meningitis meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Disease Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 337 (1) : 15-21, 1997.
 
12) Graybill JR et al : Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 30 (1) : 47-54, 2000.
 
13) Sungkanuparph S, et al : Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immne Defic Syndr 45 (5) : 595-596, 2007.
 
P.609 掲載の参考文献
1) 千葉大学真菌医学研究センターHP「輸入真菌症患者発生最新状況」. [http://clinical-r.pf.chiba-u.jp/mycosis/01.html]
 
2) Simons CM, et al : Peripheral blood eosinophilia as a clue to the diagnosis of an occult Coccidioides infection. Hum Pathol 42 (3) : 449-453, 2011.
 
3) Assi MA, et al : Disseminated coccidioidomycosis in a liver transplant recipient with negative serology : use of polymerase chain reaction. Liver Transpl 12 (8) : 1290-1292, 2006.
 
4) Oldfield EC 3rd, et al : Prediction of relapse after treatment of coccidioidomycosis. Clin Infect Dis 5 : 1205-1210, 1997.
PubMed
5) Pappagianis D : Serologic studies in coccidioidomycosis. Semin Respir Infect 16 (4) : 242-250, 2001.
PubMed
6) Thompson GR 3rd, et al : Serum (1→3) -β-D-glucan measurement in coccidioidomycosis. J Clin Microbiol 50 (9) : 3060-3062, 2012.
 
7) 千葉大学真菌医学研究センターHp「真菌症コンサルテーション及び各種検査のご案内」.[http://clinical-r.pf.chiba-u.jp/lab-examination.html]
 
8) Galgiani JN, et al : Coccidioidomycosis. Infectious Diseases Society of America Clin Infect Dis 41 (9) : 1217-1223, 2005.
 
9) 亀井克彦ほか : 輸入真菌症の診断・治療指針. 協和企画, 2011.
 
10) 深在性真菌症のガイドライン作成委員会 (編) : 深在性真菌症の診断・治療ガイドライン 2014. 協和企画, 2014.
 
P.615 掲載の参考文献
1) Vail GM1, et al : Incidence of histoplasmosis following allogeneic bone marrow transplant or solid organ transplant in a hyperendemic area. Transpl Infect Dis 4 (3) : 148-151, 2002.
 
2) Wheat J : Endemic mycoses in AIDS : a clinical review. Clin Microbiol Rev 8 (1) : 146-159, 1995.
PubMed
3) 千葉大学真菌医学研究センター : 輸入真菌症発生状況. [http://www.pf,chiba-u.ac.jp/clinical/mycosis.html]
 
4) Kamei K, et al : The trend of imported mycoses in Japan. J Infect Chemother 9 (1) : 16-20, 2003.
PubMed
5) Wheat LJ, et al : Histoplasmosis in the acquired immune deficiency syndrome. Am J Med 78 (2) : 203-210, 1985.
PubMed
6) Wheat LJ, et al. : Disseminated histoplasmosis in the acquired immune deficiency syndrome : clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 69 (6) : 361-374, 1990.
PubMed
7) Wheat J : Histoplasmosis in the acquired immunodeficiency syndrome. Curr Top Med Mycol 7 (1) : 7-18, 1996.
PubMed
8) Kauffman CA : Histoplasmosis : a clinical and laboratory update. Clin Microbiol Rev 20 (1) : 115-132, 2007.
PubMed
9) Johnson PC, et al : Progressive disseminated histoplasmosis in patients with acquired immunodeficiency syndrome. Am J Med 85 (2) : 152-158, 1988.
PubMed
10) Karimi K, et al : Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis 186 (11) : 1655-1660, 2002.
 
11) Breton G, et al : Immune reconstitution inflammatory syndrome in HIV-infected patients with disseminated histoplasmosis. AIDS 20 (1) : 119-121, 2006.
PubMed
12) Kirn DH, et al : Marked clevation of the serum ferritin is highly specific for disseminated histoplasmosis in AIDS. AIDS 9 (10) : 1204-1205, 1995.
PubMed
13) Girouard G, et al : Observations on (1-3) -beta-D-glucan detection as a diagnostic tool in endemic mycosis caused by Histoplasma or Blastomyces. J Med Microbiol 56 (Pt 7) : 1001-1002, 2007.
PubMed
14) Gonnolly PA, et al : Detection of histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol 14 (12) : 1587-1591, 2007.
 
15) Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, 2013. [http://www.aidsinfo.nif.gov/]618
 
P.618 掲載の参考文献
2) Pifer LL, et al : Pneumoocystis carinii infection : evidence for high prevalence in normal and immunosuppressed children. Pediatrics 161 : 35-41, 1978.
 
3) Ponce CA, et al : Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 50 : 347-353, 2010.
PubMed
4) 平成25 (2013) 年エイズ発生動向年報-発生動向の分析結果-. 厚生労働省エイズ動向委員会, 平成26年5月23日.
 
5) Keely SP, Stringer JR : Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol 35 : 2745-2747, 1997.
PubMed
6) Yazaki H, et al : Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients : P. jiroveci is contagious to the susceptible host. Transplantation 88 : 380-385, 2009.
 
7) Fujii T, et al : Pneumocystis pneumonia in patients with HIV infection : clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 13 : 1-7, 2007.
PubMed
8) Tasaka S, et al : Serum indicators for Hie diagnosis of Pneumocystis pneumonia. Chest 131 : 1173-1180, 2007.
 
9) Watanabe T, et al : Serum (1→3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 49 : 1128-1131, 2009.
 
10) Desmet S, et al : Serum (1-3) -beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 47 : 3871-3874, 2009.
PubMed
11) de Boer MG, etal : β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients : a prospective study. J Infect 62 : 93-100, 2011.
 
12) Sax PE, et al : Blood (1→3) -beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 53 : 197-202, 2011.
 
13) Radhi S, et al : Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis 8 : 118, 2008.
PubMed
14) Walzer PD, et al : Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients : 1985-2006. Clin Infect Dis 46 : 625-633, 2008.
PubMed
P.623 掲載の参考文献
1) Kim K, Weiss LM : Toxoplasma : the next 100 years. Microbes Infect 10 : 978-984, 2008.
PubMed
2) 松岡裕之ほか : 日本人若年成人における抗トキソプラズマ抗体の保有率. 日臨寄生虫会誌 20 : 102-104, 2009.
 
3) Sakikawa M, et al : Anti-Toxoplasma antibody prevalence, primary infection rate, and risk factors in a study of toxoplasmosis in 4,466 pregnant women in Japan. Clin Vaccine Immunol 19 : 365-367, 2012.
 
4) Tilahun B, et al : Seroprevalence and risk factors of Toxoplasma gondii infection in humans in East Hararghe Zone. Ethiopia Epidemiol Infect 15 : 1-8, 2015.
 
5) Tenter AM, et al : Toxoplasma gondii : from animals to humans. Int J Parasitol 30 : 1217-1258, 2000.
PubMed
6) Abgrall S, et al : Incidence and Risk Factors for Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected Patients before and during Hie Highly Active Antiretroviral Therapy Era. Clin Infect Dis 33 : 1747-1755, 2001.
 
7) Nagamune K, et al : Abscisic acid controls calcium-dependent egress and development in Toxoplasma gondii. Nature 451 : 207-210, 2008.
PubMed
8) Frenkel JK, et al : Toxoplasma gondii in cats : fecal stages identified as coccidian oocysts. Science 167 : 893-896, 1970.
PubMed
9) CDC : Parasites-Toxoplasmosis (Toxoplasma infection). [http://www.cdc.gpv/parasites/toxoplasmosis/biology.html]
 
10) Hurt C, Tammaro D : Diagnostic evaluation of mononucleosis-like Illnesses. Am J Med 120 : 911, e1-e8, 2007.
 
11) Porter SB, Sande MA : Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 327 : 1643-1648, 1992.
PubMed
12) Philip-Ephraim EE, et al : Stroke-Like Presentation of Cerebral Toxoplasmosis : Two HIV-Infected Cases. Cerebrovasc Dis Extra 5 : 28-30, 2015.
PubMed
13) Levy RM, et al : The efficacy and clinical impact of brain imaging in neurologically symptomatic AIDS patients : a prospective CT/MRI study. J Acquir Immune Defic Syndr 3 : 461-471, 1990.
PubMed
14) Rosenblum ML, et al : Algorithms for the treatment of AIDS patients with neurological disease. In : AIDS and the nervous system (ed by Berger JR Levy R), p 157-191, Raven Press, New York, 1988.
 
15) Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected adults and adolescents. DHHS guideline Toxoplasma gondii encephalitis (last up-dated May 7, 2013).
 
16) エイズ治療薬研究班ホームページ. [http://labo-mecLtokyo-med.ac.jp/aidsdrugmhlw/pub/portal/top/top.jsp]
 
17) Toxoplasmosis in HIV-infected patients UpToDate (Last updated Jan. 21, 2015).
 
18) 菅沼明彦ほか : 免疫再構築症候群により発症したトキソプラズマ脳症の1例. 日臨寄生虫会誌 20 : 99-101, 2009.
 
19) Ho YC. et al : Clinical presentation and outcome of toxoplasmic encephalitis in patients with human immunodeficiency virus type 1 infection. J Microbiol Immunol Infect 41 : 386-392, 2008.
PubMed
20) Garvey L, et al : HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 18 : 527-534, 2011.
PubMed
21) Kiderlen TR, et al : Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART). Eur J Clin Microbiol Infect Dis 30 : 1521-1525, 2011.
PubMed
P.628 掲載の参考文献
1) Guerrant RL : Cryptosporidiosis : an emerging, highly infectious threat Emerg Infect Dis 3 (1) : 51-57, 1997.
PubMed
2) Tumwine JK, et al : Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg 73 (5) : 921-925, 2005.
PubMed
3) Manabe YC, et al : Cryptosporidiosis in patients with AIDS : correlates of disease and survival. Clin Infect Dis 27 (3) : 536-542, 1998.
PubMed
4) 国立感染症研究所 : クリプトスポリジウム症およびジアルジア症 2014年7月現在. 病原微生物検出情報 (IASR) 35 (8) : 185-186, 2014.
 
5) 増田剛太ほか : 下痢症患者からのクリプトスポリジウムの検出 : 駒込病院での成績. 臨寄生虫会誌 12 : 89-91, 2001.
 
6) Dillingham RA, et al : Crypto spor idiosi s : epidemiology and impact Microbes Infect 4 (10) : 1059-1066, 2002.
 
7) 泉山信司, 遠藤卓郎 : わが国で発生したCryptosporidium集団感染に関する考察. Clinical Parasitology 16 : 58-60, 2005.
 
8) Current WL, Garcia LS : Cryptosporidiosis. Clin Microbiol Rev 4 (3) : 325-358, 1991.
PubMed
9) Mercado R, et al : Cryptosporidium hominis infection of the human respiratory tract Emerg Infect Dis 13 (3) : 462-464, 2007.
PubMed
10) Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, 2013. [http://www.aidsinfo.nih.gov/]
 
11) Rossignol JF, et al : Treatment of diarrhea caused by Cryptosporidium parvum : a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis 184 (1) : 103-106, 2001.
PubMed
12) Rossignol JF, et al : A double- 'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 92 (6) : 663-666, 1998.
PubMed
13) Hashmey R, et al : Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore) 76 (2) : 118-139, 1997.
PubMed
14) White AC Jr. et al : Paromomycin for cryptosporidiosis in AIDS : a prospective, double-blind trial. J Infect Dis 170 (2) : 419-424, 1994.
 
15) Hewitt RG, et al : Paromomycin : no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human imrminodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis 31 (4) : 1084-1092, 2000.
PubMed
P.631 掲載の参考文献
1) Shaffer N, et al : Chronic travelers' diarrhea in a normal host due to Isospora belli. J Infect Dis 159 : 596, 1989.
 
2) Goodgame R : Emerging Causes of Travelers' Diarrhea : Cryptosporidium, Cyclospora, Isospora, and Microsporidia. Curr Infect Dis Rep 5 : 66, 2003.
PubMed
3) Barta JR, et al : The geneus Atoxoplasma (Garnham 1950) as a junior objective synonym of the genus Isospora (Schneider 1881) species infecting birds and resurrection of Cystoisospora (Frenkel 1977) as the correct genus for Isospora species infecting mammals. J Parasitol 91 : 726-727, 2005.
 
4) Lindsay DS, et al : Biology of Isospora spp. from humans, nonhuman primates, and domestic animals. Clin Microbiol Rev 10 (1) : 19-34, 1997.
 
5) DeHovitz JA, et al : Clinical manifestations and therapy of Isospora belli infection in patients with the aquired immunodeficiency syndrome. N Engl J Med 315 : 87, 1986.
 
6) Williams DT, et al : Severe hypokalemia, paralysis, and AIDS-associated isospora belli diarrhea. J Emerg Med 41 (6) : e129-132, 2011.
PubMed
7) Lagrange-Xe'lot M, et al : Isosporiasis in patients with HIV infection in the highly active antiretroviral therapy era in France. HIV Med 9 : 126, 2008.
 
8) Benator DA, et al : Isospora belli infection associated with acalculous cholecystisis in a patients with AIDS. Ann Intern Med 121 : 663, 1994.
 
9) Gonzalez-Dominguez J, et al : Isospora belli reactive arthritis in a patient with AIDS. Ann Rheum Dis 53 (9) : 618-619, 1994.
 
10) Restrepo C, et al : Disseminated extraintestinal isosporiasis in a patient with acquired immune deficiency syndrome. Am J Clin Pathol 87 (4) : 536-542, 1987.
 
11) Bernard E, et al : Disseminated isosporiasis in an AIDS patient. Eur J Clin Microbiol Infect Dis 16 (9) : 699-701, 1997.
 
12) Anglaret X, et al : Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d' Ivoire : a randomised trial. Cotrimo-CI Study Group. Lancet 353 (9163) : 1463-1468, 1999.
 
13) Sorvillo FJ, et al : Epidemiology of isosporiasis among persons with acquired immunodeficiency syndrome in Los Angeles County. Am J Trop Med Hyg 53 (6) : 656-659, 1995.
PubMed
14) Verdier RI, et al : Trimethoprim-sulfamethoxazole compared with ciprofloxacin for treatment and prophylaxis of Isospora belli and Cyclospora cayetanensis infection in HIV-infected patients. A randomized, controlled trial. Ann Intern Med 132 (11) : 885-888, 2000.
PubMed
15) Weiss LM, et al : Isospora belli infection : treatment with pyrimethamine. Ann Intern Med 109 (6) : 474-475, 1988.
PubMed
P.635 掲載の参考文献
1) エイズ予防情報ネットAPI-net (2015/6/5アクセス). [http://api-net.jfap.or.jp/index.html]
 
2) Dankner WM, et al : Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretrovlral therapy. Pediatr Infect Dis J 20 : 40-48, 2001.
PubMed
3) Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children. Bacterial Infections (2015/6/5アクセス). [http://aidsinfo.nih.gov/guidelines]
 
4) Bartlett JG : Chapter 30 : Other HIV-related Pneumonias. "Global HIV/AIDS Medicine", 1st ed (ed by Volberding PA, et al), p323-332, Saunders, Philadelphia, 2007.
 
5) KCrothers K et al : HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 183 : 388-395. 2011.
 
6) Huson MA, et al : The effect of HIV infection on the host response to bacterial sepsis. Lancet Infect Dis 15 : 95-108, 2015.
PubMed
7) Benito N : Pulmonary infections in HIV-infected patients : an update in the 21st century. Eur Respir J 39 : 730-745, 2012.
PubMed
8) Chen TC : Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis : a systematic review and meta-analysis. Int J Infect Dis 15 : e211-216. 2011.
PubMed
9) Tin Z : Invasive pneumococcal disease among HIV-positive individuals, 2000-2009. AIDS 26 : 87-94, 2012.
 
10) French N : A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 362 : 812-822, 2010.
 
11) Frankel RE. et al : Invasive pneumococcal disease : clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. Clin Infect Dis 23 : 577-584, 1996.
PubMed
12) Moss WJ, et al : Chapter 64-Vaccination of human immunodeficiency virus-infected persons "Vaccines", 6th ed (ed by Plotokin SA, et al), p 1257-1269. Elsevier Inc, China, 2013.
 
P.639 掲載の参考文献
1) Nakadai A, et al : Prevalence of Salmonella spp. in pet reptiles in Japan. J Vet Med Sci 67 (1) : 97-101, 2005.
PubMed
2) Cummings PL, et al : Salmonellosis-related mortality in the United States, 1990-2006. Foodborne Pathog Dis 7 (11) : 1393-1399, 2010.
PubMed
3) CDC Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults.
 
4) Hung CC, et al : Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance. Clin Infect Dis 45 : e60-67, 2007.
 
5) MacLennan CA et al : Dysregulated humoral immunity to nontyphoidal Salmonella in HIVinfected African adults. Science 328 : 508-512, 2010.
PubMed
6) Hofer U, Speck RF : Disturbance of the gut-associated lymphoid tissue is associated with diseaseprogression in chronic HIV infection. Semin Immunopathol 31 : 257-266, 2009.
 
7) Celum CL, et al : Incidence of salmonellosis in patients with AIDS. J Infect Dis 156 : 998-1002, 1987.
PubMed
8) Mootsikapun P : Bacteremia in adult patients with acquired immunodeficiency syndrome in the northeast Thailand. Int J Infect Dis 11:226-231, 2007.
PubMed
9) Yen YF, et al : Prognostic Factors and Clinical Features of Non-typhoid Salmonella Bacteremia in Adults. J Clin Med Assoc 72 (8) : 408-413, 2009.
 
10) Hohmann EL : Non-typhoidal salmonellosis. Clin Infect Dis 32 : 263-269, 2001.
 
11) National Institute of Health and the HIV Medicine Association of the Infections Diseases Society of America : Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents, 2013. [http://aidsinfo.nih.gov/contentflles/lvguidelines/adultoi.pdf]
 
12) Humphries RM, et al : In vitro susceptibility testing of fluoroquinolone activity against Salmonella : recent changes to CLSI standards. Clin Infect Dis 55 (8) : 1107-1113, 2012.
PubMed
13) Sjolund-Karlsson M, et al : Fluoroquinolone susceptibility testing of Salmonella enterica : detection of acquired resistance and selection of zone diameter breakpoints for levofloxacin and ofloxacin. J Clin Microbiol 52 (3) : 877-884, 2014.
PubMed
14) Anglaret X, et al : Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving co-trimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 17:575-584, 2003.
 
15) Reller ME, et al : Sexual transmission of typhoid fever : a multistate outbreak among men who have sex with men. Clin Infect Dis 37 : 141-144, 2003.
PubMed
P.645 掲載の参考文献
1) [http://api-net.jfap.or.jp/library/MeaRelDoc/03/images/070808_03.pdf]
 
2) [http://www.who.int/mediacentre/factsheets/fs104/en/]
 
3) [http://www.unaids.org/sites/default/fles/media_asset/20150714_FS_MDG6_Report_en.pdf]
 
4) [http://api-netjfap.or.jp/status/2014/14nenpo/14nenpo_menu.html]
 
5) 安岡彰 : ART早期化と長期化に伴う日和見感染症への対処に関する研究平成26年度総括・分担研究報告書厚生労働科学研究費補助金エイズ対策研究事業.
 
6) Gardy JL, et al : Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 364 : 730-739, 2011.
PubMed
7) Jones BE, et al : Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148 : 1292-1297, 1993.
PubMed
8) WHO : Same-day diagnosis of tuberculosis by microscopy. World Health Organization, Geneva, 2011.
 
9) WhitelawA, et al : Comparative cost and performance of light-emitting diode microscopy in HIV-tuberculosis-co-infected patients. Eur Respir J 38 : 1393-1397, 2011.
PubMed
10) van Zyl-Smit RN. et al : Comparison of quantitative techniques including Xpert MTB/RIF to evaluate mycobacterial burden. PLoS One 6 : e28815, 2011.
 
11) WHO : Xpert MTB/RIF implementation manual. World Health Organization, Geneva, 2014.
 
12) WHO : The use of molecular line probe assay for the detection of resistance to second-line anti-tuberculosis drugs. World Health Organization, Geneva, 2013.
 
13) WHO : Global tuberculosis Report World Health Organization, Geneva, 2014.
 
14) Perlman DC, et al : Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression : the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Clin Infect Dis 25 : 242-246, 1997.
PubMed
15) von Reyn CF, et al : Disseminated tuberculosis in human immunodeficiency virus infection : ineffective immunity, polyclonal disease and high mortality. Int J Tuberc Lung Dis 15 : 1087-1092, 2011.
PubMed
16) Fee MJ, et al : Abdominal tuberculosis in patients infected with the human immunodeficiency virus. Clin Infect Dis 20 : 938-944, 1995.
PubMed
17) Dube MP, et al : Tuberculosis meningitis in patients with and without human immunodeficiency virus infection. Am J Med 93 : 520-524, 1992.
PubMed
18) Mudenda V, et al : Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa : the urgent need to expand and invest in routine and research autopsies. J Infect Dis 205 (Suppl 2) : S340-S346, 2012.
 
19) de Castro Cunha RM, et al : Interferon-y and tumour necrosis factor-a production by CD4+ T and CD8+ T lymphocytes in AIDS patients with tuberculosis. Clin Exp Immunol 140 : 491-497, 2005.
 
20) Andrade RM, et al : Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production. AIDS 21 (13) : 1763-1770, 2007.
PubMed
21) 日本結核病学会予防委員会 : 結核 89 (8) : 717-725, 2014.
 
22) Kaplan JE, et al : Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents : recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 58 (RR-4) : 1-207, 2009.
 
23) Perriens JH, et al : Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. N Engl J Med 332 (12) : 779-784. 1995.
PubMed
24) Nahid P, et al : Treatment outcomes of patients with HIV and tuberculosis. Am J Res Crit Care Med 175 : 1199-1206, 2007.
 
25) Pozniak AL, et al : BHIVA treatment guidelines for tuberculosis (TB) /HIV infection 2005. HIV Med 6 (Suppl 2) : 62-83, 2005.
 
26) 日本結核病学会治療委員会 : 抗結核薬の減感作療法に関する提言. 結核 72 : 697-700, 1997.
 
27) Blanc FX, et al ; CAMEUA (ANRS 1295-CIPRA KH001) Study Team : Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365 (16) : 1471-1481, 2011.
 
28) Havlir DV, et al; AIDS Clinical Trials Group Study A5221 : Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 365 (16) : 1482-1491, 2011.
 
29) Abdool Karim ss, et al : Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365 : 1492-1501, 2011.
PubMed
P.652 掲載の参考文献
1) Prokaryotic Nomenclature Up-to-date. [https://www.dsmz.de/bacterial-diversity/prokaryotic-nomenclature-up-to-date.html (平成27年7月1日閲覧)].
 
2) Buchacz K, et al : AIDS-defining opportunistic illnesses in US patients, 1994-2007 : a cohort study. AIDS 24 (10) : 1549-1559, 2010.
PubMed
3) Horsburgh CR Jr. : The pathophysiology of disseminated Mycobacterium avium complex disease in AIDS. J Infect Dis 179 (Suppl 3) : S461-465, 1999.
 
4) Pierce M, et al : A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 335 : 384, 1996.
 
5) Havlir DV, et al : Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 335 : 392, 1996.
PubMed
6) Benson CA, et al : Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS : A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. T Infect Dis 181 : 1289. 2000.
 
7) Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents : Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. [http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (平成27年7月1日参照)].
 
8) Currier JS, et al : Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, doubel-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med 133 : 493, 2000.
 
9) El-Sadr WM, et al : Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med 342 : 1085, 2000.
PubMed
10) Ward TT, et al : Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis 27 : 1278, 1998.
 
11) Benson CA et al : A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis 37 : 1234, 2003.
PubMed
12) Dautzenberg B, et al : Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 153 (3) : 368-372, 1993.
PubMed
13) Griffith DE, et al : An official ATS/IDSA statement : diagnosis, treatment and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 (4) : 367-416, 2007.
PubMed
14) Campo RE, Campo CE : Mycobacterium kansasii disease in patients infected with human immunodeficiency virus. Clin Infect Dis 24 : 1233, 1997.
PubMed
15) Evans AJ, et al : Pulmonary Mycobacterium kansasii infection : comparison of radiological appearances with pulmonary tuberculosis. Thorax 51 : 1243, 1996.
PubMed
P.655 掲載の参考文献
1) 山田秀人ほか : 妊産婦の感染症とその対策先天性サイトメガロウイルス感染症と免疫グロブリン療法. 産婦人科治療 97 : 485-493. 2008.
 
2) 平成25 (2013) 年エイズ発生動向年報-発生動向の分析結果-. 厚生労働省エイズ動向委員会, 平成26年5月23日.
 
3) Cytomegalovirus Disease : Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (米国DHHS, May 7, 2013). [https://aidsinfo.nih.gov/] よりダウンロード可能.
 
4) Philips P, et al : Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients : spectrum of disease and long-term follow-up. Clin Infect Dis 41 : 1483-1497, 2005.
 
5) Bicanic T, et al : Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis : a prospective study. J Acquir Immune Defic Syndr 51 : 130-134, 2009.
PubMed
6) Wolf DG, Spector SA : Diagnosis of human cytomegalovirus central nervous system disease in AIDS patients by DNA amplification from cerebrospinal fluid. J Infect Dis 166 : 1412-1415, 1992.
PubMed
7) Arribas JR et al : Cytomegalovirus encephalitis. Ann Intern Med 125 : 577-587, 1996.
PubMed
8) Chou S : Cytomegalovirus UL97 mutations in Hie era of ganciclovir and maribavir. Rev Med Virol 18 : 233-246, 2008.
 
P.659 掲載の参考文献
1) Siegal FP, et al : Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 305 (24) : 1439, 1981.
PubMed
2) Schacker T, et al : Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis 178 (6) : 1616, 1998.
 
3) Corey L, et al : The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission : a review of two overlapping epidemics. J Acquir Immune Defic Syndr 35 (5) : 435, 2004.
PubMed
4) Goodell SE, et al : Herpes simplex virus proctitis in homosexual men. Clinical, sigmoidoscopic, and histopathological features. N Engl J Med 308 (15) : 868-871, 1983.
PubMed
5) Corey L, et al : Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome. Lancet 1 (8575-6) : 1-4, 1983.
 
6) Levitz RE : Herpes simplex encephalitis : a review. Heart Lung 27 (3) : 209, 1998.
PubMed
7) Aurelius El, et al : Rapid diagnosis of herpes simplex encephalitis by nested polymerase chain reaction assay of cerebrospinal fluid. Lancet 337 (8735) : 189-192, 1991.
 
8) Pouplin T, et al : Valacyclovir for herpes simplex encephalitis. Antimicrob Agents Chemother 55 (7) : 3624-3626, 2011.
PubMed
P.664 掲載の参考文献
1) 山田正仁ほか : 「進行性多巣性白質脳症 (Progressive Multifocal LeukoencephaJopathy : PML) 診療ガイドライン 2013」, 厚生労働科学研究費補助金難治性疾患等克服研究事業 (難治性疾患克服研究事業), プリオン病及び遅発性ウイルス感染症に関する調査研究班, 2013.
 
2) Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of tlle Infectious Diseases Society of America.[https://aidsinfo.nih.gov/contentfiles/lvguidelines/Adult_OLpdf] Last updated : April 16. 2015.
 
3) Berger JR, et al : PML diagnostic criteria : consensus statement from the AAN Neuroinfections Disease Section. Neurology 80 (15) : 1430-1438, 2013.
 
4) Kleinschmidt-DeMasters BK. Tyler KL : Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-la for multiple sclerosis. N Engl J Med 353 : 369-374, 2005.
 
5) 中村聖香ほか : HIV感染症に関連した小脳性運動失調症の1例. 臨床神経 49 : 651-655, 2009.
 
6) Delbue S, et al : Human polyomavirus 6 DNA in Hie cerebrospinal fluid of an HIV-positive patient with leukoencephalopathy. J Clin Virol 68 : 24-27, 2015.
 
7) Muller M, et al : Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection : a systematic review and meta-analysis. Lancet Infect Dis 10 : 251-261, 2010.
PubMed
8) Tan K, et al : PML-IRIS in patient with HIV infection : clinical manifestations and treatment with steroid. Neurology 72 : 1458-1464, 2009.
PubMed
9) Brickelmaier M, et al : Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53 : 1840-1849, 2009.
PubMed
10) Clifford DB, et al : A study of mefloquine treatment for progressive multifocal leukoencephalopathy : results and exploration of predictors of PML outcomes. J Neurovirol 19 : 351-358, 2013.
 
11) Cettomai D, McArthur JC : Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 66 : 255-258. 2009.
PubMed
12) Berenguer J, et al : Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 36 : 1047-1052, 2003.
PubMed
13) Casado JL, et al : Continued declining incidence and improved survival progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 33 : 179-187, 2014.
PubMed
P.667 掲載の参考文献
1) Kaposi M : Idiopatiches multiples pigment sarcom der Haut. Arch Dermatol Syphil 4 : 265-272, 1872.
 
2) Hymes KB, et al : Kaposi's sarcoma in homosexual men-a report of eight cases. Lancet 2 (8247) : 598-600, 1981.
 
3) Jones JL, et al : Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ 48 : 1-22, 1999.
PubMed
4) Eltom MA, et al : Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94 : 1204-1210, 2002.
PubMed
5) Simard EP, et al : Cumulative incidence of cancer among individuals with aquired immunodeficiency syndrome in the United States. Cancer 117 : 1089-1096, 2011.
 
6) Goudsmit J, et al : Human herpesvirus 8 infections in the Amsterdam Cohort Studies (1984-1997) : analysis of seroconversions to ORF73. Proc Natl Acad Sci USA 97 : 4838-4843, 2000.
PubMed
7) Lodi S, et al : Kaposi sarcoma incidence and survival among HIV-infected homosexusual men after HIV seroconversion. J Natl Cancer Inst 102 : 784-792, 2010.
PubMed
8) Dezube BJ, et al : Management of AIDS-related Kaposi sarcoma : advances in target discovery and treatment AIDS Read 14 : 236-238, 243-244, 251-253, 2004.
 
9) Zibrak JD, et al : Bronchoscopic and radiologic features of Kaposi's sarcoma involving the respiratory system. Chest 90 : 476-479, 1986.
PubMed
10) Cheung MC, et al : AIDS-related malignancies : emerging challenges in the era of highly active antiretroviral therapy. Oncologist 10 : 412-426, 2005.
PubMed
11) Allen CM, et al : Imaging lung manifestations of HIV/AIDS. Ann Thorac Med 5 : 201-216, 2010.
PubMed
12) Abdel-Dayem HM, et al : Evaluation of sequential thallium and gallium scans of the chest in AIDS patients. J Nucl Med 37 : 1662-1667, 1996.
PubMed
13) Morooka M, et al : Usefulness of F-18 FDG PET/CT in a case of Kaposi sarcoma with an unexpected bone lesion. Clin Nucl Med 36 : 231-234, 2011.
 
14) Dupont C, et al : Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d' information et de soins de l' immunodeficience humaine. AIDS 14 : 987-993, 2000.
 
15) Martin-Carbonero L, et al : Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 18 : 1737-1740, 2004.
PubMed
P.672 掲載の参考文献
1) So YT, et al : Primary central nervous system lymphoma in acquired immune deficiency syndrome : a clinical and pathological study. Ann Neurol 20 : 566-572, 1986.
PubMed
2) MacMahon EME, et al : Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338 : 969-973, 1991.
 
3) Tselis A. McKendall R : Epstein-Barr virus infection and primary central nervous system lymphoma. In : The Spectrum of Neuro-AIDS Disorders (ed by Goodkin K, et al), p383-391, ASM Press, Washington,DC, 2009.
 
4) Antinori A et al : Value of combined approach with thallium-201 single-photon emission computed tomography and Ebstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 17 : 554-560, 1999.
 
5) Grimm SA et al : Primary CNS lymphoma with intraocular involvement : International PCNSL Collaborative Group Report Neurology 71 : 1355-1360, 2008.
 
6) Gopal S, et al : Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 105 : 1221-1229, 2013.
PubMed
7) Fine HA Mayer RJ : Primary central nervous system lymphoma. Ann Int Med 119 : 1093-1104, 1993.
PubMed
8) Nagai H, et al : Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol 84 : 499-505, 2010.
PubMed
9) Gonzalez-Aquilar A Soto-Hernandez JL : The management of primary central nervous system lymphoma related to AIDS in the HAART era. Curr Opin Oncol 23 : 648-653, 2011.
 
10) 向井栄一郎ほか : 中枢神経障害を示したAIDSの7症例. 神経内科 53 : 450-457, 2000.
 
11) 向井栄一郎ほか : HIV感染症に伴う神経障害の変遷. 神経内科 59 : 403-408. 2003.
 
12) 向井栄一郎 : HIV脳症 (AIDS dementia complex) のdementia. 神経内科 80 : 77-84, 2014.
 
P.676 掲載の参考文献
1) Koblin BA, et al : Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978-1990. Am J Epidemiol 144 : 916-923, 1996.
PubMed
2) Polesel J, et al : Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS 22 : 301-306, 2008.
 
3) Levine AM, et al : Evolving characteristics of AIDS-related lymphoma. Blood 96 : 4084, 2000.
PubMed
4) Guiguet M, et al : Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDHANR3 CO4) : a prospective cohort study. Lancet Oncol 10 : 1152-1159, 2009.
 
5) 大田泰徳ほか : エイズ関連リンパ腫の病理診断. 病理と臨床 30 : 195-203, 2012.
Medical*Online
6) Bissuel F, et al : Fever of unknown origin in HIV-infected patients : a critical analysis of a retrospective series of 57 cases. J Intern Med 236 : 529-535, 1994.
 
7) Heise W, et al : Malignant gastrointestinal lymphomas in patients with AIDS. Digestion 58 : 218-224, 1997.
PubMed
8) Sarker D, et al : Leptomeningeal disease in AIDS-related non-Hodgkin's lymphoma AIDS 17 : 861-865, 2003.
PubMed
9) Klatt EC, et al : Evolving trends revealed by autopsies of patients with Hie acquired immunodeficiency syndrome. 565 autopsies in adults with the acquired immunodeficiency syndrome, Los Angeles, Calif, 1982-1993 [corrected]. Arch Pathol Lab Med 118 : 884-890, 1994.
 
10) Kaplan LD, et al : Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma : AIDS-malignancies consortium trial 010. Blood 24 : 1538-1543, 2005.
 
11) Bayraktar UD, et al : Outcome of Patients with Relapsed/Refractory AIDS-Related Lymphoma Diagnosed 1999-2008 and Treated with Curative Intent in the AIDS Malignancy Consortium. Leuk Lymphoma 53 : 2383-2389, 2012.
PubMed
12) Wang ES, et al : Intensive chemotherapy with cyclophosphamide. doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOXM/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma Cancer 98 : 1196-1205, 2003.
 
13) Sparano JA, et al : Rituximab phis concurrent incisional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma Blood 115 : 3008-3016, 2010.
 
14) Castillo JJ, et al : Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist 15 : 293-299, 2010.
PubMed
P.682 掲載の参考文献
1) CDC : 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41 : 1-19. 1992.
PubMed
2) Matsuda A, et al : Cancer Incidence and Incidence Rates in Japan in 2008 : A Study of 25 Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 44 : 388-396, 2013.
 
3) 人口動態統計 (厚生労働省大臣官房統計情報部編).
 
4) Meisels A, Fortin R : Condylomatous lesions of Hie cervix and vagina. I. Cytologic patterns. Acta Cytol 20 : 505-509, 1976.
 
5) Georgakilas AG, et al : Viral-induced human carcinogenesis : an oxidative stress perspective. Mol Biosyst 6 : 1162-1172, 2010.
PubMed
6) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会 (編) : 子宮頸癌取扱い規約改訂第3版, 金原出版. 2012.
 
7) Kurman RJ. et al (eds) : World Health Organization Classification of Tumours of Female Reproductive Organs, 4th ed. p 169-206, IARC Press, Lyon, France, 2014.
 
8) Clifford GM, et al : Human papillomavirus types among women infected with HIV : a meta analysis. AIDS 20 : 2337-2344, 2006.
PubMed
9) Maiman M : Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monographs 23 : 43-49, 1998.
 
10) Kaplan JE : Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Recomm Rep 58 : 1-207, 2009.
PubMed
11) American College of Obstetricians and Gynecologists : Gynecologic care for women with human immunodeficiency virus. ACOG Practice Bulletin 117 : 1492-1509, 2010.
 
12) Parkin D, et al : Global cancer statistics, 2002. CA Cancer J Clin 55 : 74-108, 2005.
PubMed
13) 日本婦人科腫瘍学会 (編) : 子宮頸癌治療ガイドライン2011年版, 金原出版. 2011.
 
14) Chirenje ZM, et al : A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia- J Obstet Gynaecol 21 : 617-621, 2001.
PubMed
15) Chirenje ZM, et al : Effect of HIV disease in treatment outcome of cervical squamous intraepithelial lesions among Zimbabwean women. J Low Genit Tract Dis 7 : 16-21, 2003.
PubMed
16) Villa LL, et al : Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 : 1915-1927, 2007.
 
17) World Health Organization : Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 84 : 118-131, 2009.
PubMed
P.687 掲載の参考文献
1) Turett GS, et al : Recurrent pneumococcal bacteremia. Arch Intern med 161:2141-2144, 2001.
PubMed
2) Lucas GL, et al : Bacterial pulmonary infections in HIV-infected patients. Up To Date Feb, 2015.
 
3) Kohli R et al : Bacterial pneumonia, HIV therapy, and diseases progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 43 : 90-98, 2006.
 
4) Heffernan RT, et al : Declining incidence of invasive Streptococcus
PubMed
5) Sogaard OS, et al : Hospitalization for pneumonia among indivisuals with and without HIV infection, 1995-2007 : a Danish population-based, nationwide cohort study. Clin Infect Dis 47 : 1345-1353, 2008.
 
6) Grau I, et al : Epidemiologic changes in bacteremic pneumococcal diseases in patients with human immunodeficiency virus in the era of highly active antiretrovial therapy. Arch Intern Med 165 : 1533-1540, 2005.
 
7) Jordano Q, et al : Invasive pneumococcal diseases in patients infected with HIV : still a threat in the era of highly active antiretrovial therapy. Clin Infect Dis 38 : 1623-1628, 2004.
 
P.691 掲載の参考文献
1) American Thoracic Society ; European Respiratory Society : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 165 : 277-304, 2002.
PubMed
2) Centers for Disease Control and Prevention (CDC) : Revised surveillance case definition for HIV infection-United States, 2014. MMWR Recomm Rep 63 (RR-03) : 1-10, 2014.
 
3) Sharland M, et al : Respiratory morbidity from lymphocytic interstitial pneumonitis (LIP) in vertically acquired HIV infection. Arch Dis Child 76 : 334-336, 1997.
PubMed
4) Pitt J : Lymphocytic interstitial pneumonia. Pediatr Clin North Am 38 : 89-95, 1991.
PubMed
5) Das S, Miller RF : Lymphocytic interstitial pneumonitis in HIV infected adults. Sex Transm Infect 79 : 88-93, 2003.
PubMed
6) Marchevsky A, et al : Pulmonary complications of the acquired immunodeficiency syndrome : a clinicopathologic study of 70 cases. Hum Pathol 16 : 659-670, 1985.
PubMed
7) Andiman WA, et al : Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. Lancet 2 : 1390-1393, 1985.
PubMed
8) Bhoopat L, et al : Cell reservoirs of the Epstein-Barr virus in biopsy-proven lymphocytic interstitial pneumonitis in HIV-1 subtype E infected children : identification by combined in situ hybridization and immunohistochemistry. Appl Immunohistochem Mol Morphol 18 : 212-218, 2010.
PubMed
9) Toro AA et al : Epstein-Barr virus (EBV) gene expression in interstitial pneumonitis in Brazilian human immunodeficiency virus-1-infected children : is EBV associated or not? Pediatr Dev Pathol 13 : 184-191, 2010.
PubMed
10) van Zyl-Smit RN, et al : HIV associated Lymphocytic Interstitial Pneumonia : a clinical, histological and radiographic study from an HIV endemic resource-poor setting. BMC Pulm Med 15 : 38, 2015.
PubMed
11) Malamou-Mitsi V, et al : Lymphoid interstitial pneumonia not associated with HIV infection : role of Epstein-Barr virus. Mod Pathol 5 : 487-491, 1992.
 
12) Itescu S, et al : A diffuse infiltrative CD8 lymphocytosis syndrome in human immunodeficiency virus (HIV) infection : a host immune response associated with HLA-DR5. Ann Intern Med 112 : 3-10, 1990.
PubMed
13) Saito M, et al : A pathologically proven case of adult-onset HIV-related lymphocytic interstitial pneumonia with acute exacerbation treated with steroid and antiretroviral therapy. J Infect Chemother, 2015. doi : 10.1016/j.jiac.2015.07.008.
 
14) Dufour V, et al : Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Clin Infect Dis 36 : e127-130, 2003.
PubMed
15) Fagan KA, King TE Jr : Lymphoid interstitial pneumonia in adults. In : UpToDate, Post TW (Ed), UpToDate, Waltham, MA (Accessed on July 23, 2015.)
 
16) Cha SI, et al : Lymphoid interstitial pneumonia : clinical features, associations and prognosis. Eur Respir J 28:364-369, 2006.
PubMed
P.696 掲載の参考文献
1) Mateen FJ, et al : Neurologic disorders incidence in HIV+ vs HIV- men : Multicenter AIDS Cohort Study, 1996-2011. Neurology 79 (18) : 1873-1880, 2012.
PubMed
2) McDonnell J, et al : Minimal cognitive impairment in UK HIV-positive men who have sex with men : effect of case definitions and comparison with the general population and HIV-negative men. J Acquir Immune Defic Syndr 67 (2) : 120-127, 2014.
 
3) Heaton RK, et al : HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy : CHARTER Study. Neurology 75 (23) : 2087-2096, 2010.
PubMed
4) Pumpradit W, et al : Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol 16 (1) : 76-82, 2010.
PubMed
5) Valcour V, et al : Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 206 (2) : 275-282, 2012.
PubMed
6) Gonzalez-Scarano F, Martin-Garcia J : The neuropathogenesis of AIDS. Nat Rev Immunol 5 (1) : 69-81, 2005.
PubMed
7) Moroni M, Antinori S : HIV and direct damage of organs : disease spectrum before and during the highly active antiretroviral therapy era. AIDS 17 (Suppl 1) : S51-64, 2003.
 
8) Masliah E, et al : Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 14 (1) : 69-74, 2000.
PubMed
9) Ragin AB, et al : Structural brain alterations can be detected early in HIV infection. Neurology 79 (24) : 2328-2334, 2012.
PubMed
10) Eden A et al : Immune activation of the central nervous system is still present after > 4 years of effective highly active antiretroviral therapy. J Infect Dis 196 (12) : 1779-1783, 2007.
PubMed
11) Letendre S, et al : Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 196 (3) : 361-370, 2007.
PubMed
12) Schouten J, et al : HIV-1 infection and cognitive impairment in the cART era : a review. AIDS 25 (5) : 561-575, 2011.
 
13) Guideline for the use of antiretroviral agents in HIV-1 infected adults and adolescents, April 2015. [http://aidsinfo.nih.gov/guidelines] (Accessed on April 20, 2015)
 
14) Cusini A et al : Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 62 : 28-35, 2013.
PubMed
15) Navia BA et al : The AIDS Dementia Complex : 1. Clinical features. Ann Neurol 19 (6) : 517-524, 1986.
 
P.698 掲載の参考文献
1) Wanke CA et al : Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31 : 803-805, 2000.
PubMed
2) Mangili A, et al : Nutrition and HIV infection : review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort Clin Infect Dis 42 : 836-842, 2006.
PubMed
3) Mulligan K, et al : Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 77 : 956-962, 1993.
PubMed
4) Macallan DC, et al : Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 333 : 83-88, 1995.
PubMed
5) Heijligenberg R, et al : Total energy expenditure in human immunodeficiency virus-infected men and healthy controls. Metabolism 46 : 1324-1326, 1997.
PubMed
6) Macallan DC, et al : Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr 58 : 417-424, 1993.
PubMed
7) Grinspoon S, et al : Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab 82 : 1332-1337, 1997.
PubMed
8) Dobs AS, et al : Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 84 : 611-616, 1988.
PubMed
9) Grinspoon S, et al : Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 81 : 4051-4058, 1996.
PubMed
10) Frost RA, et al : Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system. Clin Endocrinol (Oxf) 44 : 501-514, 1996.
PubMed
11) Christeff N, et al : Serum Cortisol and DHEA concentrations during HIV infection. Psychoneuroendocrinology 22 : S11-18, 1997.
PubMed
12) Carr A, et al : A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy : contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14 : F25-32, 2000.
 
13) Shikuma CM, et al : AIDS Clinical Trial Group 892 Team : Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis 39 : 1223-1230, 2004.
PubMed
14) Selberg O, et al : Effect of increased protein intake and nutritional status on whole-body protein metabolism of AIDS patients with weight loss. Metabolism 44 : 1159-1165, 1995.
PubMed
15) Bhasin S, et al : Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283 : 763-770, 2000.
PubMed
16) Dobs AS, et al : The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection. Am J Med 107 : 126-132, 1999.
PubMed
P.701 掲載の参考文献
1) Moore RD, Bartlett JG : Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis 53 : 600-604, 2011.
 
2) Maartens G, et al : HIV infection : epidemiology, pathogenesis, treatment and prevention. Lancet 384 : 258-271, 2014.
PubMed
3) 「HAART時代の日和見合併症に関する研究」班平成15年度報告書 (主任研究者安岡彰).
 
4) Grant PM, et al : Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs deferred ART during an opportunistic infection. PLoS One 5 : e11416, 2010.
 
5) Sexton DJ. Ren BC : Immune reconstitution inflammatory syndrome. Up to date 2015.
 
6) Carr A, Cooper DA : Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 349 : 995, 1997.
PubMed
7) Zylberberg H, et al : Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 27 : 1255, 1998.
 
8) Manegold C, et al : Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 32 : 144-148, 2001.
PubMed
9) Yoshida M, et al : An HIV patient with hepatic flare after the initiation of HBV-active antiretroviral therapy. Intern Med 51 : 1623-1626, 2012.
PubMed
10) Anderson AM, et al : Development of fatal acute liver failure in HIV-HBV coinfected patients. World J Gastroenterol 16 : 4107-4111, 2010.
PubMed
11) Mitsumoto F, et al : Hie kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients. J Infect Chemother 21 : 264-271, 2015.
 
12) Crane M, et al : Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV) -coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 199 : 974-981, 2009.
PubMed
13) John M, et al : Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors : an immune restoration disease? AIDS 12 : 2289, 1998.
PubMed
14) Kim HN, et al : Hepatitis C virus activation in HIV-infected patients initiating highly active antiretroviral therapy. AIDS Patient Care STDS 21 : 718-723, 2007.
PubMed
15) Yunihastuti E, et al : Antibody and markers of T-cell activation illuminate the pathogenesis of HCV immune restoration disease in HIV/HCV CO-infected patients commencing ART. Clin Immunol 139 : 32-39, 2011.
PubMed
16) Panel on Antiretroviral Guidelines for Adults and Adolescents : Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. AIDSinfo [online]. [http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf]
 
P.708 掲載の参考文献
1) 国連合同エイズ計画 (UNAIDS) グローバルファクトシート 2014年7月16日. [http://apinetjfap.or.jp/stolns/pdf/GFS_jp.pdf]
 
2) 厚生労働省エイズ動向委員会平成26 (2014) 年エイズ発生動向年報 平成27年5月27日. [http://api-net.jfap.or.jp/status/2014/14nenpo/14nenpo_menu.html]
 
3) Centers for Disease Control and Prevention : Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR Recomm Rep 39 (RR 1) : 1-14, 1990.
 
4) Centers for Disease Control and Prevention : Update : provisional Public Health Service recom mendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 45 (22) : 468-480, 1996.
 
5) Centers for Disease Control and Prevention : Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 47 (RR-7) : 1-33, 1998.
 
6) Centers for Disease Control and Prevention : Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 50 (RR-11) : 1-52, 2001.
PubMed
7) Panlilio AL, et al : US Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 54 (RR-9) : 1-17, 2005.
 
8) Kuhar DT, et al : Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. US Public Health Service Working Group. Infect Control Hosp Epidemiol 34 (9) : 875-892, 2013.
 
9) Joyce MP, et al : Notes from the field : occupationally acquired HIV infection among health care workers-United States, 1985-2013. MMWR Morb Mortal Wkly Rep 63 (53) : 1245-1246, 2015.
PubMed
10) Bell DM : Occupational risk of human immunodeficiency virus infection in healthcare workers : an overview. Am J Med 102 (5B) : 9-15, 1997.
PubMed
11) Ippolito G, et al : Italian Study Group on Occupational Risk of HIV infection : The risk of occupational human immunodeficiency virus infection in health care workers : Italian multicenter study. Arch Intern Med 153 (12) : 1451-1458, 1993.
 
12) Mast ST, et al : Efficacy of gloves in reducing blood volumes transferred during simulated needlestick injury. J Infect Dis 168 (6) : 1589-1592, 1993.
PubMed
13) Sturmer M, et al : Is transmission of HIV-1 in non-viraemic serodiscordant couples possible? Antivir Ther 13 (5) : 729-732, 2008.
PubMed
14) Tubiana R, et al : Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load < 500 copies/ml at delivery : a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis 50 (4) : 585-596, 2010.
PubMed
15) Shih CC, et al : Postexposure prophylaxis with zidovudine suppresses human immunodeficiency virus type 1 infection in SCID-hu mice in a time-dependent manner. J Infect Dis 163 (3) : 625-627, 1991.
 
16) Tsai CC, et al : Effectiveness of postinoculation (R)-9- (2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SlVmne infection depends critically on timing of initiation and duration of treatment J Virol 72 (5) : 4265-4273, 1998.
PubMed
17) Kourtis AP : Antiretroviral drug use during pregnancy and risk of premature delivery : is there a connection? J Infect Dis 201 (7) : 978-980, 2010.
 
18) Panel on Treatment of HIV-infected Pregnant Women and Prevention of Perinatal Transmission : Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at [http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf] 米国2015年8月6日.
 
P.713 掲載の参考文献
1) Poiesz BJ, et al : Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma Proc Natl Acad Sci USA 77 : 7415-7419, 1980.
PubMed
2) Satake M, et al : Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 84 : 327-335, 2012.
PubMed
3) Van Dooren S, et al : Dating the origin of the African human T-cell lymphotropic virus type-I「HTLV」) subtypes. Mol Biol Evol 18 : 661-671, 2001.
 
4) Matsuoka M, Yasunaga J : Human T-cell leukemia virus type 1 : replication, proliferation and propagateon by Tax and HTLV-1 bZIP factor. Curr Opin Virol 3 : 684-691, 2013.
PubMed
5) Iwanaga M, et al : Human T-cell leukemia virus type 1 (HTLV 1) proviral load and disease progression in asymptomatic HTLV-1 carriers : a nationwide prospective study in Japan. Blood 116 : 1211-1219, 2010.
PubMed
6) 出雲周二ほか : HAM診療マニュアル, 厚生労働省科学研究費補助金難治性疾患等克服事業, 2013.
 
7) Matsuoka M, Jeang KT : Human T-cell leukemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 7 : 270-280, 2007.
PubMed
8) Satou Y, et al : HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo. PLoS Pathog 7 : e1001274, 2011.
PubMed
9) Shimoyama M : Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79 : 428-437, 1991.
 
10) Tsukasaki K, et al : VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25 : 5458-5464, 2007.
 
11) Hishizawa M, et al : Transplantation of allogeneic hemoatopoietic stem cells for adult T-cell leukemia : a nationwide retrospective study. Blood 116 : 1369-1376, 2010.
 
12) Choi I, et al : Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma : results of prospective trials. Bone Marrow Transplant 46 : 116-118, 2011.
PubMed
13) Ishida T, et al : Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukemia-lymphoma : a randomized phase II study. Br J Haematol 169 : 672-682, 2015.
PubMed
14) Yamano Y, Sato T : Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol 3 : 1-10, 2012.
PubMed
P.719 掲載の参考文献
1) Naniche D, et al : Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67 : 6025-6032, 1993.
PubMed
2) Dorig RE, etal : The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75 : 295-305, 1993.
PubMed
3) Tatsuo H, et al : SLAM (CDwl50) is a cellular receptor for measles virus. Nature 406 : 893-897, 2000.
PubMed
4) Coughlin MM, et al : Contribution of dendritic cells to measles virus induced immunosuppression. Rev Med Virol 23 : 126-138, 2013.
PubMed
5) de Swart RL, et al : Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 3 : e178, 2007.
PubMed
6) de Vries RD, et al : In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J Virol 84 : 4714-4724, 2010.
PubMed
7) Lemon K, et al : Early target cells of measles virus after aerosol infection of non-human primates. PLoS Pathog 7 : e1001263, 2011.
PubMed
8) Miihlebach MD, et al : Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 480 : 530-533, 2011.
 
9) Okada H, et al : Comparative analysis of host responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. Arch Virol 146 : 859-874, 2001.
PubMed
10) Schneider-Schaulies S, et al : Expression of measles virus RNA in peripheral blood mononuclear cells of patients with measles, SSPE, and autoimmune diseases. Virology 182:703-711, 1991.
PubMed
11) Permar SR, et al : Increased thymic output during acute measles virus infection. J Virol 77 : 7872-7879, 2003.
PubMed
12) Griffin DE : Measles virus-induced suppression of immune responses. Immunol Rev 236 : 176-189, 2010.
PubMed
13) Moss WJ, et al : Differential regulation of interleukin (IL)-4, IL-5, and IL-10 during measles in Zambian children. J Infect Dis 186 : 879-887, 2002.
 
14) Riddell MA, et al : Slow clearance of measles virus RNA after acute infection. J Clin Virol 39 : 312-317, 2007.
PubMed
15) Kerdiles YM, et al : Immunosuppression caused by measles virus : role of viral proteins. Rev Med Virol 16 : 49-63, 2006.
PubMed
16) Marie JC, et al : Mechanism of measles virus-induced suppression of inflammatory immune responses. Immunity 14 : 69-79, 2001.
PubMed
P.725 掲載の参考文献
1) Kimura H, et al : Epstein-Barr virus-associated lymphoid malignancies : the expanding spectrum of hematopoietic neoplasm. Nagoya J Med Sci 75 : 169-179, 2013.
PubMed
2) Fujiwara S, et al : Modeling EBV infection and pathogenesis in new-generation humanized mice. Exp Mol Med 47 : e135, 2015.
PubMed
3) Takeuchi K, et al : Prevalence of Epstein-Barr virus in Japan : trends and future prediction. Pathol Int 56 : 112-116, 2006.
PubMed
4) Ishii E, et al : Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 88 : 58-65, 2007.
 
5) Chen JI, et al : Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts : a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol 20 : 1472-1482, 2009.
 
6) Parvaneh N, etal : Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases. Br J Haematol 162 : 573-586, 2013.
PubMed
7) Imadome K, et al : Novel mouse xenograft models reveal a critical role of CD4+T cells in the proliferation of EBV-infected T and NK cells. PLoS Pathog 7 (10) : e1002326, 2011.
PubMed
8) Sumaya CV, Ench Y : Epstein-Barr virus infections mononucleosis in children. II. Heterophil antibody and viral-specific responses. Pediatrics 175 : 1011-1019, 1985.
 
9) Chovel-Sella A, et al : Incidence of rash after amoxicillin treatment in children with infectious mononucleosis. Pediatrics 131 : 1424-1427, 2013.
 
10) Lennon P, et al : Infectious mononucleosis. BMJ 350 : h1825, 2015.
PubMed
11) Okano M, et al : Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80 : 64-69, 2005.
PubMed
12) Henter JI, et al : HLH-2004 : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 : 124-131, 2007.
PubMed
13) Kogawa K, etal : Prognostic factor of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children : report of the Japan Histiocytosis Study Group. Pediatr Blood Cancer 61 : 1257-1262, 2014.
 
14) Sato E, et al : Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am J Hematol 83 : 721-727, 2008.
PubMed
15) Kawa K, et al : Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection. Bone Marrow Transplant 46 : 77-83, 2011.
PubMed
P.731 掲載の参考文献
1) Swerdlow SH, et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition, IARC Press, Lyon, 2008.
 
2) Roschewski M, Wilson WH : EBV-associated lymphomas in adult. Best Pract Res Clin Haematol 25 : 75-89, 2012.
PubMed
3) Foon KA, et al : The non-Hodgkin lymphoma. Williams Hematology (ed by Lichtman MA, et al), p 1047-1460, McGRAW-HILL Medical Publishing Division, 2006.
 
4) Horning SJ : Hodgkin lymphoma. Williams Hematology (ed by Lichtman MA, et al), p 1061-1482, McGRAW-HILL, Medical Publishing Division, 2006.
 
P.737 掲載の参考文献
1) Jaffe ES, et al : Pathology and Genetics. Tumour of Haemaopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. IARC Press, Lyon, 2001.
 
2) Hoppe RT, et al : Hodgkin Lymphoma (2nd edition). Wolters Kluwer, 2007.
 
3) Younes A, et al : Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363 : 1812-1821, 2010.
PubMed
4) Ansell SM, et al : PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl T Med 372 : 311-319, 2015.
 
5) 北野滋久, 塚崎邦弘 : [免疫療法の逆襲を現実化した免疫check pointの修飾]Tregによる免疫反応の制御とimmune checknointによる免疫修飾の違い. 血液内科14 (5) : 469-474, 2014.
 
6) Stathis A, Younes A : The new therapeutical scenario of Hodgkin lymphoma. Ann Oncol 26 (10) : 2026-2033, 2015.
PubMed
P.742 掲載の参考文献
1) Swerdlow SH, et al : WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, International Agency for Research on Cancer, Lyon, 2008.
 
2) Matsuda A, et al : Cancer incidence and incidence rates in Japan in 2008 : a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 44 : 388-396, 2014.
PubMed
3) Pizzo PA : Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328 : 1323-1332, 1993.
PubMed
4) Chang HY, et al : Causes of death in adults with acute leukemia. Medicine (Baltimore) 55 : 259-268, 1976.
PubMed
5) Grimwade D, et al : Refinement of cytogenetic classification in acute myeloid leukemia : determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116 : 354-365, 2010.
PubMed
6) Juliusson G, et al : Age and acute myeloid leukemia : real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113 : 4179-4187, 2009.
PubMed
P.745 掲載の参考文献
1) Tsuda H, Yamasaki H : Type I and type II T cell profiles in chronic myelogenous leukemia. Acta Haematol 103 (2) : 96-101, 2000.
 
2) Kiani A, et al : Normal intrinsic Th1/Th2 balance in patients with chronic phase chronic myeloid leukemia not treated with interferon-alpha or imatinib. Haematologica 88 (7) : 754-761, 2003.
PubMed
3) Coleman S, et al : Cytokine enhancement of immunogenicity in chronic myeloid leukaemia. Leukemia 11 (12) : 2055-2059, 1997.
PubMed
4) Chen X, et al : Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol 111 (3) : 817-825, 2000.
 
5) Li Y, et al : Decreased level of recent thymic emigrants in CD4+ and CD8+T cells from CML patients. J Transl Med 8 : 47, 2010.
PubMed
6) Zahran AM, et al : Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients. Int J Clin Oncol 19 (4) : 753-760, 2014.
 
7) Mumprecht S, et al : Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114 (8) : 1528-1536, 2009.
 
8) Nakajima H, et al : The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J Immunol 168 (2) : 643-650, 2002.
PubMed
9) Chiorean EG, et al : BCR/ABL alters the function of NK cells and the acquisition of killer immunoglobulin-like receptors (KIRs). Blood 101 (9) : 3527-3533, 2003.
PubMed
10) Mellqvist UH, et al : Natural killer cell dysfunction and apoptosis induced by chronic myelogenous leukemia cells : role of reactive oxygen species and regulation by histamine. Blood 96 (5) : 1961-1968, 2000.
PubMed
11) Ilander M, et al : Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy. PLoS One 9 (1) : e87794, 2014.
 
12) Anand M, et al : Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis. Hematol Oncol 16 (4) : 143-154, 1998.
PubMed
13) Humlova Z, et al : Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment Folia Biol (Praha) 52 (3) : 47-58, 2006.
PubMed
P.751 掲載の参考文献
1) Dispenzieri A, et al : Multiple Myeloma. In : Wintrobe's Clinical Hematology, 11th ed (ed by John PG, et al), p2591, Lippincott and Wilkins, Philadelphia, 2004.
 
2) Nucci M, Anaissie E : Infections in patients with multiple myeloma. Semin Hematol 46 : 277-288, 2009.
PubMed
3) Salonen J, Nikoskelainen J : Lethal infections in patients with hematological malignancies. Eur J Haematol 51 : 102-108, 1993.
PubMed
4) Snowden JA, et al : Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 154 : 76-103, 2011.
PubMed
5) Robertson JD, et al : Immunogenicity of vaccination against influenza, Streptococcus pneumonia and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 82 : 1261-1265, 2000.
 
6) Oken MM, et al : Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100 : 624-628, 1996.
PubMed
7) Vesole DH, et al : Oral antibiotics prophylaxis of early infection in multiple myeloma : a URCC/ECOG randomized phase 3 study. Leukemia 26 : 2517-2520, 2012.
 
8) Schutt P, et al : Immune parameters in multiple myeloma patients : influence of treatment and correlation with opportunistic infections. Leuk lymphoma 47 : 1570-1582, 2006.
PubMed
9) Raanani P, et al : Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma : systematic review and meta-analysis. Leuk Lymphoma 50 : 764-772, 2009.
PubMed
10) Stern A, et al : Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10 : CD005590, 22014.
 
11) Richardson PG, et al : Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352 : 2487-2498, 2005.
 
12) 一般社団法人日本血液学会 (編) : 造血器腫瘍診療ガイドライン 2013年版, p304, 金原出版, 2013.
 
13) Marchesi F, et al : High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based rejimens : a survey from the Rome transplant network. Transpl Infect Dis 16 : 158-164, 2014.
PubMed
14) Rajkumar SV, et al : Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106:4050-4053, 2005.
PubMed
15) Dimopoulos MA, et al : Expert panel consensus statement on the optimal use of pomakidomide in relapsed and refractory multiple myeloma. Leukemia 28 : 1573-1585, 2014.
 
P.757 掲載の参考文献
1) Horibe K, et al : Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010) : based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol 98 : 74-88, 2013.
PubMed
2) 水谷修紀 : 遺伝, 胎児, 環境からみた小児白血病. 臨床血液 55 : 2233-2241, 2014.
 
3) Pui CH, et al : Biology, risk stratification, and therapy of pediatric acute leukemias : an update. J Clin Oncol 29 : 551-565, 2011.
PubMed
4) Izraeli S, et al : How I treat ALL in Down's syndrome : pathobiology and management. Blood 123 : 35-40, 2014.
 
5) Urayama KY, Manabe A : Genomic evaluations of childhood acute lymphoblastic leukemia susceptibility across race/ethnicities. Rinsho Ketsueki 55 : 2242-2248, 2014.
PubMed
6) Hunger SP, Mullighan CG : Redefining ALL classification : toward detecting high-risk ALL and implementing precision medicine. Blood 125 : 3977-3987, 2015.
PubMed
7) Mullighan CG : Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest 122 : 3407-3415, 2012.
PubMed
8) Paulsson K, et al : The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Nat Genet 47 : 672-676, 2015.
PubMed
9) Swaminathan S, et al : Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat Immunol 16 : 766-774, 2015.
PubMed
10) Mansour MR, et al : Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346 : 1373-1377, 2014.
PubMed
11) Pui CH, et al : Acute lymphoblastic leukaemia. Lancet 371 : 1030-1043, 2008.
PubMed
12) 堀部敬三 : 小児ALLの治療方針. 臨床血液 53 : 1538-1548, 2012.
 
13) 竹内仁 : 成人ALLの治療方針. 臨床血液 53 : 1528-1537, 2012.
 
14) Perez-Andreu V, et al : Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 45 : 1494-1498, 2013.
 
15) Diouf B, et al : Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313 : 815-823, 2015.
PubMed
P.763 掲載の参考文献
1) Morrison VA : Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2007 : 332-338, 2007.
PubMed
2) ScrivenerS, et al : Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 44 (3) : 383-389, 2003.
 
3) Gorgun G, et al : Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115 (7) : 1797-1805, 2005.
PubMed
4) Buggins AG, et al : Tumor-derived IL-6 may contribute to the immunological defect in CLL Leukemia 22 (5) : 1084-1087, 2008.
 
5) Kimby E, et al : Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (BMLUS). Leukemia 3 (7) : 501-504, 1989.
PubMed
6) Itala M, et al : Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol 57 (1) : 46-53, 1996.
PubMed
7) Davey FR, et al : Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia. Am J Clin Pathol 87 (1) : 60-65, 1987.
PubMed
8) Sampalo A, et al : Humoral immunodeficiency in chronic lymphocytic leukemia : role of CD95/CD95L in tumoral damage and escape. Leuk Lymphoma 43 (4) : 881-884, 2002.
PubMed
9) Wadhwa PD, et al : Infectious complications of chronic lymphocytic leukemia. Semin Oncol 33 (2) : 240-249, 2006.
PubMed
10) Kowal M, et al : Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL) -Polish multicentre study. Leuk Lymphoma 45 (6) : 1159-1165, 2004.
PubMed
11) Hainsworth JD, et al : Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma : a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21 (9) : 1746-1751, 2003.
 
12) Wierda W, et al : Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23 (18) : 4070-4078, 2005.
PubMed
13) Keating MJ, et al : Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine : results of a large international study. Blood 99 (10) : 3554-3561, 2002.
 
14) O'Brien SM, et al : Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7 (2) : 125-130, 2006.
PubMed
15) Molica S, et al : Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 81 (2) : 121-126, 1996.
PubMed
16) Morrison VA, Infectious complications in patients with chronic lymphocytic leukemia : pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 9 (5) : 365-370, 2009.
PubMed
17) Sinisalo M, et al : Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 114 (1) : 107-110, 2001.
PubMed
18) Hamblin TJ : Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 33 (2) : 230-239, 2006.
PubMed
19) Dearden C : Disease-specific complications of chronic lymphocytic leukemia. Hematology. Am Soc Hematol Educ Program 2008 : 450-456, 2008.
PubMed
20) Visco C, et al : Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 111 (3) : 1110-1116, 2008.
PubMed
21) DiGiacomo J, et al : Primary acquired red cell aplasia in the adult J Mt Sinai Hosp N Y 33 (5) : 382-395, 1966.
PubMed
22) Barcellini W, et al : Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 91 (12) : 1689-1692, 2006.
 
23) Kipps TJ, et al : Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 81 (10) : 2475-2487, 1993.
PubMed
24) Hodgson EM, et al : Variation in Miscanthus chemical composition and implications for conversion by pyrolysis and thermo-chemical bio-refining for fuels and chemicals. Bioresour Technol 102 (3) : 3411-3418, 2011.
PubMed
25) Caligaris-Cappio F : Relationship between autoimmunity and immunodeficiency in CLL. Hematol Cell Ther 39 (Suppl 1) : S13-16, 1997.
 
26) Ghia P, et al : From normal to clonal B cells : Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 7 (2) : 127-131, 2007.
PubMed
27) Hall AM, et al : Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 105 (5) : 2007-2015, 2005.
PubMed
28) Narra K, et al : Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab : report of two cases and review of the literature. Leuk Res 30 (1) : 109-114, 2006.
 
29) Dungarwalla M, et al : Lack of clinical efficacy of rituximab in the treatment of autoimmune neu tropenia and pure red cell aplasia : implications for their pathophysiology. Ann Hematol 86 (3) : 191-197, 2007.
 
30) Bussel JB, et al : Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113 (10) : 2161-2171, 2009.
PubMed
31) Hallek M, et al; International Workshop on Chronic Lymphocytic Leukemia : Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008.
 
P.769 掲載の参考文献
1) Tefferi A : Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms : JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24 (6) : 1128-1138, 2010.
PubMed
2) Vannucchi AM, et al : Mutations and prognosis in primary myelofibrosis. Leukemia 27 (9) : 1861-1869, 2013.
PubMed
3) Baxter EJ, et al : Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (9464) : 1054-1061, 2005.
PubMed
4) Moran-Crusio K, et al : Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20 (1) : 11-24, 2011.
PubMed
5) Shide K, et al : TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 26 (10) : 2216-2223, 2012.
PubMed
6) Quivoron C, et al : TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20 (1) : 25-38, 2011.
PubMed
7) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues (ed by Swerdlow SH, et al), p40-50, IARC press, Lyon, 2008.
 
8) Cervantes F, et al : New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113 (13) : 2895-2901, 2009.
 
9) Gangat N, et al : DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol 29 (4) : 392-397, 2011.
 
10) Verstovsek S, et al : A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366 (9) : 799-807, 2012.
PubMed
11) Harrison C, et al : JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366 (9) : 787-798, 2012.
PubMed
12) Verstovsek S, et al : Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis : results of a median 2-year follow-up of COMFORT-I. Haematologica 98 (12) : 1865-1871, 2013.
PubMed
13) Cervantes F, et al : Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122 (25) : 4047-4053, 2013.
 
14) Passamonti F, et al : Impact of ruxolitinib on the natural history of primary myelofibrosis : a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 123 (12) : 1833-1835, 2014.
PubMed
15) 日本血液学会 (編) : 造血器腫瘍診療ガイドライン 2013年版, 金原出版, 2013.
 
P.775 掲載の参考文献
1) Dispenzieri A, et al : Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance : a retrospective population-based cohort study. Lancet 375 (9727) : 1721-1728, 2010.
PubMed
2) Kyle RA, et al : A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346 : 564-569, 2002.
PubMed
3) Agarwal A, Ghobrial IM : Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma : a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res 19:985-994, 2013.
 
4) Dosani T, et al : The cellular immune system in myelomagenesis : NK cells and T cells in the development of MM and their uses in immunotherapies. Blood Cancer J 5 : e306, 2015.
 
5) Ramachandran IR, et al : Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 190 : 3815-3823, 2013.
PubMed
6) Pessoa de Magalhaes RJ, et al : Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98 : 79-86, 2013.
PubMed
7) Blotta S, et al : Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 114 : 3276-3284, 2009.
PubMed
8) Perez-Andres M, et al : Characterization of bone marrow T cells in monoclonal gammopathy of undetermined significance, multiple myeloma, and plasma cell leukemia demonstrates increased infiltration by cytotoxic/Th1 T cells demonstrating a squed TCR-Vbeta repertoire. Cancer 106 : 1296-1305, 2006.
PubMed
9) Liu J, et al : Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110:296-304, 2007.
 
10) Dong H, et al : Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion. Nat Med 8 : 793-800, 2002.
PubMed
11) Tamura H, et al : Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia 27 : 464-472, 2013.
PubMed
12) Feyler S, et al : CD4 (+) CD25 (+) FoxP3 (+) regulatory T cells are increased whilst CD3 (+) CD4 (-) CD8 (-) alphabetaTCR (+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 144 : 686-695, 2009.
PubMed
13) Bernal M, et al : Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma : implications for tumor evasion of T and NK cells. Hum Immunol 70 : 854-857, 2009.
PubMed
14) Landgren O, et al : Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma : a prospective study. Blood 113 : 5412-5417, 2009.
PubMed
15) Turesson I, et al : Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies : 728 cases followed up to 30 years in Sweden. Blood 123 : 338-345, 2014.
PubMed
P.780 掲載の参考文献
1) LamyT, Loughran TP Jr : How I treat LGL leukemia. Blood 117 (10) : 2764-2774, 2011.
 
2) Swerdlow SH (ed), et al : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC, 2008.
 
3) Oshimi K : Granular lymphocyte proliferative disorders : report of 12 cases and review of the literature. Leukemia 2 (10) : 617-627, 1988.
PubMed
4) Semenzato G, et al : The lymphoproliferative disease of granular lymphocytes : updated criteria for diagnosis. Blood 89 (1) : 256-260, 1997.
PubMed
5) Ishida F, et al : Aggressive natural killer cell leukemia : therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation. Cancer Sci 103 (6) : 1079-1083, 2012.
PubMed
6) Zhang D, Loughran TP Jr : Large granular lymphocytic leukemia : molecular pathogenesis, clinical manifestations, and treatment Hematology Am Soc Hematol Educ Program 2012 : 652-659, 2012.
PubMed
7) Epling-Burnette PK, et al : Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107 (3) : 351-362, 2001.
PubMed
8) Koskela HL, et al : Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 366 (20) : 1905-1913, 2012.
PubMed
9) Teramo A, et al : Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood 121 (19) : 3843-3854, S1. 2013
 
10) Jerez A, et al : STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120 (15) : 3048-3057, 2012.
 
11) Ishida F, et al : STAT3 gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. Cancer Sci 105 (3) : 342-346, 2014.
PubMed
12) Loughran TP Jr : Clonal diseases of large granular lymphocytes. Blood 82 (1) : 1-14, 1993.
PubMed
13) Kawahara S, et al : Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan. Eur J Haematol 82 (4) : 308-314, 2009.
PubMed
14) Handgretinger R, et al : Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med 340 (4) : 278-284, 1999.
PubMed
15) Fujishima N, et al : Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia : a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica 93 (10) : 1555-1559, 2008.
 
16) Shimodaira S, et al : The detection of clonal proliferation in granular lymphocyte-proliferative disorders of natural killer cell lineage. Br J Haematol 90 (3) : 578-584, 1995.
PubMed
17) Suzuki R, et al : Prognostic factors for mature natural killer (NK) cell neoplasms : aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 21 (5) : 1032-1040, 2010.
PubMed
18) Sekiguchi N, et al : Elevated serum granulysin and its clinical relevance in mature NK-cell neoplasms. Int J Hematol 96 (4) : 461-468, 2012.
PubMed
19) Hirokawa M, et al : Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia : a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica 93 (1) : 27-33, 2008.
 
20) Loughran TP Jr, et al : Immunosuppressive therapy of LGL leukemia : prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 29 (4) : 886-894, 2015.
PubMed
21) Suzuki R et al : Aggressive natural killer-cell leukemia revisited : large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 18 (4) : 763-770, 2004.
PubMed
P.786 掲載の参考文献
1) Berres ML, et al : Progress in understanding the pathogenesis of Langerhans cell histiocytosis : back to Histiocytosis X? Br J Haematol 169 : 3-13, 2015.
PubMed
2) Morimoto A, et al : Recent advances in Langerhans cell histiocytosis. Pediatr Int 56 : 451-461, 2014.
PubMed
3) Morimoto A, et al : Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Int J Hematol 97 : 103-108, 2013.
 
4) Badalian-Very G, et al : Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116 : 1919-1923, 2010.
PubMed
5) Chakraborty R, et al : Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124 : 3007-3015, 2014.
PubMed
6) Nelson DS, et al : MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer 54 : 361-368, 2015.
PubMed
7) Berres ML, et al : BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 211 : 669-683, 2014.
PubMed
8) Simko SJ, et al : Differentiating skin-limited and multisystem Langerhans cell histiocytosis. J Pediatr 165 : 990-996, 2014.
PubMed
9) Oh Y, et al : High serum osteopontin levels in pediatric patients with high risk Langerhans cell histiocytosis. Cytokine 70 : 194-197, 2014.
PubMed
10) Oh Y, et al : Osteopontin has a crucial role in osteoclast-like multinucleated giant cell formation. J Cell Biochem 115 : 585-595, 2014.
 
11) Murakami I, et al : Merkel cell polyomavirus DNA sequences in peripheral blood and tissues from patients with Langerhans cell histiocytosis. Hum Pathol 45 : 119-126, 2014.
PubMed
12) Morimoto A, et al : Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis : Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 107:613-619, 2006.
 
13) Gadner H, et al : Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 121 : 5006-5014, 2013.
PubMed
14) Minkov M, et al : Reactivations in multisystem Langerhans cell histiocytosis : data of the international LCH registry. J Pediatr 153 : 700-705, 2008.
PubMed
15) Imashuku S, et al : Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH) -related neurodegenerative CNS disease. Int J Hematol 101 : 191-197, 2015.
PubMed
P.788 掲載の参考文献
1) Henter JI, et al : HLH-2004. Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 : 124-131, 2007.
PubMed
2) Janka GE, etal : Hemophagocytic syndrome-an update. Blood Rev 28 : 135-142, 2014.
PubMed
3) Schram AM, et al : How I treat hemophagocytic lymphohistiocytosis in the adult patient Blood 125 : 2908-2914, 2015.
 
4) Chin M, et al : Hemophagocytic syndrome and hepatosplenic γδ T-cell lymphoma with isochromosome 7q and 8 trisomy. J Pediatr Hematol Oncol 26 : 375-378, 2004.
 
5) Shimada K, et al : Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 10 : 895-902, 2009.
 
6) Fox CP, et al : Epstein-Barr virus associated hemophagocytic lympho-histiocytosis in adults characterized by high viral genome load within circulating natural killer cells. Clin Infect Dis 51 : 66-69, 2010.
 
7) Sovinz P, et al : Recurrent episodes of fever and pancytopenia due to haemophagocytosis during maintenance therapy for acute myeloid leukemia. Br J Haematol 143 : 605, 2008.
PubMed
8) Wang L, et al : Acute myeloid leukemia initially presenting as hemophagocytic lymphohistiocytosis-a case report and review of the literature. Leuk Res 34 : e46-e49, 2010.
PubMed
9) Yamazaki S, et al : Haemophagocytic lymphohistiocytosis is a recurrent and specific complication of acute erythroid leukemia. Br J Haematol 153 : 669-672, 2011.
PubMed
10) Chandrakasan S, et al : Hemophagocytic lymphohistiocytosis : advances in pathophysiology, diagnosis, and treatment J Pediatr 163 : 1253-1259, 2013.
PubMed
11) Janka GE : Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 166 : 95-109, 2007.
PubMed
12) Stinchcombe JC, Griffiths GM : Secretory mechanisms in cell-mediated cytotoxicity. Annu Rev Cell Dev Biol 23 : 495-517, 2007.
PubMed
13) Osugi Y, et al : Cytokine production regulating Thl and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89 : 4100-4103, 1997.
 
14) Schneider EM, et al : Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 100 : 2891-2898, 2002.
PubMed
15) Parikh SA, et al : Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc 89 : 484-492, 2014.
PubMed
16) Lay JD, et al : Upregulation of tumor necrosis factor a gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest 100 : 1969-1979, 1997.
 
17) Schram AM, et al : Marked hyperferritinemia does not predict for HLH in the adult population. Blood 125 : 1548-1552, 2015.
 
18) Joel SP, et al : Predicting etoposide toxicity. Relationship to organ function and protein binding. J Clin Oncol 14 : 257-267, 1996.
PubMed
19) Acra M, et al : Prognostic factors of early death in a cohort of 162 ault haemophagocytic syndrome : impact of triggering disease and early treatment with etoposide. Br J Haematol 168 : 63-68, 2015.
 
20) Home A, et al : Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 129 : 622-630, 2005.
 
P.793 掲載の参考文献
1) Ishii E, et al : Nationwide study of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86 : 58-65, 2007.
PubMed
2) Henter JI, et al : HLH-2004 : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 : 124-131, 2007.
PubMed
3) Kogawa K, et al : Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children : Report of the Japan Histiocytosis Study Group. Pediatr Blood Cancer 61 : 1257-1262, 2014.
 
4) Matsuda K, et al : Detection of T-cell receptor gene rearrangement in children with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis using the IOMED-2 multiplex polymerase chain reaction combined with GeneScan analysis. Clin Chim Acta 412 : 1554-1558, 2011.
 
5) Imashuku S, et al : Occurrence of haemophagocytic lymphohistiocytosis at less than 1 year of age : analysis of 96 patients. Eur J Pediatr 164 : 315-319, 2005.
PubMed
6) Suzuki N, et al : Characteristics of hemophagocytic lymphohistiocytosis in neonates : a nationwide survey in Japan. J Pediatr 155 : 235-238, 2009.
PubMed
P.796 掲載の参考文献
1) Scott RB, Robb-Smith AH : Histiocytic medullary reticulocytosis. Lancet 2 : 194-198, 1939.
 
2) Komp DM, et al : Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood 73 : 2128-2132, 1989.
PubMed
3) Imashuku S, Hibi S : Cytokines in haemophagocytic syndrome. Br J Haematol 77 : 438-440, 1991.
 
4) HenterJI, et al : Diagnostic guidelines for hemophagocytic lymphohistiocytosis. Semin Oncol 18 : 29-33, 1991.
PubMed
5) Henter JI, et al : HLH-2004 : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 : 124-131, 2007.
PubMed
6) Imashuku S : Differential diagnosis of hemophagocytic syndrome : underlying disorders and selection of the most effective treatment IntJHematol 66 : 135-151, 1997.
PubMed
7) Tsuda H : Hemophagocytic syndrome (HPS) in children and adults. Int J Hematol 65 : 215-226, 1997.
PubMed
8) Manuel RC, et al : Adult haemophagocytic syndrome. Lancet 383 : 1503-1516, 2014.
 
9) Risdall RJ, et al : Virus-associated hemophagocytic syndrome : a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 44 : 993-1002, 1979.
PubMed
10) Risdall RJ, et al : Bacteria-associated hemophagocytic syndrome. Cancer 54 : 2968-2972, 1984
PubMed
11) Brastianos PK, et al : Tuberculosis-associated hemophagocytic syndrome. Lancet Infect Dis 6 : AA7-A^A 9IYlfi
 
12) 片桐誠一朗ほか : 治療経過中に播種性Mycobacterium abscessus感染症による血球貪食症候群を合併した慢性リンパ性白血病. 日内会誌 103 (3) : 734-737, 2014.
 
P.802 掲載の参考文献
1) Kumakura S, et al : Autoimmune-associated hemophagocytosis. Am J Hematol 50 : 148-149, 1995.
PubMed
2) Kumakura S, et al : Autoimmune-associated hemophagocytic syndrome. Am J Med 102 : 113-115, 1997.
PubMed
3) Kumakura S, et al : Adult onset Still's disease-associated hemophagocytosis. J Rheumatol 24 : 1645-1648, 1997.
PubMed
4) Kumakura S, et al : Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol 14 : 205-215, 2004.
PubMed
5) Kumakura S, Murakawa Y : Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol 66 : 2297-2307, 2014.
PubMed
6) Wong KF, et al : The acute lupus hemophagocytic syndrome. Ann Intern Med 114 : 387-390, 1991.
PubMed
7) Fukaya S, et al : Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases : analysis of 30 cases. Rheumatology 47 : 1686-1691, 2008.
PubMed
8) Arlet JB, et al : Reactive haemophagocytic syndrome in adult-onset Still's disease : a report of six patients and a review of the literature. Ann Rheum Dis 65 : 1596-1602, 2006.
 
9) Min JK, et al : Bone marrow findings in patients with adult Still's disease. Scand J Rheumatol 32 : 119-121, 2003.
PubMed
10) Behrens EM, et al : Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 34 : 1133-1138, 2007.
PubMed
11) Ishii E, et al : Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86 : 58-65, 2007.
PubMed
12) Indik ZK, et al : The molecular dissection of Fc gamma receptor-mediated phagocytosis. Blood 86 : 4389-4399, 1995.
PubMed
13) Simpson DM, Ross R : Effects of heterologus anti-neutrophil serum in guinea pigs. Hematologic and ultrastructural observations. Am J Pathol 65 : 79-102, 1971.
 
14) Kumakura S, et al : Hemophagocytosis associated with MPO-ANCA positive vasculitis in systemic sclerosis. Clin Exp Rheumatol 20 : 411-414, 2002.
PubMed
15) Henter JI, et al : 2004 : Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 : 124-131, 2007.
PubMed
16) Kumakura S : Validity in the diagnosis of reactive hemophagocytic syndrome : comment on the article by Fardet et al. Arthritis Rheumatol 67 : 587-588, 2015.
PubMed
17) Lehmberg K, Ehl S : Diagnostic evaluation of patients with suspected haemophagocytic lymphohistiocytosis. Br J Haematol 160 : 275-287, 2013.
PubMed
18) Schram AM, et al : Marked hyperferritinemia does not predict for HLH in the adult population. Blood 125 : 1548-1552, 2015.
 
P.807 掲載の参考文献
1) 菊池昌弘 : 特異な組織像を呈するリンパ節炎について. 日血会誌 35 : 379-380, 1972.
 
2) Tanaka K, et al : DNA typing of HLA class II genes (HLA-DR, -DQ and-DP) in Japanese patients with histiocytic necrotizing lymphadenitis (Kikuchi's disease). Tissue Antigens 54 : 246-253, 1999.
 
3) Ishimura M, et al : A non-invasive diagnosis of histiocytic necrotizing lymphadenitis by means of gene expression profile analysis of peripheral blood mononuclear cells. J Clin Immunol 33 : 1018-1026, 2013.
PubMed
4) Hollingsworth HC, et al : An investigation of the viral pathogenesis of Kikuchi-Fujimoto's disease. Lack of evidence for Epstein-Barr virus or human herpes type 6 as the causative agent. Arch Pathol Lab Med 118 : 134-140, 1994.
PubMed
5) Eimoto T, et al : Histiocytic necrotizing lymphadenitis. An ultrastructural study in comparison with other types of lymphadenitis. Acta Pathol Jpn 33 : 863-879, 1983.
PubMed
6) Chong Y, Kang CS : Causative agents of Kikuchi-Fujimoto disease (histiocytic necrotizing lymphadenitis) : a meta-analysis. Int J Pediatr Otorhinolaryngol 78 : 1890-1897, 2014.
 
7) Rosado FG, et al : Kikuchi-Fujimoto lymphadenitis : role of parvovirus B-19, Epstein-Barr virus, human herpesvirus 6, and human herpesvirus 8. Hum Pathol 44 : 255-259, 2013.
 
8) Kikuchi M, et al : Histiocytic necrotizing lymphadenitis : Clinicopathologic, immunologic and HLA typing study. In : Lymphoid Malignancy, Immunology and Cytogenetics (ed by Hanaoka M, et al), p 251-257, Field & Wood, New York, 1990.
 
9) Nomura Y, et al : Phenotype for activated tissue macrophages in histiocytic necrotizing lymphadenitis. Pathol Int 59 : 631-635, 2009.
PubMed
10) Ohshima K, et al : Proliferating cells in histiocytic necrotizing lymphadenitis. Virchows Arch B Cell Pathol Incl Mod Pathol 61 : 97-100, 1991.
 
11) Nomura Y, et al : Estimation of apoptosis and cell proliferation in histiocytic necrotizing lymphadenitis using immunohistochemical double staining. Pathol Int 58 : 98-103, 2008.
PubMed
12) Ohshima K, et al : Apoptosis- and cell cycle-associated gene expression profiling of histiocytic necrotizing lymphadenitis. Eur J Haematol 72 : 322-329, 2004.
PubMed
P.814 掲載の参考文献
1) 日本臨床腫瘍学会 (編) : 発熱性好中球減少症 (FN) 診療ガイドライン, 南江堂, 2012.
 
2) Smith TJ, et al : 2006 Update of ASCO Practice Guideline Recommendations for the Use of White Blood Cell Growth Factors. J Clin Oncol 24 : 3187-3205, 2006.
PubMed
3) Lenz HJ : Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12 : 601-609, 2007.
PubMed
P.819 掲載の参考文献
1) 田中良哉 (編) : 免疫・アレルギー疾患の分子標的と治療薬辞典, 羊土社, 2013.
 
2) Wands JR et al : Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68 : 105-112, 1975.
PubMed
3) 坪内博仁ほか : 免疫抑制・化学療法により発症するB型肝炎対策 : 厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療標準化に関する研究」班合同報告. 肝臓 50 : 38-42, 2009.
 
4) Oketani M, et al : Etiology and prognosis of fulminant hepatitis and late onset hepatic failure in Japan : Summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 43 : 97-105, 2013.
PubMed
5) 持田智, 中山伸朗 : 我が国における急性肝不全および遅発性肝不全 (LOHF)の実態 (2013年) : 平成26年度全国調査. 厚生労働科学研究費補助金 (難治性疾患克服研究事業)「難治性の肝・胆道疾患に関する調査研究班」平成26年度報告書. p92-116, 2015.
 
6) Uemoto S, et al : Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants- Transplantation 65 : 494-499, 1998.
PubMed
7) Marusawa H, et al : Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31 : 488-495, 2000.
PubMed
8) Dhedin N, et al : Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation : a retrospective study of 37 patients with pretransplant anti-HBs and antiHBc. Transplantation 66 : 616-619, 1998.
PubMed
9) Dervite I, et al : Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344 : 68-69, 2001.
 
10) Oshima Y, et al : Association of hepatitis B with antirheumatic drugs : a case-control study. Mod Rheumatol 23 : 694-704, 2013.
PubMed
11) Calabrese LH, et al : Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases : assessment and preventive strategies. Ann Rheum Dis 65 : 983-989, 2006.
PubMed
12) Perez-Alvarez R, et al : Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF) -targeted therapy : analysis of 257 cases. Medicine (Baltimore) 90 : 359-371, 2011.
PubMed
13) Lee YH, et al : Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 31 : 118-121, 2013.
PubMed
14) 持田智ほか : 「がん北学療法および免疫抑制療法中のB型肝炎ウイルス再活性化予防対策法の確立を目指したウイルス要因と宿主要因の包括的研究」班平成24年度研究報告書, p7-16, 2013.
 
15) 日本肝臓学会・肝炎診療ガイドライン作成委員会 (編) : B型肝炎治療ガイドライン (第2.1版) 2015.[http://www.jsh.or.jp/files/uploads/HBV_GL_ver2.1_May11 .pdf]
 
P.823 掲載の参考文献
1) 厚生労働省 : 平成25年国民健康・栄養調査結果の概要, 2013.
 
2) Persson MD, et al : Nutritional status using mini nutritional assessment and subjective global assessment predict mortality in geriatric patients. J Am Geriatr Soc 50 : 1996-2002, 2002.
PubMed
3) Ramer-Quinn DS. et al : Activated T helper l and helper 2 cell differentially express the β-2 adrenergic receptor. J Immunol 159 : 4857-4867, 1997.
 
4) Heyland DK, et al : Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. JPEN J Parenter Enteral Nutr 27 : 355-373. 2003.
PubMed
5) Peter JV, et al : A metaanalysis of treatment outcomes of early enteral versus early parenteral nutrition in hospitalized patients. Crit Care Med 33 : 213-220, 2005.
PubMed
6) King BK, et al : Route and type of nutrition influence mucosal immunity to bacterial pneumonia. Ann Surg 229 : 272-278, 1999.
PubMed
P.828 掲載の参考文献
1) Alarcon Segovia D, et al : Systemic lupus erythematosus following thymectomy for myasthenia gravis, report of two cases. Lancet 2 : 662-665, 1963.
PubMed
2) Hancock DM : Thymectomy for autoimmune disease. Br Med J 1 : 860, 1965.
PubMed
3) KarrasA etal : Groupe d'Etudes des Nephropathies Associees aux T. Renal and thymic pathology in thymoma-associated nephropathy : report of 21 cases and review of the literature. Nephrol Dial Transplant 20 : 1075-1082, 2005.
 
4) Matsuda M, et al : Myasthenia gravis with membranous nephropathy, successfully treated with extended total thymectomy. Intern Med 39 : 490-494, 2000.
PubMed
5) Kister I, et al : Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 63 : 851-856, 2006.
PubMed
6) Masaoka A, et al : Thymectomy and malignancy. Eur J Cardiothorac Surg 8 : 251-253, 1994.
PubMed
7) Zandman-Goddard G, et al : Systemic lupus erythematosus and thymoma-a double-edged sword. Int Arch Allergy Immunol 108 : 99-102, 1995.
PubMed
8) Crispin JC, et al : Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21 : 273-276, 2003.
PubMed
9) Halnon NJ, et al : Immune dysregulation after cardiothoracic surgery and incidental thymectomy : maintenance of regulatory T cells despite impaired thymopoiesis. Clin Dev Immunol 2011 : 915864, 2011.
PubMed
10) Shalhoub RJ : Pathogenesis of lipoid nephrosis : a disorder of T-cell function. Lancet 2 : 556-560, 1974.
PubMed
11) Miyamoto N, et al : [A case of myasthenia gravis accompanied by steroid-resistant nephritic syndrome and CD57+ lymphocytes expansion in peripheral blood]. Rinsho Shinkeigaku 39 : 629-633, 1999.
PubMed
12) Shimizu S, et al : Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 175:7185-7192, 2005.
PubMed
13) Bagavant H, Tung KS : Failure of CD25+ T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialadenitis. J Immunol 175:944-950, 2005.
PubMed
14) Gerli R, et al : Long-term immunologic effects of thymectomy in patients with myasthenia gravis. J Allergy Clin Immunol 103 : 865-872, 1999.
PubMed
15) Link J, et al : Organ-specific autoantigens induce transforming growth factor-beta mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Ann Neurol 35 : 197-203, 1994.
PubMed
P.832 掲載の参考文献
1) Ejstrud P, et al : Risk and patterns of bacteraemia after splenectomy : a population-based study. Scand J Infect Dis 32 : 521-525, 2000.
PubMed
2) Cullingford GL, et al : Severe late postsplenectomy infection. Br J Surg 78 : 716-721, 1991.
PubMed
3) Lynch AM, Kapila R : Overwhelming postsplenectomy infection. Infect Dis Clin North Am 10 : 693-707, 1996.
PubMed
4) Di Sabatino A, et al : Post-splenectomy and hyposplenic states. Lancet 378 (9785) : 86-97, 2011.
PubMed
5) Morgan TL, Tomich EB : Overwhelming post-splenectomy infection (OPSI) : a case report and review of the literature. J Emerg Med 43 : 758-763, 2012.
PubMed
6) Mourtzoukou EG, et al : Vaccination of asplenic or hyposplenic adults. Br J Surg 95 : 273-280, 2008.
PubMed
7) Centers for Disease Control and Prevention (CDC) : Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 62 : 521-524, 2013.
PubMed
8) Kim DK, et al; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP) ; ACIP Adult Immunization Work Group : Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older-United States, 2015. MMWR Morb Mortal Wkly Rep 64 : 91-92, 2015.
 
9) Tomczyk S, et al; Centers for Disease Control and Prevention (CDC) : Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged > 65 years : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63 : 822-825, 2014.
PubMed
10) Forstner C, et al : Effectiveness and immunogenicity of pneumococcal vaccination in splenectomized and functionally asplenic patients. Vaccine 30 : 5449-5452, 2012.
PubMed
11) Papadatou I, et al : Antigen-specific B-cell response to 13-valent pneumococcal conjugate vaccine in asplenic individuals with β-thalassemia previously immunized with 23-valent pneumococcal polysaccharide vaccine. Clin Infect Dis 59 : 862-865, 2014.
 
12) National Center for Immunization and Respiratory Diseases : General recommendations on immunization-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60 (2) : 1-64, 2011.
PubMed
13) Rodeghiero F, Ruggeri M : Short- and long-term risks of splenectomy for benign haematological disorders : should we revisit the indications? Br J Haematol 158 : 16-29, 2012.
 
14) Rother RP, et al : The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin : a novel mechanism of human disease. JAMA 293 : 1653-1662, 2005.
PubMed
15) Schilling RF : Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis-a personal view. Br J Haematol 145 : 728-732, 2009.
PubMed
P.837 掲載の参考文献
1) Dowd JB, Aiello AE : Socioeconomic differentials in immune response. Epidemiology 20 : 902-908, 2009.
PubMed
2) Fraga S, et al : Association of socioeconomic status with inflammatory markers : a two cohort comparison. Prev Med 71 : 12-19, 2015.
PubMed
3) Karasek RA : Job demands, job decision latitude, and mental strain : Implication for job design. Admin Sci Q 24 : 285-307, 1979.
 
4) Nakata A : Psychosocial job stress and immunity : a systematic review. Methods Mol Biol 934 : 39-75, 2012.
PubMed
5) Shirom A, et al : The job demand-control-support model and stress-related low-grade inflammatory responses among healthy employees : A longitudinal study. Work Stress 22 : 138-152, 2008.
 
6) Siegrist J : Adverse health effects of high-effort/low-reward conditions. J Occup Health Psychol 1 : 27-41, 1996.
PubMed
7) Nakata A et al : Effort-reward imbalance, overcommitment and cellular immune measures among white-collar employees. Biol Psychol 88 : 270-279, 2011.
PubMed
8) Hertting A Theorell T : Physiological changes associated with downsizing of personnel and reorganisation in the health care sector. Psychother Psychosom 71 : 117-122, 2002.
PubMed
9) Cohen F, et al : Immune function declines with unemployment and recovers after stressor termination. Psychosom Med 69 : 225-234, 2007.
PubMed
10) Kiecolt-Glaser JK, et al : Chronic stress and age-related increases in the proinflammatory cytokine IL-6. Proc Natl Acad Sci USA 100 : 9090-9095, 2003.
PubMed
11) Chida Y, Steptoe A : Positive psychological well-being and mortality : a quantitative review of prospective observational studies. Psychosom Med 70 : 741-756, 2008.
PubMed
12) Steptoe A, et al : Neuroendocrine and inflammatory factors associated with positive affect in healthy men and women : the Whitehall II study. Am J Epidemiol 167 : 96-102, 2008.
PubMed
13) Bennett MP, et al : The effect of mirthful laughter on stress and natural killer cell activity. Altern Ther Health Med 9 : 38-45, 2003.
PubMed
14) Kimata H : Effect of humor on allergen-induced wheal reactions. JAMA 285 : 738, 2001.
PubMed
15) Broadbent E, Koschwanez HE : The psychology of wound healing. Curr Opin Psychiatry 25 : 135-140, 2012.
PubMed
P.842 掲載の参考文献
1) Gepts W : Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes 14 : 619-633, 1965.
PubMed
2) Bottazzo GF, et al : Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2 : 1279-1283, 1974.
PubMed
3) Kawasaki E : Type 1 diabetes and autoimmunity. Clin Pediatr Endocrinol 23 : 99-105, 2014.
PubMed
4) Kawasaki E : ZnT8 and type 1 diabetes. Endocr J 59 : 531-537, 2012.
PubMed
5) Drell DW, et al : Multiple immunological abnormalities in patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30 : 132-143, 1987.
PubMed
6) Peterson P, et al : Steroid 21-hydroxylase autoantibodies in insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. Clin Immunol Immunopathol 82 : 37-42, 1997.
 
7) Lampasona V, et al : Antibodies to tissue transglutaminase C in type 1 diabetes. Diabetologia 42 : 1195-1198, 1999.
PubMed
8) Ejskjaer N, et al : Prevalence of autoantibodies to autonomic nervous tissue structures in Type 1 diabetes mellitus. Diabet Med 16 : 544-549, 1999.
PubMed
9) Gray RS, et al : The clinical features of diabetes with coexisting autoimmune thyroid disease. Diabetologia 20 : 602-606, 1981.
PubMed
10) Mimura G, et al : Immunogenetics of early-onset insulin-dependent diabetes mellitus among the Japanese : HLA, Gm, BF, GLO, and organ-specific autoantibodies-the J.D.S. study. Diabetes Res Clin Pract 8 : 253-262, 1990.
 
11) 日比逸郎ほか : 18歳以下で発症した若年型 (インスリン依存型) 糖尿病の日本における現状. ホルモンと臨床 30 : 981, 1982.
 
12) Kawasaki E, et al : Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease. Diabetes 43 : 80-86, 1994.
PubMed
13) Kawasaki E, et al : Sequential elevation of autoantibodies to thyroglobulin and glutamic acid decarboxylase in type 1 diabetes. World J Diabetes 4 : 227-230, 2013.
PubMed
14) Eisenbarth GS, et al : Joslin's Diabetes Mellitus (ed by Weir GC, Kahn CR), Vol 13, p216, Lea & Febiger, Philadelphia, 1994.
 
15) 川崎英二 : 多腺性自己免疫症候群ってなに? プラクティス 25 : 11, 2008.
Medical*Online
16) Brewer K, et al : Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency. N Engl J Med 337 : 202, 1997.
PubMed
17) Yu L, et al : DRB1*04 and DQ alleles : expression of 21-hydroxylase autoantibodies and risk of progression to Addison's disease. J Clin Endocrinol Metab 84 : 328-335, 1999.
PubMed
P.847 掲載の参考文献
1) 菊池正知 : H免疫系. 最新の熱傷臨床-その理論と実際- (平山峻, 島崎修次編). p67-75, 克誠堂, 1994.
 
2) Wood GW, et al : Dynamics of T-lymphocyte subpopulations and T-lymphocyte function following thermal injury. Clin Exp Immunol 31 : 291-297. 1978.
 
3) Antonacci AC, et al : Flow cytometric analysis of lymphocyte subpopulations after thermal injury in human beings. Surg Gynecol Obstet 159 : 1-8, 1984.
PubMed
4) 木所昭夫 : 熱傷における免疫不全に関する実験的研究. 熱傷 7 : 285-301, 1982.
 
5) 真部正志ほか : 熱傷の免疫学的変動. 熱傷 7 : 24-29, 1982.
 
6) Arturson G, et al : Changes in immunoglobulin levels in severely burned patients. Lancet 1 : 546-548, 1969.
PubMed
7) 島津岳士ほか : 熱傷急性期における補体系を中心とした免疫能の変化の検討. 熱傷 16 : 9-13, 1990.
 
8) 大橋教良ほか : 熱傷時の補体機能の変動について. 熱傷 9 : 43, 1983.
 
9) 遠藤重厚 : 免疫とサイトカイン. 熱傷 治療マニュアル (改訂2版), p66-70, 中外医学社, 2013.
 
10) Kinoshita M, et al : Restration of natural IgM production from liver B cells by exogenous IL-18 improves the survival of burn-injured mice infected with Pseudomonas aeruginosa. J Immunol 177 : 4627-4635, 2006.
 
11) Lam NN, et al : Early enteral feeding for burned patients-an effective method which should be encouraged in developing countries. Burns 34 : 192-196, 2008.
PubMed
12) Dylewksi ML, et al : The safety and efficacy of parenteral nutrition among pediatric patients with burn injuries. Pediatr Crit Care Med 14 : 120-125, 2013.
 
13) Zhou YP, et al : The effect of supplemental enteral glutamine on plasma levels, gut function, and outcome in severe burns : a randomized double-blind, controlled clinical trial. J Parenteral Nutr 27 : 241-245, 2003.
 
14) Peng X, et al : Glutamine granule-supplemented enteral nutrition maintains immunological function in severely burned patients. Burns 32 : 589-593. 2006.
PubMed
15) Wischmeyer PE, et al : Glutamine administration reduces Gram-negative bacteremia in severely burned patients : a prospective. randomized, double-blind trial versus isonitrogenous control Crit Care Med 29 : 2075-2080, 2001.
PubMed
P.850 掲載の参考文献
1) Iwanaga M, et al : Risk of Myelodysplasia syndromes in people exposed to ionizing radiation : a retrospective cohort study of Nagasaki at survivors. J Clin Oncol 29 : 428-438, 2011.
 
2) Hsu WL, et al : The incidence of leukemia, lymphoma, and multiple myeloma among atomic bomb survivors : 1950-2001. Radiat Res 179 (3) : 361-382, 2013.
PubMed
3) 木村昭郎 : 放射線障害としての血液疾患 骨髄異形成症候群・白血病を中心に 日内会誌 100 : 2612-2618, 2011.
 
P.855 掲載の参考文献
1) Cohen G, Horl WH : Immune dysfunction in uremia-An update. Toxins 4 : 962-990, 2012.
PubMed
2) Vaziri ND, et al : Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol 37 : 518-525, 2013.
PubMed
3) 鈴木亨 : 慢性腎不全, 尿毒症. 別冊日本臨牀 免疫症候群 (下巻), p 494-496, 日本臨牀社, 2000.
 
4) 稲本元 : 尿毒症における免疫不全と結核症. 人工透析研究会誌 12 : 21-36. 1979.
 
5) 富野康日己 : 老年者の腎不全. 老人科診療 6 : 244-247, 1985.
 
6) Devoto G, et al : Prealbumin serum concentrations as a useful tool in the assessment of malnutrition in hospitalized patients. Clin Chem 52 : 2281-2285, 2006.
PubMed
7) Fock RA, et al : Protein energy malnutrition modifies the production of interleukin-10 in response to lipo polysaccharide (LPS) in a murine model. J Nutr Sci Vitaminol (Tokyo) 54 : 371-377, 2008.
 
P.859 掲載の参考文献
1) Dressier W : The post myocardial syndrome. AMA Arch Intern Med 103 : 28-42, 1959.
 
2) Webb GD, et al : Disease of the heart, pericardium, and pulmonary vasculature bed. In : Brawnwald's Heart Disease, 8th ed (ed by Libby P, et al), p 1849-1850, Saunders Elsevier, Philadelphia, 2007.
 
3) Reinecke H, et al : Left ventricular pseudoaneurysm in a patient with Dressier's syndrome after myocardial infarction. Heart 80 : 98-100, 1998.
 
4) Kibos A, et al : Postcardiac injury syndrome complicating radiofrequency catheter ablation of the atrioventricular node. Acute Card Care 8 : 122-124, 2006.
PubMed
5) Rovang KS, et al : Dressier's syndrome complicating radiofrequency ablation of an accessory atrioventricular pathway. Pacing Clin Electrophysiol 16 : 251-253, 1993.
 
6) Porter G, et al : Dressier's syndrome post-pacemaker insertion. Br J Hosp Med (Lond) 69 (5) : 294, 2008.
 
7) Lichstein E, et al : Current incidence of post myocardial infarction (Dressier's) syndrome. Am J Card 50 : 1269-1271, 1982.
 
8) Van der Geld H : Anti-heart antibodies in the postpericardiotomy and the post myocardialinfarction syndromes. Lancet 2 : 617-621, 1964.
 
9) Luckie M, et al : Dressier's syndrome following pulmonary vein isolation for atrial fibrillation. Acute Card Care 10 : 234-235, 2008.
 
10) Maisch B, Ristic AD : Practical aspects of the management of pericardial disease. Heart 89 : 1096-1103, 2003.
PubMed

書評

最近チェックした商品履歴

Loading...